2003, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, 2003

Aarli JA, Romi F, Skeie GO, Gilhus NE. Myasthenia gravis in individuals over 40. Ann. N. Y. Acad. Sci. 998: 424-431 (2003). *
Abdallah A, Sato H, Grutters JC, Veeraraghavan S, Lympany PA, Ruven HJ, van den Bosch JM, Wells AU, du Bois RM, Welsh KI. Inhibitor kappa B-alpha (IkappaB-alpha) promoter polymorphisms in UK and Dutch sarcoidosis. Genes Immun. 4: 450-454 (2003). *
Abdel-Ghaffar YT, Amin E, Abdel-Rasheed M, Fouad HH. Essential fatty acid status in infants and children with chronic liver disease. East. Mediterr. Health J. 9: 61-69 (2003).
Abdo A, Klassen J, Urbanski S, Raber E, Swain MG. Reversible sclerosing cholangitis secondary to cryptosporidiosis in a renal transplant patient. J. Hepatol. 38: 688-691 (2003). *
Abdo AA, Beck P. Diagnosis and management of microscopic colitis. Can. Fam. Physician 49: 1473-1478 (2003).
Abe M, Furukawa S, Takayama S, Michitaka K, Minami H, Yamamoto K, Horiike N, Onji M. Drug-induced hepatitis with autoimmune features during minocycline therapy. Intern. Med. 42: 48-52 (2003). *
Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am. J. Pathol. 162: 1515-1520 (2003). *
Abe T, Iinuma Y, Ando M, Yokoyama T, Yamamoto T, Nakashima K, Takagi N, Baba H, Hasegawa Y, Shimokata K. NRAMP1 polymorphisms, susceptibility and clinical features of tuberculosis. J. Infect. 46: 215-220 (2003).
Abei M, Tanaka N. Prevention of black pigment gallstone formation after cardiac surgery by ursodeoxycholic acid. J. Gastroenterol. 38: 1113-1115 (2003). *
Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 125: 320-327 (2003). *
Abid S. Helicobacter pylori: what test for diagnosis and what treatment for eradication? J. Pak. Med. Assoc. 53: 88-89 (2003).
Aboutwerat A, Pemberton PW, Smith A, Burrows PC, McMahon RF, Jain SK, Warnes TW. Oxidant stress is a significant feature of primary biliary cirrhosis. Biochim. Biophys. Acta 1637: 142-150 (2003). *
Abraham E. Computational design of variant TNF molecules: a novel methodology for inhibition of proinflammatory cascades. Sci. STKE 208: PE51 (2003). *
Abraham SC, Cruz-Correa M, Argani P, Furth EE, Hruban RH, Boitnott JK. Diffuse lymphoplasmacytic chronic cholecystitis is highly specific for extrahepatic biliary tract disease but does not distinguish between primary and secondary sclerosing cholangiopathy. Am. J. Surg. Pathol. 27: 1313-1320 (2003).
Abraham SC, Cruz-Correa M, Argani P, Furth EE, Hruban RH, Boitnott JK. Lymphoplasmacytic chronic cholecystitis and biliary tract disease in patients with lymphoplasmacytic sclerosing pancreatitis. Am. J. Surg. Pathol. 27: 441-451 (2003).
Abraham SC, Wilentz RE, Yeo CJ, Sohn TA, Cameron JL, Boitnott JK, Hruban RH. Pancreaticoduodenectomy (Whipple resections) in patients without malignancy: are they all 'chronic pancreatitis'? Am. J. Surg. Pathol. 27: 110-120 (2003).
Abrantes EF, Pires EG, Carvalho AF, Costa FF, Savino W, Reis LF. Identification, structural characterization, and tissue distribution of Tsg-5: a new TNF-stimulated gene. Genes Immun. 4: 298-311 (2003). *
Abreu MT. Immunologic regulation of Toll-like receptors in gut epithelium. Curr. Opin. Gastroenterol. 19: 559-564 (2003).
Abu-Abed S, Dolle P, Metzger D, Wood C, MacLean G, Chambon P, Petkovich M. Developing with lethal RA levels: genetic ablation of Rarg can restore the viability of mice lacking Cyp26a1. Development 130: 1449-1459 (2003). *
Abu-Mouch S, Selmi C, Benson GD, Kenny TP, Invernizzi P, Zuin M, Podda M, Rossaro L, Gershwin ME. Geographic clusters of primary biliary cirrhosis. Clin. Dev. Immunol. 10: 127-131 (2003). *
Ackerman HC, Ribas G, Jallow M, Mott R, Neville M, Sisay-Joof F, Pinder M, Campbell RD, Kwiatkowski DP. Complex haplotypic structure of the central MHC region flanking TNF in a West African population. Genes Immun. 4: 476-486 (2003). *
Ackerman Z, Karmeli F, Cohen P, Rachmilewitz D. Experimental colitis in rats with portal hypertension and liver disease. Inflamm. Bowel Dis. 9: 18-24 (2003). *
Acuto O, Michel F. CD28-mediated co-stimulation: a quantitative support for TCR signalling. Nat. Rev. Immunol. 3: 939-951 (2003).
Adam O. Dietary fatty acids and immune reactions in synovial tissue. Eur. J. Med. Res. 8: 381-387 (2003).
Adam O, Beringer C, Kless T, Lemmen C, Adam A, Wiseman M, Adam P, Klimmek R, Forth W. Anti-inflammatory effects of a low arachidonic acid diet and fish oil in patients with rheumatoid arthritis. Rheumatol. Int. 23: 27-36 (2003). *
Adams DD, Knight JG. Principles of autoimmune disease: pathogenesis, genetics and specific immunotherapy. J. Clin. Lab. Immunol. 52: 1-22 (2003).
Adams DH, Afford SC, Lalor PF. Cellular immunoreactions in the development of primary biliary cirrhosis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 27. October 15-16 (2003). *
Adani GL, Baccarani U, Risaliti A, Donini A, Aoki T, Avital I. Appendicectomy and Crohn's disease: clinical and genetic associations. Gastroenterology 125: 1562-1563 (2003). *
Adcock K, Hedberg C, Loggins J, Kruger TE, Baier RJ. The TNF-alpha -308, MCP-1 -2518 and TGF-beta1 +915 polymorphisms are not associated with the development of chronic lung disease in very low birth weight infants. Genes Immun. 4: 420-426 (2003). *
Adibi SA. Regulation of expression of the intestinal oligopeptide transporter (Pept-1) in health and disease. Am. J. Physiol. Gastrointest. Liver Physiol. 285: G779-G788 (2003). *
Adler G, Reinshagen M; German Society for Digestive and Metabolic Diseases. Extraintestinal manifestations. Z. Gastroenterol. 41: 54-61 (2003).
Afolabi AO. Recurrent leg ulcers in a 16-year old Nigerian girl. Afr. J. Med. Med. Sci. 32: 93-94 (2003).
Aganna E, Hammond L, Hawkins PN, Aldea A, McKee SA, van Amstel HK, Mischung C, Kusuhara K, Saulsbury FT, Lachmann HJ, Bybee A, McDermott EM, La Regina M, Arostegui JI, Campistol JM, Worthington S, High KP, Molloy MG, Baker N, et al. Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum. 48: 2632-2644 (2003). *
Agarwal B, Swaroop P, Protiva P, Raj SV, Shirin H, Holt PR. Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells. Apoptosis 8: 649-654 (2003). *
Aggarwal A, Ong JP, Goormastic M, Nelson DR, Arroliga AC, Farquhar L, Mayes J, Younossi ZM. Survival and resource utilization in liver transplant recipients: the impact of admission to the intensive care unit. Transplant. Proc. 35: 2998-3002 (2003). *
Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3: 745-756 (2003). *
Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278: 1910-1914 (2003). *
Aghamohammadi A, Farhoudi A, Moin M, Pourpak Z, Rezaei N, Nikzad M, Movahedi M, Gharagozlou M, Atarod L, Ahmadi Afshar A, Bazargan N, Abolmaali K, Mahmoudi M. Adverse effects of intravenous immunoglobulin therapy in patients with antibody deficiency. Iran. J. Allergy Asthma Immunol. 2: 121-126 (2003).
Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, Allard JP. Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress. a randomized controlled trial. Am. J. Gastroenterol. 98: 348-353 (2003). *
Agnholt J, Dahlerup JF, Buntzen S, Tottrup A, Nielsen SL, Lundorf E. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Aliment. Pharmacol. Ther. 17: 703-710 (2003). *
Agnholt J, Dahlerup JF, Kaltoft K. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 23: 76-85 (2003). *
Agrawal D, Chen T, Irby R, Quackenbush J, Chambers AF, Szabo M, Cantor A, Coppola D, Yeatman TJ. Osteopontin identified as colon cancer tumor progression marker. C.R. Biol. 326: 1041-1043 (2003).
Aguilar F, Nunez-Roldan A, Torres B, Wichmann I, Sanchez-Roman J, Gonzalez-Escribano MF. Chemokine receptor CCR2/CCR5 polymorphism in Spanish patients with systemic lupus erythematosus. J. Rheumatol. 30: 1770-1774 (2003).
Aguilar F, Torres B, Sanchez-Roman J, Nunez-Roldan A, Gonzalez-Escribano MF. CTLA4 polymorphism in Spanish patients with systemic lupus erythematosus. Hum. Immunol. 64: 936-940 (2003).
Aguillon JC, Contreras J, Dotte A, Cruzat A, Catalan D, Salazar L, Molina MC, Guerrero J, Lopez M, Soto L, Salazar-Onfray F, Cuchacovich M. New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies. Rev. Med. Chil. 131: 1445-1453 (2003).
Ahmad A, Govil Y, Frank BB. Gastric mucosa-associated lymphoid tissue lymphoma. Am. J. Gastroenterol. 98: 975-986 (2003). *
Ahmad T, Armuzzi A, Neville M, Bunce M, Ling KL, Welsh KI, Marshall SE, Jewell DP. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. Tissue Antigens 62: 527-535 (2003). *
Ahmad T, Marshall S, Jewell D. Genotype-based phenotyping heralds a new taxonomy for inflammatory bowel disease. Curr. Opin. Gastroenterol. 19: 327-335 (2003).
Ahmad T, Neville M, Marshall SE, Armuzzi A, Mulcahy-Hawes K, Crawshaw J, Sato H, Ling KL, Barnardo M, Goldthorpe S, Walton R, Bunce M, Jewell DP, Welsh KI. Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC. Hum. Mol. Genet. 12: 647-656 (2003). *
Ahmad T, Wallace GR, James T, Neville M, Bunce M, Mulcahy-Hawes K, Armuzzi A, Crawshaw J, Fortune F, Walton R, Stanford MR, Welsh KI, Marshall SE, Jewell DP. Mapping the HLA association in Behcet's disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum. 48: 807-813 (2003). *
Ahmadi KR, Lanchbury JS, Reed P, Chiano M, Thompson D, Galley M, Line A, Lank E, Wong HJ, Strachan D, Spector TD. Novel association suggests multiple independent QTLs within chromosome 5q21-33 region control variation in total humans IgE levels. Genes Immun. 4: 289-297 (2003). *
Ahmed N, Corey M, Forstner G, Zielenski J, Tsui LC, Ellis L, Tullis E, Durie P. Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut 52: 1159-1164 (2003). *
Ahmed SS, Tan FK. Identification of novel targets in scleroderma: update on population studies, cDNA arrays, SNP analysis, and mutations. Curr. Opin. Rheumatol. 15: 766-771 (2003).
Ahuja HS, Szanto A, Nagy L, Davies PJ. The retinoid X receptor and its ligands: versatile regulators of metabolic function, cell differentiation and cell death. J. Biol. Regul. Homeost. Agents 17: 29-45 (2003).
Ai T, Azemoto R, Saisho H. Prevention of gallstones by ursodeoxycholic acid after cardiac surgery. J. Gastroenterol. 38: 1071-1076 (2003). *
Aires V, Hichami A, Moutairou K, Khan NA. Docosahexaenoic acid and other fatty acids induce a decrease in pHi in Jurkat T-cells. Br. J. Pharmacol. 140: 1217-1226 (2003). *
Ajit C, Suvannasankha A, Zaeri N, Munoz SJ. Terbinafine-associated hepatotoxicity. Am. J. Med. Sci. 325: 292-295 (2003).
Akamizu T, Hiratani H, Ikegami S, Rich SS, Bowden DW. Association study of autoimmune thyroid disease at 5q23-q33 in Japanese patients. J. Hum. Genet. 48: 236-242 (2003). *
Akin K, Beyler AR, Kaya M, Erden E. The importance of iron and copper accumulation in the pathogenesis of non-alcoholic steatohepatitis. Turk. J. Gastroenterol. 14: 228-233 (2003). *
Akira S. Mammalian Toll-like receptors. Curr. Opin. Immunol. 15: 5-11 (2003).
Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 85: 85-95 (2003).
Akira S, Hoshino K. Myeloid differentiation factor 88-dependent and -independent pathways in Toll-like receptor signaling. J. Infect. Dis. 187 Suppl. 2: S356-S363 (2003). *
Akkari V, Donadieu J, Piguet C, Bordigoni P, Michel G, Blanche S, Casanova JL, Thomas C, Vilmer E, Fischer A, Bertrand Y; French Langerhans Cell Study Group. Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: experience of the French Langerhans Cell Study Group. Bone Marrow Transplant. 31: 1097-1103 (2003).
Akoume MY, Perwaiz S, Yousef IM, Plaa GL. Synergistic role of 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol 7alpha-hydroxylase in the pathogenesis of manganese-bilirubin-induced cholestasis in rats. Toxicol. Sci. 73: 378-385 (2003). *
Al-Jabri AA, Al Belushi MS, Nsanze H. Frequency and levels of autoantibodies in healthy adult Omanis. Ann. Saudi Med. 23: 372-375 (2003).
Alarcon-Riquelme ME. A RUNX trio with a taste for autoimmunity. Nat. Genet. 35: 299-300 (2003). *
Alba LM, Lindor K. Review article: non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 17: 977-986 (2003). *
Albanis E, Safadi R, Friedman SL. Treatment of hepatic fibrosis: almost there. Curr. Gastroenterol. Rep. 5: 48-56 (2003).
Albers R, Bol M, Bleumink R, Willems AA, Pieters RH. Effects of supplementation with vitamins A, C, and E, selenium, and zinc on immune function in a murine sensitization model. Nutrition 19: 940-946 (2003). *
Albrecht J. Glucose-derived osmolytes and energy impairment in brain edema accompanying liver failure: the role of glutamine reevaluated. Gastroenterology 125: 976-978 (2003). *
Albrecht M, Domingues FS, Schreiber S, Lengauer T. Structural localization of disease-associated sequence variations in the NACHT and LRR domains of PYPAF1 and NOD2. FEBS Lett. 554: 520-528 (2003). *
Albrecht M, Domingues FS, Schreiber S, Lengauer T. Identification of mammalian orthologs associates PYPAF5 with distinct functional roles. FEBS Lett. 538: 173-177 (2003). *
Albrecht M, Lengauer T, Schreiber S. Disease-associated variants in PYPAF1 and NOD2 result in similar alterations of conserved sequence. Bioinformatics 19: 2171-2175 (2003). *
Alcami A. Viral mimicry of cytokines, chemokines and their receptors. Nat. Rev. Immunol. 3: 36-50 (2003). *
Aldemir M, Faruk Gey I K M, Faruk Kokoglu O, Buyukbayram HI, Hosoglu SI, Yagmur Y. Effects of ursodeoxycholic acid, glutamine and polyclonal immunoglobulins on bacterial translocation in common bile duct ligated rats. ANZ J. Surg. 73: 722-726 (2003). *
Aldhous MC, Nimmo ER, Satsangi J. NOD2/CARD15 and the Paneth cell: another piece in the genetic jigsaw of inflammatory bowel disease. Gut 52: 1533-1535 (2003). *
Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. 1: CD003459 (2003). *
Alfke H, Alfke B, Froelich JJ, Klose KJ, Wagner HJ. Treatment of malignant biliary occlusion by means of transhepatic percutaneous biliary drainage with insertion of metal stents - results of an 8-year follow-up and analysis of the prognostic parameters. Rofo. 175: 1125-1129 (2003).
Alison MR. Characterization of the differentiation capacity of rat-derived hepatic stem cells. Semin. Liver Dis. 23: 325-336 (2003).
Alizadeh M, Babron MC, Birebent B, Matsuda F, Quelvennec E, Liblau R, Cournu-Rebeix I, Momigliano-Richiardi P, Sequeiros J, Yaouanq J, Genin E, Vasilescu A, Bougerie H, Trojano M, Martins Silva B, Maciel P, Clerget-Darpoux F, Clanet M, Edan G, et al. Genetic interaction of CTLA-4 with HLA-DR15 in multiple sclerosis patients. Ann. Neurol. 54: 119-122 (2003). *
Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res. 16: 208-214 (2003). *
Allen A, Obaro S, Bojang K, Awomoyi AA, Greenwood BM, Whittle H, Sirugo G, Newport MJ. Variation in Toll-like receptor 4 and susceptibility to group A meningococcal meningitis in Gambian children. Pediatr. Infect. Dis. J. 22: 1018-1019 (2003).
Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 63: 1339-1344 (2003). *
Allen M, Heinzmann A, Noguchi E, Abecasis G, Broxholme J, Ponting CP, Bhattacharyya S, Tinsley J, Zhang Y, Holt R, Jones EY, Lench N, Carey A, Jones H, Dickens NJ, Dimon C, Nicholls R, Baker C, Xue L, Townsend E, Kabesch M, Weiland SK, Carr D et al. Positional cloning of a novel gene influencing asthma from chromosome 2q14. Nat. Genet. 35: 258-263 (2003). *
Allgayer H. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment. Pharmacol. Ther. 18 Suppl. 2: 10-14 (2003). *
Allgayer H, Kruis W. PPAR-ligands: a clinically important regulatory system with multiple options in the treatment of diabetes mellitus, inflammatory bowel disease and in the chemoprevention of colon cancer? Z. Gastroenterol. 41: 1035-1038 (2003).
Alonso D, Elgart GW, Schachner LA. Blau syndrome: a new kindred. J. Am. Acad. Dermatol. 49: 299-302 (2003).
Alper CA, Xu J, Cosmopoulos K, Dolinski B, Stein R, Uko G, Larsen CE, Dubey DP, Densen P, Truedsson L, Sturfelt G, Sjoholm AG. Immunoglobulin deficiencies and susceptibility to infection among homozygotes and heterozygotes for C2 deficiency. J. Clin. Immunol. 23: 297-305 (2003).
Alpini G, Ueno Y, Tadlock L, Glaser SS, LeSage G, Francis H, Taffetani S, Marzioni M, Alvaro D, Patel T. Increased susceptibility of cholangiocytes to tumor necrosis factor-alpha cytotoxicity after bile duct ligation. Am. J. Physiol. Cell. Physiol. 285: C183-C194 (2003). *
Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst. Rev. 2: CD001939 (2003). *
Alsaeid K, Haider MZ, Ayoub EM. Angiotensin converting enzyme gene insertion-deletion polymorphism is associated with juvenile rheumatoid arthritis. J. Rheumatol. 30: 2705-2709 (2003).
Alsaeid KM, Haider MZ, al-Awadhi AM, Srivastva BS, Ayoub EM. Role of human leukocyte antigen DRB1*0307 and DRB1*0308 in susceptibility to juvenile rheumatoid arthritis. Clin. Exp. Rheumatol. 21: 399-402 (2003).
Alstead EM, Nelson-Piercy C. Inflammatory bowel disease in pregnancy. Gut 52: 159-161 (2003). *
Alzoghaibi MA, Walsh SW, Willey A, Fowler Iii AA, Graham MF. Linoleic acid, but not oleic acid, upregulates the production of interleukin-8 by human intestinal smooth muscle cells isolated from patients with Crohn's disease. Clin. Nutr. 22: 529-535 (2003). *
Amano M, Galvan M, He J, Baum LG. The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death. J. Biol. Chem. 278: 7469-7475 (2003). *
Amante MF, Trigo P, Lendoire J, Imventarza O, Parisi C. Transthyretin familial amyloidotic polyneuropathy: histopathological study of the explanted livers. Ann. Hepatol. 2: 171-174 (2003). *
Amarapurkar DN, Patel ND, Amarapurkar AD. Hepatic sarcoidosis. Indian J. Gastroenterol. 22: 98-100 (2003).
Amarapurkar DN, Patel ND, Amarapurkar AD, Kankonkar SR. HLA genotyping in type-I autoimmune hepatitis in Western India. J. Assoc. Physicians India 51: 967-969 (2003).
Amat di San Filippo C, Wang Y, Longo N. Functional domains in the carnitine transporter OCTN2, defective in primary carnitine deficiency. J. Biol. Chem. 278: 47776-47784 (2003). *
Amati L, Caradonna L, Leandro G, Magrone T, Minenna M, Faleo G, Pellegrino NM, Jirillo E, Caccavo D. Immune abnormalities and endotoxemia in patients with ulcerative colitis and in their first degree relatives: attempts at neutralizing endotoxin-mediated effects. Curr. Pharm. Design 9: 1937-1945 (2003).
Ambrosino G, Naso A, Feltracco P, Carraro P, Basso SM, Varotto S, Cillo U, Zanus. Cytokines and liver failure: modification of TNF- and IL-6 in patients with acute on chronic liver decompensation treated with Molecular Adsorbent Recycling System (MARS). Acta Biomed. Ateneo Parmense 74 Suppl. 2: 7-9 (2003). *
American Gastroenterological Association. American Gastroenterological Association medical position statement: osteoporosis in hepatic disorders. Gastroenterology 125: 937-940 (2003). *
American Gastroenterological Association Clinical Practice Committee. American Gastroenterological Association medical position statement: perianal Crohn's disease. Gastroenterology 125: 1503-1507 (2003). *
Amerio P, Frezzolini A, Feliciani C, Verdolini R, Teofoli P, De Pita O, Puddu P. Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: therapeutical implications. Curr. Drug Targets Inflamm. Allergy 2: 81-94 (2003).
Amre DK, Seidman EG. DNA variants in cytokine and NOD2 genes, exposures to infections and risk for Crohn's disease. Paediatr. Perinat. Epidemiol. 17: 302-312 (2003).
Amsaguine-Safir S, Bianchi A, Collet P, Huin-Schohn C, Jeanvoine A, Becuwe P, Kremarik-Bouillaud P, Domenjoud L, Keller JM, Schohn H, Dauca M. Induction of the expression of the peroxisome proliferator-activated receptor alpha (PPARalpha) by clofibrate in jerboa tissues. Microsc. Res. Tech. 61: 185-190 (2003). *
Anagnostopoulos GK, Margantinis G, Tsiakos S, Kostopoulos P, Pantes A, Arvanitidis D. Myopericarditis associated with ulcerative colitis. N. Z. Med. J. 116: U667 (2003).
Anakk S, Kalsotra A, Shen Q, Vu MT, Staudinger JL, Davies PJ, Strobel HW. Genomic characterization and regulation of CYP3a13: role of xenobiotics and nuclear receptors. FASEB J. 17: 1736-1738 (2003). *
Anand AC. Bioartificial liver support for fulminant hepatic failure. Indian J. Gastroenterol. 22 Suppl. 2: S69-S74 (2003).
Anantharaju A, Baluch M, Van Thiel DH. Transverse myelitis occurring in association with primary biliary cirrhosis and Sjogren's syndrome. Dig. Dis. Sci. 48: 830-833 (2003). *
Anastassopoulou CG, Kostrikis LG. The impact of human allelic variation on HIV-1 disease. Curr. HIV Res. 1: 185-203 (2003).
Anaya JM, Rivera D, Palacio LG, Arcos-Burgos M, Correa PA. D6S439 microsatellite identifies a new susceptibility region for primary Sjogren's syndrome. J. Rheumatol. 30: 2152-2156 (2003).
Anderson P, May B, Morris H. Vitamin D metabolism: new concepts and clinical implications. Clin. Biochem. Rev. 24: 13-26 (2003). *
Anderson P, Sundstedt A, Li L, O'Neill EJ, Li S, Wraith DC, Wang P. Differential activation of signal transducer and activator of transcription (STAT)3 and STAT5 and induction of suppressors of cytokine signalling in T(h)1 and T(h)2 cells. Int. Immunol. 15: 1309-1317 (2003). *
Anderson WF, Umar A, Hawk ET. Cyclooxygenase inhibition in cancer prevention and treatment. Expert Opin. Pharmacother. 4: 2193-2204 (2003).
Andersson P, Olaison G, Hallbook O, Boeryd B, Sjodahl R. Increased anal resting pressure and rectal sensitivity in Crohn's disease. Dis. Colon Rectum 46: 1685-1689 (2003).
Andersson RE, Olaison G, Tysk C, Ekbom A. Appendectomy is followed by increased risk of Crohn's disease. Gastroenterology 124: 40-46 (2003). *
Andersson U, Tracey KJ. HMGB1 in sepsis. Scand. J. Infect. Dis. 35: 577-584 (2003).
Andoh A, Tsujikawa T, Fujiyama Y. Role of dietary fiber and short-chain fatty acids in the colon. Curr. Pharm. Des. 9: 347-358 (2003).
Andoh A, Tsujikawa T, Ishizuka I, Araki Y, Sasaki M, Koyama S, Fujiyama Y. n-3 Fatty acid-rich diet prevents early response of interleukin-6 elevation in trinitrobenzene sulfonic acid-induced enteritis. Int. J. Mol. Med. 12: 721-725 (2003). *
Andrault JB, Gaillard I, Giorgi D, Rouquier S. Expansion of the BPI family by duplication on human chromosome 20: characterization of the RY gene cluster in 20q11.21 encoding olfactory transporters/antimicrobial-like peptides. Genomics 82: 172-184 (2003). *
Andreeva-Gateva P. Peroxisome proliferator activated receptors PPARs: their role in carbohydrate and lipid metabolism. Ann. Biol. Clin. (Paris) 61: 295-303 (2003).
Andrews T, Sullivan KE. Infections in patients with inherited defects in phagocytic function. Clin. Microbiol. Rev. 16: 597-621 (2003). *
Andrieu T, Thibault V, Malet I, Laporte J, Bauvois B, Agut H, Cahour A. Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections. J. Clin. Virol. 27: 59-68 (2003).
Andus T, Gross V, Caesar I, Schulz HJ, Lochs H, Strohm WD, Gierend M, Weber A, Ewe K, Scholmerich J; German/Austrian Budesonide Study Group. Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial. Dig. Dis. Sci. 48: 373-378 (2003). *
Andus T, Klebl F, Rogler G, Bregenzer N, Scholmerich J, Straub RH. Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment. Pharmacol. Ther. 17: 409-414 (2003). *
Andus T, Stange EF, Hoffler D, Keller-Stanislawski B. Suspected cases of severe side effects after infliximab (Remicade) in Germany. Med. Klin. (Munich) 98: 429-436 (2003).
Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, Baldwin AS. A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature 423: 659-663 (2003). *
Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? J. Rheumatol. 30: 2315-2318 (2003).
Ang TL, Fock KM, Ng TM, Teo EK, Tan YL. Clinical utility, safety and tolerability of capsule endoscopy in urban Southeast Asian population. World J. Gastroenterol. 9: 2313-2316 (2003). *
Angermayr B, Cejna M, Karnel F, Gschwantler M, Koenig F, Pidlich J, Mendel H, Pichler L, Wichlas M, Kreil A, Schmid M, Ferlitsch A, Lipinski E, Brunner H, Lammer J, Ferenci P, Gangl A, Peck-Radosavljevic M. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 52: 879-885 (2003). *
Angio LG, Pirrone G, Rivoli G, Fracassi MG, Rosato A, Piazzese E, Pacile V, Sfuncia G, Fiumara F. Pyoderma gangrenosum of the "sinus mammarum" in ulcerative colitis. G. Chir. 24: 247-254 (2003).
Angulo P. Non-alcoholic steatohepatitis. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 87-88. October 17 - 19 (2003). *
Angulo P. Current best treatment for non-alcoholic fatty liver disease. Expert Opin. Pharmacother. 4: 611-623 (2003).
Annacker O, Asseman C, Read S, Powrie F. Interleukin-10 in the regulation of T cell-induced colitis. J. Autoimmun. 20: 277-279 (2003).
Annese V, Latiano A, Andriulli A. Genetics of inflammatory bowel disease: the beginning of the end or the end of the beginning? Dig. Liver Dis. 35: 442-449 (2003).
Annese V, Latiano A, Palmieri O, Li HH, Forabosco P, Ferraris A, Andriulli A, Vecchi M, Ardizzone S, Cottone M, Dallapiccola B, Rappaport E, Fortina P, Devoto M. Linkage of ulcerative colitis to the pericentromeric region of chromosome 16 in Italian inflammatory bowel disease families is independent of the presence of common CARD15 mutations. J. Med. Genet. 40: 837-841 (2003). *
Annibale B, Capurso G, Baccini F, Lahner E, D'Ambra G, Di Giulio E, Delle Fave G. Role of small bowel investigation in iron deficiency anaemia after negative endoscopic/histologic evaluation of the upper and lower gastrointestinal tract. Dig. Liver Dis. 35: 784-787 (2003).
Annilo T, Chen ZQ, Shulenin S, Dean M. Evolutionary analysis of a cluster of ATP-binding cassette (ABC) genes. Mamm. Genome 14: 7-20 (2003). *
Ansell SM, Ackerman MJ, Black JL, Roberts LR, Tefferi A. Primer on medical genomics. Part VI: Genomics and molecular genetics in clinical practice. Mayo Clin. Proc. 78: 307-317 (2003). *
Anzai C, Morokawa N, Okada H, Kamidono S, Eto Y, Yoshimura K. CFTR gene mutations in Japanese individuals with congenital bilateral absence of the vas deferens. J. Cyst. Fibros. 2: 14-18 (2003).
Appleby MW, Ramsdell F. A forward-genetic approach for analysis of the immune system. Nat. Rev. Immunol. 3: 463-471 (2003). *
Aqel B, Bishop M, Krishna M, Cangemi J. Collagenous colitis evolving into ulcerative colitis: a case report and review of the literature. Dig. Dis. Sci. 48: 2323-2327 (2003). *
Aqui NA, Stein SH, Konkle BA, Abrams CS, Strobl FJ. Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura. J. Clin. Apher. 18: 51-54 (2003).
Aquilina P, Savage NW, Lynham A. Crohn's disease with oral presenting signs masquerading as chronic osteomyelitis. Aust. Dent. J. 48: 134-137 (2003).
Araki A, Hazama S, Oka M, Hinoda Y. Polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 in colorectal cancer. Nippon Rinsho 61 Suppl. 7: 229-232 (2003).
Araki Y, Andoh A, Bamba H, Yoshikawa K, Doi H, Komai Y, Higuchi A, Fujiyama Y. The cytotoxicity of hydrophobic bile acids is ameliorated by more hydrophilic bile acids in intestinal cell lines IEC-6 and Caco-2. Oncol. Rep. 10: 1931-1936 (2003).
Arch-Ferrer JE, Smith JK, Bynon S, Eckhoff DE, Sellers MT, Bland KI, Heslin MJ. Radio-frequency ablation in cirrhotic patients with hepatocellular carcinoma. Am. Surg. 69: 1067-1071 (2003).
Ardaillou R. Genetic polymorphisms linked to myocardial ischemia in a Japanese population. Med. Sci. (Paris) 19: 413-414 (2003).
Ardavín C. Origin, precursors and differentiation of mouse dendritic cells. Nat. Rev. Immunol. 3: 582-590 (2003). *
Ardizzone S. Ulcerative colitis. Orphanet encyclopedia [http://www.orpha.net/data/patho/GB/uk-UC.pdf] (2003). *
Ardizzone S, Bollani S, Manzionna G, Colombo E, Maconi G, Imbesi V, Bianchi Porro G. Efficacy of medical therapy in preventing the post-surgical recurrence in Crohn's disease. Ann. Ital. Chir. 74: 621-625 (2003).
Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig. Liver Dis. 35: 619-627 (2003).
Arend SM, Breedveld FC, van Dissel JT. TNF-alpha blockade and tuberculosis: better look before you leap. Neth. J. Med. 61: 111-119 (2003). *
Arguelles Arias F, Arguelles Martin F, Caunedo Alvarez A, Rodriguez-Tellez M, Herrerias Gutierrez JM. Utility of capsule endoscopy in pediatric gastroenterology. An. Pediatr. (Barc.) 59: 586-589 (2003).
Arico M, Girschikofsky M, Genereau T, Klersy C, McClain K, Grois N, Emile JF, Lukina E, De Juli E, Danesino C. Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur. J. Cancer 39: 2341-2348 (2003). *
Ariyan C, Salvalaggio P, Fecteau S, Deng S, Rogozinski L, Mandelbrot D, Sharpe A, Sayegh MH, Basadonna GP, Rothstein DM. Cutting edge: transplantation tolerance through enhanced CTLA-4 expression. J. Immunol. 171: 5673-5677 (2003). *
Armuzzi A, Ahmad T, Ling KL, De Silva A, Cullen S, van Heel D, Orchard TR, Welsh KI, Marshall SE, Jewell DP. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 52: 1133-1139 (2003). *
Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment. Pharmacol. Ther. 17: 1451-1457 (2003). *
Arnott ID, Satsangi J. Crohn's disease or Crohn's diseases? Gut 52: 460-461 (2003). *
Arnott ID, Watts D, Satsangi J. Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. Pharmacol. Res. 47: 1-10 (2003). *
Arrese M, Accatino L. Is intrahepatic cholestasis of pregnancy an MDR3-related disease? Gastroenterology 125: 1922-1923 (2003). *
Arrese M, Trauner M. Molecular aspects of bile formation and cholestasis. Trends Mol. Med. 9: 558-564 (2003). *
Arrese M, Trauner M, Ananthanarayanan M, Pizarro M, Solis N, Accatino L, Soroka C, Boyer JL, Karpen SJ, Miquel JF, Suchy FJ. Down-regulation of the Na+/taurocholate cotransporting polypeptide during pregnancy in the rat. J. Hepatol. 38: 148-155 (2003). *
Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J. Hepatol. 38 Suppl. 1: S69-S89 (2003). *
Arroyo V, Colmenero J. Use of albumin in the management of patients with decompensated cirrhosis. An independent verdict. Dig. Liver Dis. 35: 668-672 (2003).
Arslan S, Kav T, Besisik F, Kaymakoglu S, Pinarbasi B, Tozun N, Hamzaoglu HO, Duman D, Ulker A, Parlak E, Palabiyikoglu M, Dokmeci A. Clinical outcome of Crohn's disease treated with infliximab. Hepatogastroenterology 50: 952-956 (2003).
Arthur LG, Kuenzler KA, Schwartz MZ. Hepatocyte growth factor ameliorates inflammatory bowel disease in a rat model. J. Gastrointest. Surg. 7: 1062-1068 (2003).
Artlett CM, O'Hanlon TP, Lopez AM, Song YW, Miller FW, Rider LG. HLA-DQA1 is not an apparent risk factor for microchimerism in patients with various autoimmune diseases and in healthy individuals. Arthritis Rheum. 48: 2567-2572 (2003). *
Asherson RA, Cervera R. Unusual manifestations of the antiphospholipid syndrome. Clin. Rev. Allergy Immunol. 25: 61-78 (2003).
Ashrafian H. Hepcidin: the missing link between hemochromatosis and infections. Infect. Immun. 71: 6693-6700 (2003). *
Ashwood P, Anthony A, Pellicer AA, Torrente F, Walker-Smith JA, Wakefield AJ. Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. J. Clin. Immunol. 23: 504-517 (2003). *
Askari FK, Greenson J, Dick RD, Johnson VD, Brewer GJ. Treatment of Wilson's disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J. Lab. Clin. Med. 142: 385-390 (2003). *
Asnani S, Theuma P, Fonseca VA. PPARgamma agonists and vascular risk factors: potential effects on cardiovascular disease. Metab. Syndr. Relat. Disord. 1: 23-32 (2003).
Assaraf YG, Rothem L, Hooijberg JH, Stark M, Ifergan I, Kathmann I, Dijkmans BA, Peters GJ, Jansen G. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. J. Biol. Chem. 278: 6680-6686 (2003). *
Asumalahti K, Ameen M, Suomela S, Hagforsen E, Michaelsson G, Evans J, Munro M, Veal C, Allen M, Leman J, David Burden A, Kirby B, Connolly M, Griffiths CE, Trembath RC, Kere J, Saarialho-Kere U, Barker JN. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J. Invest. Dermatol. 120: 627-632 (2003). *
Asumalahti K, Laitinen T, Lahermo P, Suomela S, Itkonen-Vatjus R, Jansen C, Karvonen J, Karvonen SL, Reunala T, Snellman E, Uurasmaa T, Saarialho-Kere U, Kere J. Psoriasis susceptibility locus on 18p revealed by genome scan in Finnish families not associated with PSORS1. J. Invest. Dermatol. 121: 735-740 (2003). *
Atalay G, Cardoso F, Paesmans M, Goldberg RM, Bleiberg H. Second-line treatment in advanced colon cancer: are multiple phase II trials informative enough to guide clinical practice? Anticancer Drugs 14: 703-713 (2003).
Atarod L, Raissi A, Aghamohammadi A, Farhoudi A, Khodadad A, Moin M, Pourpak Z, Movahedi M, Charagozlou M, Rezaei N. A review of gastrointestinal disorders in patients with primary antibody immunodeficiencies during a 10-year period (1990-2000), in Children's Hospital Medical Center. Iran. J. Allergy Asthma Immunol. 2: 75-79 (2003).
Attwood SE, Lewis CJ, Bronder CS, Morris CD, Armstrong GR, Whittam J. Eosinophilic oesophagitis: a novel treatment using Montelukast. Gut 52: 181-185 (2003). *
Aucan C, Walley AJ, Hennig BJ, Fitness J, Frodsham A, Zhang L, Kwiatkowski D, Hill AV. Interferon-alpha receptor-1 (IFNAR1) variants are associated with protection against cerebral malaria in the Gambia. Genes Immun. 4: 275-282 (2003). *
Auerbach SS, Ramsden R, Stoner MA, Verlinde C, Hassett C, Omiecinski CJ. Alternatively spliced isoforms of the human constitutive androstane receptor. Nucleic Acids Res. 31: 3194-3207 (2003). *
Augarten A, Berman H, Aviram M, Diver-Habber A, Akons H, Ben Tur L, Blau H, Kerem E, Rivlin J, Katznelson D, Szeinberg A, Kerem BS, Theodor L, Paret G, Yahav Y. Serum CA 19-9 levels as a diagnostic marker in cystic fibrosis patients with borderline sweat tests. Clin. Exp. Med. 3: 119-123 (2003). *
Augoustides-Savvopoulou P, Luka Z, Karyda S, Stabler SP, Allen RH, Patsiaoura K, Wagner C, Mudd SH. Glycine N-methyltransferase deficiency: a new patient with a novel mutation. J. Inherit. Metab. Dis. 26: 745-759 (2003). *
Aune TM, Maas K, Moore JH, Olsen NJ. Gene expression profiles in human autoimmune disease. Curr. Pharm. Des. 9: 1905-1917 (2003).
Autran B, Debre P, Walker B, Katlama C. Therapeutic vaccines against HIV need international partnerships. Nat. Rev. Immunol. 3: 503-508 (2003).
Auvin S, Dalle JH, Ganga-Zandzou PS, Ythier H. Is agranulocytosis following infectious mononucleosis caused by autoimmunity? Pediatr. Hematol. Oncol. 20: 611-615 (2003).
Auwerx J, Cock TA, Knouff C. PPAR-gamma: a thrifty transcription factor. Nucl. Recept. Signal. 1: e006 (2003). *
Avenaud P, Le Bail B, Mayo K, Marais A, Fawaz R, Bioulac-Sage P, Megraud F. Natural history of Helicobacter hepaticus infection in conventional A/J mice, with special reference to liver involvement. Infect. Immun. 71: 3667-3672 (2003). *
Awada H, Abi-Karam G, Fayad F. Musculoskeletal and other extrapulmonary disorders in sarcoidosis. Best Pract. Res. Clin. Rheumatol. 17: 971-987 (2003).
Awadallah S, Hamad M. A study of haptoglobin phenotypes in patients with chronic renal failure. Ann. Clin. Biochem. 40: 680-683 (2003).
Ayala de la Cruz Mdel C, Gonzalez Diaz R, Lopez Lara ND. Wegener's granulomatosis. Report of a pediatric case and review of the literature. Rev. Alerg. Mex. 50: 71-75 (2003).
Aydogdu S, Ozgenc F, Yurtsever S, Akman SA, Tokat Y, Yagci RV. Our experience with fulminant hepatic failure in Turkish children: etiology and outcome. J. Trop. Pediatr. 49: 367-370 (2003). *
Azzali G. Structure, lymphatic vascularization and lymphocyte migration in mucosa-associated lymphoid tissue. Immunol. Rev. 195: 178-189 (2003). *
Babior BM, Takeuchi C, Ruedi J, Gutierrez A, Wentworth P Jr. Investigating antibody-catalyzed ozone generation by human neutrophils. Proc. Natl. Acad. Sci. U.S.A. 100: 3031-3034 (2003). *
Babron MC, Nilsson S, Adamovic S, Naluai AT, Wahlstrom J, Ascher H, Ciclitira PJ, Sollid LM, Partanen J, Greco L, Clerget-Darpoux F; European Genetics Cluster on Coeliac Disease. Meta and pooled analysis of European coeliac disease data. Eur. J. Hum. Genet. 11: 828-834 (2003). *
Baburajan B, Parkes M. The genetics of inflammatory bowel disease. Hosp. Med. 64: 599-602 (2003).
Baccarani U, Risaliti A, Sainz-Barriga M, Adani GL, Donini A, Toniutto P, Bresadola F. Ileosplenic fistula and splenic abscesses caused by migration of biliary stents in a liver transplant recipient. Gastrointest. Endosc. 58: 811-813 (2003).
Bach JF. Regulatory T cells under scrutiny. Nat. Rev. Immunol. 3: 189-198 (2003). *
Bach N, Bodian C, Bodenheimer H, Croen E, Berk PD, Thung SN, Lindor KD, Therneau T, Schaffner F. Methotrexate therapy for primary biliary cirrhosis. Am. J. Gastroenterol. 98: 187-193 (2003). *
Bach N, Odin JA. Primary biliary cirrhosis: a Mount Sinai perspective. Mt. Sinai J. Med. 70: 242-250 (2003). *
Bachmeyer C, Charoud A, Turc Y, Callot V, Blum L, Aractingi S. Isotretinoin-induced bilateral sacroiliitis. Dermatology 206: 285-286 (2003).
Badenhoop K, Seidl C. Fine-tuning of T lymphocytes in autoimmunity: genetic association of CTLA-4 variants and Graves' disease revisited. Clin. Endocrinol. (Oxf.) 59: 555-557 (2003). *
Bader TR, Beavers KL, Semelka RC. MR imaging features of primary sclerosing cholangitis: patterns of cirrhosis in relationship to clinical severity of disease. Radiology 226: 675-685 (2003). *
Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348: 601-608 (2003). *
Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc. Natl. Acad. Sci. U.S.A. 100: 1751-1756 (2003). *
Bahillo P, Cantero T, Solis P, Aragon P, Gomez S, Cambronero R. Hyper-IgM syndrome with CHARGE association. Pediatr. Allergy Immunol. 14: 487-489 (2003). *
Bahrami H, Daryani NE, Mirmomen S, Kamangar F, Haghpanah B, Djalili M. Clinical and histological features of nonalcoholic steatohepatitis in Iranian patients. BMC Gastroenterol. 3: 27 (2003). *
Bai J, Odin JA. Apoptosis and the liver: relation to autoimmunity and related conditions. Autoimmun. Rev. 2: 36-42 (2003). *
Bailey LB. Folate, methyl-related nutrients, alcohol, and the MTHFR 677C-->T polymorphism affect cancer risk: intake recommendations. J. Nutr. 133: 3748S-3753S (2003). *
Baiocchi L, Alpini G, Glaser S, Angelico M, Alvaro D, Francis H, Marzioni M, Phinizy JL, Barbaro B, LeSage G. Taurohyodeoxycholate- and tauroursodeoxycholate-induced hypercholeresis is augmented in bile duct ligated rats. J. Hepatol. 38: 136-147 (2003).
Bairead E, Harmon DL, Curtis AM, Kelly Y, O'Leary C, Gardner M, Leahy DT, Vaughan P, Keegan D, O'Morain C, O'Donoghue D, Shanahan F, Parfrey NA, Quane KA. Association of NOD2 with Crohn's disease in a homogenous Irish population. Eur. J. Hum. Genet. 11: 237-244 (2003). *
Baixauli J, Kiran RP, Delaney CP. Investigation and management of ischemic colitis. Cleve. Clin. J. Med. 70: 920-921, 925-926, 928-930 (2003). *
Bak D, Sobczynska-Tomaszewska A, Bal J. Hereditary aspects of pancreatitis. Med. Wieku. Rozwoj. 7: 57-66 (2003).
Bak-Romaniszyn L, Planeta-Malecka I, Czkwianianc E, Rozynek E, Dzierzanowska D, Laszewicz W. Drug sensitivity of Helicobacter pylori strains in children and young people from the region of Lodz. Med. Wieku. Rozwoj. VII: 129-135 (2003).
Baker DE. Pharmacogenomics of azathioprine and 6-mercaptopurine in gastroenterologic therapy. Rev. Gastroenterol. Disord. 3: 150-157 (2003). *
Baker DE. Bioequivalence of azathioprine products. Rev. Gastroenterol. Disord. 3: 219-223 (2003). *
Bakland G, Nordvag BY, Nossent HC. Efficacy of anti-tumour necrosis factor alpha therapy with etanercept in chronic polyarthritis. Tidsskr. Nor. Laegeforen. 123: 2561-2564 (2003).
Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am. J. Gastroenterol. 98: 833-838 (2003). *
Balding J, Healy CM, Livingstone WJ, White B, Mynett-Johnson L, Cafferkey M, Smith OP. Genomic polymorphic profiles in an Irish population with meningococcaemia: is it possible to predict severity and outcome of disease? Genes Immun. 4: 533-540 (2003). *
Balding J, Kane D, Livingstone W, Mynett-Johnson L, Bresnihan B, Smith O, FitzGerald O. Cytokine gene polymorphisms: association with psoriatic arthritis susceptibility and severity. Arthritis Rheum. 48: 1408-1413 (2003). *
Balistreri WF. Genetic liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).
Ballot E, Bruneel A, Labas V, Johanet C. Identification of rat targets of anti-soluble liver antigen autoantibodies by serologic proteome analysis. Clin. Chem. 49: 634-643 (2003). *
Balotescu C, Israil A, Radu R, Alexandru I, Dobre G. Aspects of constitutive and acquired antibioresistance in Aeromonas hydrophila strains isolated from water sources. Roum. Arch. Microbiol. Immunol. 62: 179-189 (2003).
Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, Loftus EV Jr, Yawn BP, Dickson ER, Melton LJ 3rd. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 125: 1364-1369 (2003). *
Bamias G, Martin C 3rd, Marini M, Hoang S, Mishina M, Ross WG, Sachedina MA, Friel CM, Mize J, Bickston SJ, Pizarro TT, Wei P, Cominelli F. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J. Immunol. 171: 4868-4874 (2003). *
Bamias G, Sugawara K, Pagnini C, Cominelli F. The Th1 immune pathway as a therapeutic target in Crohn's disease. Curr. Opin. Investig. Drugs 4: 1279-1286 (2003).
Ban M, Sawcer SJ, Heard RN, Bennetts BH, Adams S, Booth D, Perich V, Setakis E, Compston A, Stewart GJ. A genome-wide screen for linkage disequilibrium in Australian HLA-DRB1*1501 positive multiple sclerosis patients. J. Neuroimmunol. 143: 60-64 (2003).
Ban Y, Davies TF, Greenberg DA, Kissin A, Marder B, Murphy B, Concepcion ES, Villanueva RB, Barbesino G, Ling V, Tomer Y. Analysis of the CTLA-4, CD28, and inducible costimulator (ICOS) genes in autoimmune thyroid disease. Genes Immun. 4: 586-593 (2003). *
Ban Y, Greenberg DA, Concepcion E, Skrabanek L, Villanueva R, Tomer Y. Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease. Proc. Natl. Acad. Sci. U.S.A. 100: 15119-15124 (2003). *
Ban Y, Tomer Y. The contribution of immune regulatory and thyroid specific genes to the etiology of Graves' and Hashimoto's diseases. Autoimmunity 36: 367-379 (2003).
Banares Canizares R, Catalina Rodriguez MV. Indications and therapeutic possibilities of albumin dialysis (MARS). Rev. Esp. Enferm. Dig. 95: 876-889 (2003).
Bancroft LK, Lupton JR, Davidson LA, Taddeo SS, Murphy ME, Carroll RJ, Chapkin RS. Dietary fish oil reduces oxidative DNA damage in rat colonocytes. Free Radic. Biol. Med. 35: 149-159 (2003).
Banerjee B. The light at the end of the tunnel. Inflamm. Bowel Dis. 9: 395 (2003). *
Bangert C, Friedl J, Stary G, Stingl G, Kopp T. Immunopathologic features of allergic contact dermatitis in humans: participation of plasmacytoid dendritic cells in the pathogenesis of the disease? J. Invest. Dermatol. 121: 1409-1418 (2003). *
Banks C, Bateman A, Payne R, Johnson P, Sheron N. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J. Pathol. 199: 28-35 (2003). *
Banyer JL, Halliday DC, Thomson SA, Hamilton NH. Combinations of IFN-gamma and IL-4 induce distinct profiles of dendritic cell-associated immunoregulatory properties. Genes Immun. 4: 427-440 (2003). *
Banz A, Peixoto A, Pontoux C, Cordier C, Rocha B, Papiernik M. A unique subpopulation of CD4+ regulatory T cells controls wasting disease, IL-10 secretion and T cell homeostasis. Eur. J. Immunol. 33: 2419-2428 (2003). *
Bao F, Babu SR, Roberts CM, Martin AK, Gowan K, Eisenbarth GS, Fain PR. Single nucleotide polymorphism study of IDDM 17 in a Bedouin Arab family. Ann. N. Y. Acad. Sci. 1005: 348-351 (2003). *
Bar-Oz B, Bulkowstein M, Benyamini L, Greenberg R, Soriano I, Zimmerman D, Bortnik O, Berkovitch M. Use of antibiotic and analgesic drugs during lactation. Drug Saf. 26: 925-935 (2003).
Barak AJ, Beckenhauer HC, Mailliard ME, Kharbanda KK, Tuma DJ. Betaine lowers elevated S-adenosylhomocysteine levels in hepatocytes from ethanol-fed rats. J. Nutr. 133: 2845-2848 (2003). *
Barbier M, Vidal H, Desreumaux P, Dubuquoy L, Bourreille A, Colombel JF, Cherbut C, Galmiche JP. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol. Clin. Biol. 27: 987-991 (2003). *
Barbier O, Duran-Sandoval D, Pineda-Torra I, Kosykh V, Fruchart JC, Staels B. Peroxisome proliferator-activated receptor alpha induces hepatic expression of the human bile acid glucuronidating UDP-glucuronosyltransferase 2B4 enzyme. J. Biol. Chem. 278: 32852-32860 (2003). *
Barbier O, Torra IP, Sirvent A, Claudel T, Blanquart C, Duran-Sandoval D, Kuipers F, Kosykh V, Fruchart JC, Staels B. FXR induces the UGT2B4 enzyme in hepatocytes: a potential mechanism of negative feedback control of FXR activity. Gastroenterology 124: 1926-1940 (2003). *
Barbier O, Villeneuve L, Bocher V, Fontaine C, Torra IP, Duhem C, Kosykh V, Fruchart JC, Guillemette C, Staels B. The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J. Biol. Chem. 278: 13975-13983 (2003). *
Barbosa DS, Cecchini R, El Kadri MZ, Rodriguez MA, Burini RC, Dichi I. Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids. Nutrition 19: 837-842 (2003). *
Barbuscia M, Pratico C, Di Pietro N, Rizzo AG, Melita G, De Luca M, Castriciano G, Vita F, Sano M, Gorgone S. Diagnosis and treatment of Crohn's disease. G. Chir. 24: 428-434 (2003).
Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E, Goodin DS, Pelletier D, Lincoln RR, Bucher P, Swerdlin A, Pericak-Vance MA, Haines JL, Hauser SL; Multiple Sclerosis Genetics Group. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am. J. Hum. Genet. 72: 710-716 (2003). *
Barcelo-Coblijn G, Kitajka K, Puskas LG, Hogyes E, Zvara A, Hackler L Jr, Farkas T. Gene expression and molecular composition of phospholipids in rat brain in relation to dietary n-6 to n-3 fatty acid ratio. Biochim. Biophys. Acta 1632: 72-79 (2003). *
Bardaro T, Falco G, Sparago A, Mercadante V, Gean Molins E, Tarantino E, Ursini MV, D'Urso M. Two cases of misinterpretation of molecular results in incontinentia pigmenti, and a PCR-based method to discriminate NEMO/IKKgamma dene deletion. Hum. Mutat. 21: 8-11 (2003).
Barnes BJ, Field AE, Pitha-Rowe PM. Virus-induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes. J. Biol. Chem. 278: 16630-16641 (2003). *
Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res. 63: 6424-6431 (2003). *
Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348: 891-899 (2003). *
Barone M, Maiorano E, Ladisa R, Cuomo R, Pece A, Berloco P, Caruso ML, Valentini AM, Iolascon A, Francavilla A, Di Leo A, Ierardi E. Influence of ursodeoxycholate-enriched diet on liver tumor growth in HBV transgenic mice. Hepatology 37: 880-886 (2003). *
Barrison AF, Smith C, Oviedo J, Heeren T, Schroy PC 3rd. Colorectal cancer screening and familial risk: a survey of internal medicine residents' knowledge and practice patterns. Am. J. Gastroenterol. 98: 1410-1416 (2003). *
Barta Z, Csipo I, Szabo GG, Szegedi G. Seroreactivity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease. World J. Gastroenterol. 9: 2308-2312 (2003). *
Bartfai Z, Gaede KI, Russell KA, Murakozy G, Muller-Quernheim J, Specks U. Different gender-associated genotype risks of Wegener's granulomatosis and microscopic polyangiitis. Clin. Immunol. 109: 330-337 (2003). *
Barthet M, Dubucquoy L, Garcia S, Gasmi M, Desreumaux P, Colombel JF, Grimaud JC, Iovanna J, Dagorn JC. Pancreatic changes in TNBS-induced colitis in mice. Gastroenterol. Clin. Biol. 27: 895-900 (2003). *
Bartnik W. Inflammatory bowel disease - Polish contribution. J. Physiol. Pharmacol. 54 Suppl. 3: 205-210 (2003). *
Barton A, Lamb R, Symmons D, Silman A, Thomson W, Worthington J, Donn R. Macrophage migration inhibitory factor (MIF) gene polymorphism is associated with susceptibility to but not severity of inflammatory polyarthritis. Genes Immun. 4: 487-491 (2003). *
Barton SG, Rampton DS, Winrow VR, Domizio P, Feakins RM. Expression of heat shock protein 32 (hemoxygenase-1) in the normal and inflamed human stomach and colon: an immunohistochemical study. Cell Stress Chaperones 8: 329-334 (2003). *
Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment. Pharmacol. Ther. 18: 1121-1127 (2003). *
Bartunkova J, Tesar V, Sediva A. Diagnostic and pathogenetic role of antineutrophil cytoplasmic autoantibodies. Clin. Immunol. 106: 73-82 (2003). *
Barutca S, Kadikoylu G, Meydan N, Bolaman Z, Gokcen A, Bal F. Two autoimmune diseases: Hashimoto's thyroiditis and vitiligo accompanying breast cancer; a coincidence? J. BUON 8: 177-179 (2003).
Bason C, Corrocher R, Lunardi C, Puccetti P, Olivieri O, Girelli D, Navone R, Beri R, Millo E, Margonato A, Martinelli N, Puccetti A. Interaction of antibodies against cytomegalovirus with heat-shock protein 60 in pathogenesis of atherosclerosis. Lancet 362: 1971-1977 (2003). *
Bassas A, Chehab M, Hebby H, Al Shahed M, Al Husseini H, Al Zahrani A, Wali S. Living related liver transplantation in 13 cases of progressive familial intrahepatic cholestasis. Transplant. Proc. 35: 3003-3005 (2003). *
Bataller R, North KE, Brenner DA. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 37: 493-503 (2003). *
Bathon JM, Genovese MC. The Early Rheumatoid Arthritis (ERA) trial comparing the efficacy and safety of etanercept and methotrexate. Clin. Exp. Rheumatol. 21 (5 Suppl. 31): S195-S197 (2003).
Batra AK, Levey JM, Trister J, Patwardhan R. Pyoderma gangrenosum in a patient with collagenous colitis. J. Am. Acad. Dermatol. 49: 277-279 (2003).
Batra Y, Acharya SK. Acute liver failure: prognostic markers. Indian J. Gastroenterol. 22 Suppl. 2: S66-S68 (2003).
Battelino T, Ursic-Bratina N, Dolzan V, Stopar-Obreza M, Pozzilli P, Krzisnik C, Vidan-Jeras B. The HLA-DRB, -DQB polymorphism and anti-insulin antibody response in Slovenian patients with type 1 diabetes. Eur. J. Immunogenet. 30: 223-227 (2003). *
Baughman RP, Iannuzzi M. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs 17: 425-431 (2003).
Baughman RP, Koehler A, Bejarano PA, Lower EE, Weber FL Jr. Role of liver function tests in detecting methotrexate-induced liver damage in sarcoidosis. Arch. Intern. Med. 163: 615-620 (2003). *
Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 361: 1111-1118 (2003). *
Baumann U, Schmidt RE, Gessner JE. New insights into the pathophysiology and in vivo function of IgG Fc receptors through gene deletion studies. Arch. Immunol. Ther. Exp. (Warsz.) 51: 399-406 (2003).
Baumert TF. Novel vaccine strategies. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 58-59. October 20 - 21 (2003). *
Baumgart DC, Dignass AU. Tacrolimus (FK506) in refractory ulcerative colitis: an alternative to proctocolectomy? Z. Gastroenterol. 41: 478-479 (2003).
Baumgart DC, Wiedenmann B, Dignass AU. Biologic therapy of inflammatory bowel disease. Z. Gastroenterol. 41: 1017-1032 (2003).
Bayat A, Stanley JK, Watson JS, Ferguson MW, Ollier WE. Genetic susceptibility to Dupuytren's disease: transforming growth factor beta receptor (TGFbetaR) gene polymorphisms and Dupuytren's disease. Br. J. Plast. Surg. 56: 328-333 (2003).
Bayat A, Watson JS, Stanley JK, Ferguson MW, Ollier WE. Genetic susceptibility to Dupuytren disease: association of Zf9 transcription factor gene. Plast. Reconstr. Surg. 111: 2133-2139 (2003).
Bayle FJ, Bouvard MP. Anorexia nervosa and Crohn's disease dual diagnosis: a case study. Eur. Psychiatry 18: 421-422 (2003).
Bayley JP, Baggen JM, van der Pouw-Kraan T, Crusius JB, Huizinga TW, Verweij CL. Association between polymorphisms in the human chemokine receptor genes CCR2 and CX3CR1 and rheumatoid arthritis. Tissue Antigens 62: 170-174 (2003). *
Bayley JP, Bakker AM, Kaijzel EL, Huizinga TW, Verweij CL. Association of polymorphisms of the tumour necrosis factor receptors I and II and rheumatoid arthritis. Rheumatology (Oxford) 42: 969-971 (2003). *
Beamer LJ. Structure of human BPI (bactericidal/permeability-increasing protein) and implications for related proteins. Biochem. Soc. Trans. 31: 791-794 (2003). *
Beath SV. Hepatic function and physiology in the newborn. Semin. Neonatol. 8: 337-346 (2003).
Beckebaum S, Cicinnati V, Broelsch CE. Liver transplantation, rejection and disease recurrence. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 55-56. October 15-16 (2003). *
Becker A, Smulders YM, van Guldener C, Stehouwer CD. Epidemiology of homocysteine as a risk factor in diabetes. Metab. Syndr. Relat. Disord. 1: 105-120 (2003).
Becker C, Wirtz S, Blessing M, Pirhonen J, Strand D, Bechthold O, Frick J, Galle PR, Autenrieth I, Neurath MF. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J. Clin. Invest. 112: 693-706 (2003). *
Bednarczuk T, Hiromatsu Y, Fukutani T, Jazdzewski K, Miskiewicz P, Osikowska M, Nauman J. Association of cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) gene polymorphism and non-genetic factors with Graves' ophthalmopathy in European and Japanese populations. Eur. J. Endocrinol. 148: 13-18 (2003). *
Bednarczuk T, Placha G, Jazdzewski K, Kurylowicz A, Kloza M, Makowska U, Hiromatsu Y, Nauman J. Interleukin-13 gene polymorphisms in patients with Graves' disease. Clin. Endocrinol. (Oxf.) 59: 519-525 (2003). *
Beehler BC, Hei YJ, Chen S, Lupisella JA, Ostrowski J, Starrett JE, Tortolani D, Tramposch KM, Reczek PR. Inhibition of disease progression by a novel retinoid antagonist in animal models of arthritis. J. Rheumatol. 30: 355-363 (2003).
Befeler AS. New developments in hepatocellular carcinoma. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).
Beghe B, Barton S, Rorke S, Peng Q, Sayers I, Gaunt T, Keith TP, Clough JB, Holgate ST, Holloway JW. Polymorphisms in the interleukin-4 and interleukin-4 receptor alpha chain genes confer susceptibility to asthma and atopy in a Caucasian population. Clin. Exp. Allergy 33: 1111-1117 (2003). *
Beglinger Ch. Treatment of Crohn's disease. Ther. Umsch. 60: 159-163 (2003).
Beil WJ, McEuen AR, Schulz M, Wefelmeyer U, Kraml G, Walls AF, Jensen-Jarolim E, Pabst R, Pammer J. Selective alterations in mast cell subsets and eosinophil infiltration in two complementary types of intestinal inflammation: ascariasis and Crohn's disease. Pathobiology 70: 303-313 (2003).
Bejaoui M, Mellouli F, Chouanine R, Dellagi K, Barbouche MR. The hyper-IgM syndrome: 13 observations. Presse. Med. 32: 544-549 (2003).
Belaiche J, Louis E. Early obstructive colon after treatment of active refractory Crohn's disease with infliximab. Gastroenterol. Clin. Biol. 27: 1045 (2003).
Bell SJ, Chisholm SA, Owen RJ, Borriello SP, Kamm MA. Evaluation of Helicobacter species in inflammatory bowel disease. Aliment. Pharmacol. Ther. 18: 481-486 (2003). *
Bellamy R. Susceptibility to mycobacterial infections: the importance of host genetics. Genes Immun. 4: 4-11 (2003). *
Bellanti JA, Zeligs BJ, Malka-Rais J, Sabra A. Abnormalities of Th1 function in non-IgE food allergy, celiac disease, and ileal lymphonodular hyperplasia: a new relationship? Ann. Allergy Asthma Immunol. 90: 84-89 (2003).
Beltowski J, Wojcicka G, Jamroz A. Peroxisome proliferator-activated receptors (PPAR) in pathophysiology of the circulatory system and prospective use of agonists of these receptors in therapy. Postepy. Hig. Med. Dosw. 57: 199-217 (2003).
Ben-Ari Z, Schmilovotz-Weiss H, Belinki A, Pappo O, Sulkes J, Neuman MG, Kaganovsky E, Kfir B, Tur-Kaspa R, Klein T. Circulating soluble cytochrome c in liver disease as a marker of apoptosis. J. Intern. Med. 254: 168-175 (2003). *
Benahmed M, Mention JJ, Matysiak-Budnik T, Cerf-Bensussan N. Celiac disease: a future without gluten-free diet?? Gastroenterology 125: 1264-1267 (2003). *
Bencsath M, Blaskovits A, Borvendeg J. Biomolecular cytokine therapy. Pathol. Oncol. Res. 9: 24-29 (2003). *
Bender IB. Paget's disease. J. Endod. 29: 720-723 (2003).
Benharouga M, Sharma M, So J, Haardt M, Drzymala L, Popov M, Schwapach B, Grinstein S, Du K, Lukacs GL. The role of the C terminus and Na+/H+ exchanger regulatory factor in the functional expression of cystic fibrosis transmembrane conductance regulator in nonpolarized cells and epithelia. J. Biol. Chem. 278: 22079-22089 (2003). *
Beniwal RS, Arena VC, Thomas L, Narla S, Imperiale TF, Chaudhry RA, Ahmad UA. A randomized trial of yogurt for prevention of antibiotic-associated diarrhea. Dig. Dis. Sci. 48: 2077-2082 (2003). *
Benjaminov FS, Prentice M, Sniderman KW, Siu S, Liu P, Wong F. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 52: 1355-1362 (2003). *
Bentinger M, Turunen M, Zhang XX, Wan YJ, Dallner G. Involvement of retinoid X receptor alpha in coenzyme Q metabolism. J. Mol. Biol. 326: 795-803 (2003). *
Bentrem DJ, Joehl RJ. Pancreas: healing response in critical illness. Crit. Care Med. 31: S582-S589 (2003).
Beranek H, Teich N, Witt H, Schulz HU, Mossner J, Keim V. Analysis of tumour necrosis factor alpha and interleukin 10 promotor variants in patients with chronic pancreatitis. Eur. J. Gastroenterol. Hepatol. 15: 1223-1227 (2003).
Bergasa NV. Pruritus and fatigue in primary biliary cirrhosis. Clin. Liver Dis. 7: 879-900 (2003).
Bergasa NV. Management of complications of cholestasis: pruritus, fatigue and bone disease. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 54. October 15-16 (2003). *
Bergasa NV. Studying pruritus in the 21st century. Clin. Gastroenterol. Hepatol. 1: 249-251 (2003). *
Berger J, Kowdley KV. Is silymarin hepatoprotective in alcoholic liver disease? J. Clin. Gastroenterol. 37: 278-279 (2003).
Bergquist A. Tumor markers and genetic markers in the diagnosis of bile duct carcinoma. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 91. October 15-16 (2003). *
Bernal W. Changing patterns of causation and the use of transplantation in the United Kingdom. Semin. Liver Dis. 23: 227-237 (2003).
Bernard D, Christophe A, Delanghe J, Langlois M, De Buyzere M, Comhaire F. The effect of supplementation with an antioxidant preparation on LDL-oxidation is determined by haptoglobin polymorphism. Redox Rep. 8: 41-46 (2003).
Bernardino AL, Guarita DR, Mott CB, Pedroso MR, Machado MC, Laudanna AA, Tani CM, Almeida FL, Zatz M. CFTR, PRSS1 and SPINK1 mutations in the development of pancreatitis in Brazilian patients. JOP 4: 169-177 (2003). *
Bernstein CL, Stiffler HL, Jowell PS, Branch MS, Baillie J. Classifying low-grade dysplasia (LGD) as "negative" for malignancy increases the specificity but not the sensitivity of biliary brush cytology in primary sclerosing cholangitis (PSC). Gastrointest. Endosc. 57: AB198 (2003).
Bernstein CN, Bector S, Leslie WD. Lack of relationship of calcium and vitamin D intake to bone mineral density in premenopausal women with inflammatory bowel disease. Am. J. Gastroenterol. 98: 2468-2473 (2003). *
Bernstein CN, Blanchard JF, Metge C, Yogendran M. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am. J. Gastroenterol. 98: 2784-2788 (2003). *
Bernstein CN, Leslie WD. The pathophysiology of bone disease in gastrointestinal disease. Eur. J. Gastroenterol. Hepatol. 15: 857-864 (2003).
Bernstein CN, Nayar G, Hamel A, Blanchard JF. Study of animal-borne infections in the mucosas of patients with inflammatory bowel disease and population-based controls. J. Clin. Microbiol. 41: 4986-4990 (2003). *
Bernuau J. Hepatic complications of pregnancy. Rev. Prat. 53: 1889-1893 (2003).
Berrebi D, Maudinas R, Hugot JP, Chamaillard M, Chareyre F, De Lagausie P, Yang C, Desreumaux P, Giovannini M, Cezard JP, Zouali H, Emilie D, Peuchmaur M. Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon. Gut 52: 840-846 (2003). *
Berstad P, Seljeflot I, Veierod MB, Hjerkinn EM, Arnesen H, Pedersen JI. Supplementation with fish oil affects the association between very long-chain n-3 polyunsaturated fatty acids in serum non-esterified fatty acids and soluble vascular cell adhesion molecule-1. Clin. Sci. (Lond.) 105: 13-20 (2003). *
Berthiaume F, MacDonald AD, Kang YH, Yarmush ML. Control analysis of mitochondrial metabolism in intact hepatocytes: effect of interleukin-1beta and interleukin-6. Metab. Eng. 5: 108-123 (2003). *
Bertolotti M, Zambianchi L, Carulli L, Simonini MS, Del Puppo M, Kienle MG, Loria P, Pinetti A, Carulli N. Influence of newly synthesized cholesterol on bile acid synthesis during chronic inhibition of bile acid absorption. Hepatology 38: 939-946 (2003). *
Betterle C, Zanchetta R. Update on autoimmune polyendocrine syndromes (APS). Acta Biomed. Ateneo. Parmense. 74: 9-33 (2003).
Bettinardi N, Felicetta I, Tomasi PA, Colombo C. Carbohydrate 19-9 antigen is not a marker of liver disease in patients with cystic fibrosis. Clin. Chem. Lab. Med. 41: 311-316 (2003).
Bettoun DJ, Burris TP, Houck KA, Buck DW 2nd, Stayrook KR, Khalifa B, Lu J, Chin WW, Nagpal S. Retinoid X receptor is a nonsilent major contributor to vitamin D receptor-mediated transcriptional activation. Mol. Endocrinol. 17: 2320-2328 (2003). *
Beuers U. Mechanisms of action of ursodeoxycholic acid in cholestasis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 49-50. October 15-16 (2003). *
Beuers U, Denk GU, Soroka CJ, Wimmer R, Rust C, Paumgartner G, Boyer JL. Taurolithocholic acid exerts cholestatic effects via phosphatidylinositol 3-kinase-dependent mechanisms in perfused rat livers and rat hepatocyte couplets. J. Biol. Chem. 278: 17810-17818 (2003). *
Beumer C, Wulferink M, Raaben W, Fiechter D, Brands R, Seinen W. Calf intestinal alkaline phosphatase, a novel therapeutic drug for lipopolysaccharide (LPS)-mediated diseases, attenuates LPS toxicity in mice and piglets. J. Pharmacol. Exp. Ther. 307: 737-744 (2003). *
Beutler B. Science review: key inflammatory and stress pathways in critical illness - the central role of the Toll-like receptors. Crit. Care 7: 39-46 (2003). *
Beutler B. Innate immune responses to microbial poisons: discovery and function of the Toll-like receptors. Annu. Rev. Pharmacol. Toxicol. 43: 609-628 (2003). *
Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat. Rev. Immunol. 3: 169-176 (2003). *
Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology (Am. Soc. Hematol. Educ. Program) 2003: 40-61 (2003). *
Bevins CL. The role of gut flora and innate immunity in pathogenesis of inflammatory bowel disease. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 58. September 12 - 13 (2003). *
Beyan H, Buckley LR, Yousaf N, Londei M, Leslie RD. A role for innate immunity in type 1 diabetes? Diabetes Metab. Res. Rev. 19: 89-100 (2003).
Beytout J, Tournilhac O, Laurichesse H. Asplenia and hyposplenism. Presse. Med. 32: S5-S9 (2003).
Beyzade S, Zhang S, Wong YK, Day IN, Eriksson P, Ye S. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J. Am. Coll. Cardiol. 41: 2130-2137 (2003). *
Bhatnagar A, Wig JD, Majumdar S. Immunological findings in acute and chronic pancreatitis. ANZ J. Surg. 73: 59-64 (2003). *
Bhattacharya R, Kowdley KV. Iron and HFE mutations in nonalcoholic steatohepatitis: innocent bystanders or accessories to the crime? Gastroenterology 125: 615-616 (2003). *
Bi L, Triadafilopoulos G. Exercise and gastrointestinal function and disease: an evidence-based review of risks and benefits. Clin. Gastroenterol. Hepatol. 1: 345-355 (2003). *
Bi LC, Kaunitz JD. Gastroduodenal mucosal defense: an integrated protective response. Curr. Opin. Gastroenterol. 19: 526-532 (2003).
Biancone L, Fiori R, Tosti C, Marinetti A, Catarinacci M, De Nigris F, Simonetti G, Pallone F. Virtual colonoscopy compared with conventional colonoscopy for stricturing postoperative recurrence in Crohn's disease. Inflamm. Bowel Dis. 9: 343-350 (2003). *
Biancone L, Palmieri G, Lombardi A, Colantoni A, Tonelli F, Das KM, Pallone F. Tropomyosin expression in the ileal pouch: a relationship with the development of pouchitis in ulcerative colitis. Am. J. Gastroenterol. 98: 2719-2726 (2003). *
Biancone L, Tosti C, Fina D, Fantini M, De Nigris F, Geremia A, Pallone F. Review article: maintenance treatment of Crohn's disease. Aliment. Pharmacol. Ther. 17 Suppl. 2: 31-37 (2003).
Biasiotto G, Belloli S, Ruggeri G, Zanella I, Gerardi G, Corrado M, Gobbi E, Albertini A, Arosio P. Identification of new mutations of the HFE, hepcidin, and transferrin receptor 2 genes by denaturing HPLC analysis of individuals with biochemical indications of iron overload. Clin. Chem. 49: 1981-1988 (2003). *
Bickston SJ. Keeping the M in mind: recombinant human GMCSF and Crohn's disease. Inflamm. Bowel Dis. 9: 132 (2003). *
Bickston SJ, Comerford LW, Cominelli F. Future therapies for inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 518-523 (2003).
Bickston SJ, Cominelli F. Optimal dosing of 5-aminosalicylic acid: 5 decades of choosing between politicians. Clin. Gastroenterol. Hepatol. 1: 3-4 (2003). *
Biecker E, Stieger M, Zimmermann A, Reichen J. Autoimmune hepatitis, cryoglobulinaemia and untreated coeliac disease: a case report. Eur. J. Gastroenterol. Hepatol. 15: 423-427 (2003).
Bienvenu T. Cystic fibrosis: relationship between genotype and phenotype. Arch. Pediatr. 10 Suppl. 2: 318s-324s (2003).
Bihl F, Salez L, Beaubier M, Torres D, Lariviere L, Laroche L, Benedetto A, Martel D, Lapointe JM, Ryffel B, Malo D. Overexpression of Toll-like receptor 4 amplifies the host response to lipopolysaccharide and provides a survival advantage in transgenic mice. J. Immunol. 170: 6141-6150 (2003). *
Bilbao I, Armadans L, Lazaro JL, Hidalgo E, Castells L, Margarit C. Predictive factors for early mortality following liver transplantation. Clin. Transplant. 17: 401-411 (2003). *
Bilbao JR, Martin-Pagola A, Perez De Nanclares G, Calvo B, Vitoria JC, Vazquez F, Castano L. HLA-DRB1 and MICA in autoimmunity: common associated alleles in autoimmune disorders. Ann. N. Y. Acad. Sci. 1005: 314-318 (2003). *
Bishop-Bailey D, Wray J. Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediat. 71: 1-22 (2003).
Bismuth M, Aguilar-Martinez P, Michel H. Hereditary haemochromatosis. Presse. Med. 32: 1716-1723 (2003).
Bistrian BR. Clinical aspects of essential fatty acid metabolism: Jonathan Rhoads Lecture. JPEN J. Parenter. Enteral Nutr. 27: 168-175 (2003). *
Biswas P, Mantelli B, Hasson H, Vecchi A, Saniabadi A, Lazzarin A, Beretta A. In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: implications for treatment of HIV infection and other immune disorders. Clin. Immunol. 109: 355-358 (2003). *
Bittencourt PL, Palacios SA, Cancado EL, Porta G, Carrilho FJ, Laudanna AA, Kalil J, Goldberg AC. Cytotoxic T lymphocyte antigen-4 gene polymorphisms do not confer susceptibility to autoimmune hepatitis types 1 and 2 in Brazil. Am. J. Gastroenterol. 98: 1616-1620 (2003). *
Bittencourt PL, Palacios SA, Farias AQ, Abrantes-Lemos CP, Cancado EL, Carrilho FJ, Laudanna AA, Kalil J, Goldberg AC. Analysis of major histocompatibility complex and CTLA-4 alleles in Brazilian patients with primary biliary cirrhosis. J. Gastroenterol. Hepatol. 18: 1061-1066 (2003). *
Bitton A, Sewitch MJ, Peppercorn MA, deB Edwardes MD, Shah S, Ransil B, Locke SE. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am. J. Gastroenterol. 98: 2203-2208 (2003). *
Bizzaro N, Villalta D, Tonutti E, Doria A, Tampoia M, Bassetti D, Tozzoli R. IgA and IgG tissue transglutaminase antibody prevalence and clinical significance in connective tissue diseases, inflammatory bowel disease, and primary biliary cirrhosis. Dig. Dis. Sci. 48: 2360-2365 (2003). *
Bizzaro N, Villalta D, Tonutti E, Tampoia M, Bassetti D, Tozzoli R. Association of celiac disease with connective tissue diseases and autoimmune diseases of the digestive tract. Autoimmun. Rev. 2: 358-363 (2003).
Bjarnason I, Helgason KO, Geirsson AJ, Sigthorsson G, Reynisdottir I, Gudbjartsson D, Einarsdottir AS, Sherwood R, Kristjansson K, Kjartansson O, Thjodleifsson B. Subclinical intestinal inflammation and sacroiliac changes in relatives of patients with ankylosing spondylitis. Gastroenterology 125: 1598-1605 (2003). *
Bjornsson E, Chapman RW. Sclerosing cholangitis. Curr. Opin. Gastroenterol. 19: 270-275 (2003).
Black M. Drug hepatotoxicity. Clin. Liver Dis. 7: xi-xii (2003). *
Blackwell JM, Searle S, Mohamed H, White JK. Divalent cation transport and susceptibility to infectious and autoimmune disease: continuation of the Ity/Lsh/Bcg/Nramp1/Slc11a1 gene story. Immunol. Lett. 85: 197-203 (2003).
Blakelock RT, Beasley SW. Infection and the gut. Semin. Pediatr. Surg. 12: 265-274 (2003).
Blanc P, Phelip JM, Bertolino JG, Atger J, Roblin X. Watermelon stomach: a rare cause of iron deficiency anemia, surgically treatable; a new case with review of the literature. Ann. Chir. 128: 462-464 (2003).
Blanchet E, Beau P. Efficacy of hydrostatic balloon dilatation of anastomotic Crohn's disease strictures. Gastroenterol. Clin. Biol. 27: 1105-1109 (2003).
Blanquart C, Barbier O, Fruchart JC, Staels B, Glineur C. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J. Steroid Biochem. Mol. Biol. 85: 267-273 (2003).
Blau H, Livne M, Mussaffi H. Cystic fibrosis in adults: a changing scene. Isr. Med. Assoc. J. 5: 491-495 (2003). *
Bliss SK, Alcaraz A, Appleton JA. IL-10 prevents liver necrosis during murine infection with Trichinella spiralis. J. Immunol. 171: 3142-3147 (2003). *
Bloomfeld RS, Onken JE. Mercaptopurine metabolite results in clinical gastroenterology practice. Aliment. Pharmacol. Ther. 17: 69-73 (2003). *
Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat. Rev. Immunol. 3: 253-257 (2003). *
Blum S, Schiffrin EJ. Intestinal microflora and homeostasis of the mucosal immune response: implications for probiotic bacteria? Curr. Issues Intest. Microbiol. 4: 53-60 (2003).
Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, Tugwell P, Wells G. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. 4: CD004525 (2003). *
Boberg KM, Egeland T, Schrumpf E. Long-term effect of corticosteroid treatment in primary sclerosing cholangitis patients. Scand. J. Gastroenterol. 38: 991-995 (2003). *
Boberg KM, Jebsen P, Clausen OP, Aabakken L, Brekke I, Schrumpf E. Cholangiocarcinoma in situ in primary sclerosing cholangitis: diagnosis by brush cytology and treatment by liver transplantation. J. Hepatol. 39: 453 (2003). *
Boberg KM, Schrumpf E. Diagnosis and differential diagnosis of primary sclerosing cholangitis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 59-60. October 15-16 (2003). *
Bochud PY, Hawn TR, Aderem A. Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. J. Immunol. 170: 3451-3454 (2003). *
Bocker U, Nebe T, Herweck F, Holt L, Panja A, Jobin C, Rossol S, B Sartor R, Singer MV. Butyrate modulates intestinal epithelial cell-mediated neutrophil migration. Clin. Exp. Immunol. 131: 53-60 (2003). *
Bocko D, Bilinska M, Dobosz T, Zoledziewska M, Suwalska K, Tutak A, Gruszka E, Frydecka I. Lack of association between an exon 1 CTLA-4 gene polymorphism A(49)G and multiple sclerosis in a Polish population of the Lower Silesia region. Arch. Immunol. Ther. Exp. (Warsz.) 51: 201-205 (2003).
Boden E, Tang Q, Bour-Jordan H, Bluestone JA. The role of CD28 and CTLA4 in the function and homeostasis of CD4+CD25+ regulatory T cells. Novartis Found. Symp. 252: 55-63 (2003).
Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B. Differential modulation of the human liver conjugate transporters MRP2 and MRP3 by bile acids and organic anions. J. Biol. Chem. 278: 23529-23537 (2003). *
Boedeker EC. Gastrointestinal infections. Curr. Opin. Gastroenterol. 19: 1-3 (2003).
Boehncke WH. Immunomodulatory drugs for psoriasis. BMJ 327: 634-635 (2003). *
Bogdanos DP, Baum H, Butler P, Rigopoulou EI, Davies ET, Ma Y, Burroughs AK, Vergani D. Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection. Dig. Liver Dis. 35: 801-805 (2003).
Bogdanos DP, Baum H, Vergani D. Antimitochondrial and other autoantibodies. Clin. Liver Dis. 7: 759-777, vi (2003).
Bohan A, Chen WS, Denson LA, Held MA, Boyer JL. Tumor necrosis factor alpha-dependent up-regulation of Lrh-1 and Mrp3(Abcc3) reduces liver injury in obstructive cholestasis. J. Biol. Chem. 278: 36688-36698 (2003). *
Boitier E, Gautier JC, Roberts R. Advances in understanding the regulation of apoptosis and mitosis by peroxisome-proliferator activated receptors in pre-clinical models: relevance for human health and disease. Comp. Hepatol. 2: 3 (2003). *
Boixeda D, Martin De Argila C, Bermejo F, Lopez Sanroman A, Hernandez Ranz F, Garcia Plaza A. Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy. Factors that influence Helicobacter pylori eradications success. Rev. Esp. Enferm. Dig. 95: 206-209 (2003).
Bokarewa MI, Jin T, Tarkowski A. Intraarticular release and accumulation of defensins and bactericidal/permeability-increasing protein in patients with rheumatoid arthritis. J. Rheumatol. 30: 1719-1724 (2003).
Bokszczanin A, Levinson AI. Coexistent yellow nail syndrome and selective antibody deficiency. Ann. Allergy Asthma Immunol. 91: 496-500 (2003).
Bolognesi E, Karell K, Percopo S, Coto I, Greco L, Mantovani V, Suoraniemi E, Partanen J, Mustalahti K, Maki M, Momigliano-Richiardi P. Additional factor in some HLA DR3/DQ2 haplotypes confers a fourfold increased genetic risk of celiac disease. Tissue Antigens 61: 308-316 (2003). *
Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J. Hepatol. 39: 1076-1084 (2003). *
Bombieri C, Belpinati F, Pignatti PF, Luisetti M. Comment on 'CFTR gene mutations in sarcoidosis'. Eur. J. Hum. Genet. 11: 553-554 (2003). *
Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A, Bianchi ME. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J. 22: 5551-5560 (2003). *
Bonaz B, Boitard J, Marteau P, Lemann M, Coffin B, Flourie B, Belaiche J, Cadiot G, Metman EH, Cortot A, Colombel JF; Getaid. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment. Pharmacol. Ther. 18: 401-408 (2003). *
Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 124: 521-536 (2003). *
Bonen DK, Ogura Y, Nicolae DL, Inohara N, Saab L, Tanabe T, Chen FF, Foster SJ, Duerr RH, Brant SR, Cho JH, Nunez G. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 124: 140-146 (2003). *
Bonet ML, Ribot J, Felipe F, Palou A. Vitamin A and the regulation of fat reserves. Cell. Mol. Life Sci. 60: 1311-1321 (2003).
Boniotto M, Braida L, Ventura A, Percopo S, Amoroso A, Crovella S. Promoter polymorphisms of the CD14 gene in Italian patients with coeliac disease. J. Med. Genet. 40: e108 (2003). *
Boniotto M, Radillo O, Braida L, Pirulli D, Citta A, Not T, Amoroso A, Crovella S. Detection of MBL-2 gene expression in intestinal biopsies of celiac patients by in situ reverse transcription polymerase chain reaction. Eur. J. Histochem. 47: 177-180 (2003).
Boniotto M, Tossi A, DelPero M, Sgubin S, Antcheva N, Santon D, Masters J, Crovella S. Evolution of the beta defensin 2 gene in primates. Genes Immun. 4: 251-257 (2003). *
Boone DL, Ma A. Connecting the dots from Toll-like receptors to innate immune cells and inflammatory bowel disease. J. Clin. Invest. 111: 1284-1286 (2003). *
Borchers AT, Keen CL, Gershwin ME. Use and misuse of corticosteroids. Compr. Ther. 29: 157-165 (2003).
Borchers AT, Naguwa SM, Keen CL, Gershwin ME. Immunopathogenesis of Sjogren's syndrome. Clin. Rev. Allergy Immunol. 25: 89-104 (2003).
Borchers AT, So C, Naguwa SM, Keen CL, Gershwin ME. Clinical and immunologic components of sarcoidosis. Clin. Rev. Allergy Immunol. 25: 289-303 (2003).
Borda F, Oquinena S, Borobio E, Vila J, Frauca A, Martinez B. Is pre-operative treatment with ursodeoxycholic acid useful in reducing relapses in acute biliary pancreatitis? An. Sist. Sanit. Navar. 26: 225-229 (2003).
Borges-Walmsley MI, McKeegan KS, Walmsley AR. Structure and function of efflux pumps that confer resistance to drugs. Biochem. J. 376: 313-338 (2003). *
Borini P, Guimaraes RC. Noninvasive classification of liver disease in asymptomatic and oligosymptomatic male alcoholics. Braz. J. Med. Biol. Res. 36: 1367-1373 (2003). *
Bosch J. Invasive imaging. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 40. October 17 - 19 (2003). *
Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J. Hepatol. 38 Suppl. 1: S54-S68 (2003). *
Bosco P, Gueant-Rodriguez RM, Anello G, Barone C, Namour F, Caraci F, Romano A, Romano C, Gueant JL. Methionine synthase (MTR) 2756 (A --> G) polymorphism, double heterozygosity methionine synthase 2756 AG/methionine synthase reductase (MTRR) 66 AG, and elevated homocysteinemia are three risk factors for having a child with Down syndrome. Am. J. Med. Genet. A. 121A: 219-224 (2003).
Bosma PJ. Inherited disorders of bilirubin metabolism. J. Hepatol. 38: 107-117 (2003). *
Bosse Y, Weisnagel SJ, Bouchard C, Despres JP, Perusse L, Vohl MC. Combined effects of PPARgamma2 P12A and PPARalpha L162V polymorphisms on glucose and insulin homeostasis: the Quebec Family Study. J. Hum. Genet. 48: 614-621 (2003). *
Botchkarev VA. Neurotrophins and their role in pathogenesis of alopecia areata. J. Investig. Dermatol. Symp. Proc. 8: 195-198 (2003). *
Botsios C, Ostuni P, Sfriso P, Furlan A, Fiocco U, Sgarabotto D, Todesco S. Infections in patients with rheumatoid arthritis receiving anti-cytokine therapy: biological mechanisms and clinical aspects. Reumatismo. 55: 224-235 (2003).
Bott C, Lembcke B, Stein J. Colorectal cancer and folate. Z. Gastroenterol. 41: 263-270 (2003).
Botti F, Carrara A, Antonelli B, Quadri F, Maino M, Cesana B, Contessini-Avesani E. The minimal bowel resection in Crohn's disease: analysis of prognostic factors on the surgical recurrence. Ann. Ital. Chir. 74: 627-633 (2003).
Botto N, Andreassi MG, Manfredi S, Masetti S, Cocci F, Colombo MG, Storti S, Rizza A, Biagini A. Genetic polymorphisms in folate and homocysteine metabolism as risk factors for DNA damage. Eur. J. Hum. Genet. 11: 671-678 (2003). *
Boubaker J, Feki M, Hsairi M, Fekih M, Kaabachi N, Filali A, Mebazaa A. Osteoporosis and inflammatory bowel disease: prevalence and risk factors in Tunisian patients. Gastroenterol. Clin. Biol. 27: 901-907 (2003).
Boulanger A, McLemore P, Copeland NG, Gilbert DJ, Jenkins NA, Yu SS, Gentleman S, Redmond TM. Identification of beta-carotene 15, 15'-monooxygenase as a peroxisome proliferator-activated receptor target gene. FASEB J. 17: 1304-1306 (2003). *
Boulanger MJ, Chow DC, Brevnova EE, Garcia KC. Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science 300: 2101-2104 (2003). *
Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3: 521-533 (2003). *
Bouqbis L, Izaabel H, Akhayat O, Perez-Lezaun A, Calafell F, Bertranpetit J, Comas D. Association of the CTLA4 promoter region (-1661G allele) with type 1 diabetes in the South Moroccan population. Genes Immun. 4: 132-137 (2003). *
Bour-Jordan H, Grogan JL, Tang Q, Auger JA, Locksley RM, Bluestone JA. CTLA-4 regulates the requirement for cytokine-induced signals in T(H)2 lineage commitment. Nat. Immunol. 4: 182-188 (2003). *
Bourlioux P, Koletzko B, Guarner F, Braesco V. The intestine and its microflora are partners for the protection of the host: report on the Danone Symposium "The Intelligent Intestine," held in Paris, June 14, 2002. Am. J. Clin. Nutr. 78: 675-683 (2003). *
Bourreille A, Doubremelle M, de la Bletiere DR, Segain JP, Toquet C, Buelow R, Galmiche JP. RDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn disease. Scand. J. Gastroenterol. 38: 526-532 (2003). *
Bowcock AM, Barker JN. Genetics of psoriasis: the potential impact on new therapies. J. Am. Acad. Dermatol. 49: S51-S56 (2003).
Bowlus CL. The role of iron in T cell development and autoimmunity. Autoimmun. Rev. 2: 73-78 (2003).
Braat H, Peppelenbosch MP, Hommes DW. Interleukin-10-based therapy for inflammatory bowel disease. Expert Opin. Biol. Ther. 3: 725-731 (2003).
Braddock M. Inflammatory Processes in Drug Discovery - SRI Conference. 22-23 September 2003, Philadelphia, PA, USA. IDrugs 6: 1049-1052 (2003).
Bradesi S, McRoberts JA, Anton PA, Mayer EA. Inflammatory bowel disease and irritable bowel syndrome: separate or unified? Curr. Opin. Gastroenterol. 19: 336-342 (2003).
Brand DD, Kang AH, Rosloniec EF. Immunopathogenesis of collagen arthritis. Springer Semin. Immunopathol. 25: 3-18 (2003). *
Brandsaeter B, Broome U, Isoniemi H, Friman S, Hansen B, Schrumpf E, Oksanen A, Ericzon BG, Hockerstedt K, Makisalo H, Olsson R, Olausson M, Kirkegaard P, Bjoro K. Liver transplantation for primary sclerosing cholangitis in the Nordic countries: outcome after acceptance to the waiting list. Liver Transpl. 9: 961-969 (2003). *
Brandsaeter B, Friman S, Broome U, Isoniemi H, Olausson M, Backman L, Hansen B, Schrumpf E, Oksanen A, Ericzon BG, Hockerstedt K, Makisalo H, Kirkegaard P, Bjoro K. Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand. J. Gastroenterol. 38: 1176-1183 (2003). *
Brandtzaeg P. Mucosal immunity. Dev. Biol. (Basel) 115: 111-117 (2003).
Brandtzaeg P. Role of secretory antibodies in the defence against infections. Int. J. Med. Microbiol. 293: 3-15 (2003).
Brandtzaeg P. Mucosal immunity: integration between mother and the breast-fed infant. Vaccine 21: 3382-3388 (2003). *
Brandtzaeg P. Impact of immunodeficiency on immunological hoemostasis in the gut. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 61-62. September 12 - 13 (2003). *
Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, Zhang L, Swanson E, Datta LW, Moran T, Ravenhill G, Duerr RH, Achkar JP, Karban AS, Cho JH. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am. J. Hum. Genet.73: 1282-1292 (2003). *
Brant SR, Picco MF, Achkar JP, Bayless TM, Kane SV, Brzezinski A, Nouvet FJ, Bonen D, Karban A, Dassopoulos T, Karaliukas R, Beaty TH, Hanauer SB, Duerr RH, Cho JH. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm. Bowel Dis. 9: 281-289 (2003). *
Braun J, Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin. Biol. Ther. 3: 141-168 (2003).
Braun J, van der Heijde D. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert Opin. Investig. Drugs 12: 1097-1109 (2003).
Breban M, Said-Nahal R, Hugot JP, Miceli-Richard C. Familial and genetic aspects of spondyloarthropathy. Rheum. Dis. Clin. North Am. 29: 575-594 (2003).
Brennan MT, Sankar V, Leakan RA, Grisius MM, Collins MT, Fox PC, Baum BJ, Pillemer SR. Sex steroid hormones in primary Sjogren's syndrome. J. Rheumatol. 30: 1267-1271 (2003).
Brenner S, Srebrnik A, Goldberg I. Pemphigus can be induced by topical phenol as well as by foods and drugs that contain phenols or thiols. J. Cosmet. Dermatol. 2: 161-165 (2003).
Brentjens MH, Yeung-Yue KA, Lee PC, Tyring SK. Vaccines for viral diseases with dermatologic manifestations. Dermatol. Clin. 21: 349-369 (2003).
Brentnall T. UC for UC: ursodiol chemoprevention for ulcerative colitis. Inflamm. Bowel Dis. 9: 338 (2003). *
Brentnall TA. Molecular underpinnings of cancer in ulcerative colitis. Curr. Opin. Gastroenterol. 19: 64-68 (2003).
Brentnall TA. Ursodiol: good drug makes good. Gastroenterology 124: 1139-1140 (2003). *
Bresalier RS. Aspirin and the prevention of colorectal neoplasia. Gastroenterology 125: 1539-1541 (2003). *
Breuning MH, Hamdy NA. From gene to disease; SLC3A1, SLC7A9 and cystinuria. Ned. Tijdschr. Geneeskd. 147: 245-247 (2003).
Brewer HB Jr, Santamarina-Fojo S. New insights into the role of the adenosine triphosphate-binding cassette transporters in high-density lipoprotein metabolism and reverse cholesterol transport. Am. J. Cardiol. 91: 3E-11E (2003). *
Brewerton DA. Discovery: HLA and disease. Curr. Opin. Rheumatol. 15: 369-373 (2003).
Bridle KR, Frazer DM, Wilkins SJ, Dixon JL, Purdie DM, Crawford DH, Subramaniam VN, Powell LW, Anderson GJ, Ramm GA. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet 361: 669-673 (2003). *
Briganti S, Picardo M. Antioxidant activity, lipid peroxidation and skin diseases. What's new. J. Eur. Acad. Dermatol. Venereol. 17: 663-669 (2003). *
Brigelius-Flohe R. Vitamin E and drug metabolism. Biochem. Biophys. Res. Commun. 305: 737-740 (2003). *
Brinckerhoff CE, Sporn MB. Retinoids and rexinoids for the 21st century: a brave new world for arthritis. J. Rheumatol. 30: 211-213 (2003).
Brinkmeier T, Angelkort B, Frosch PJ, Herbst RA. Vancomycin-induced linear IgA disease. J. Dtsch. Dermatol. Ges. 1: 212-214 (2003).
Bristow CA, Shore P. Transcriptional regulation of the human MIP-1alpha promoter by RUNX1 and MOZ. Nucleic Acids Res. 31: 2735-2744 (2003). *
British Committee for Standards in Haematology, Blood Transfusion Task Force. Guidelines for the use of platelet transfusions. Br. J. Haematol. 122: 10-23 (2003). *
Brodanova M. Cholestasis. Vnitr. Lek. 49: 689-695 (2003).
Brodmerkel CM, Vaddi K. Transgenic animals in inflammatory disease models. Curr. Opin. Biotechnol. 14: 652-658 (2003). *
Broering DC, Sterneck M, Rogiers X. Living donor liver transplantation. J. Hepatol. 38 Suppl. 1: S119-S135 (2003). *
Brogan BL, Olsen NJ. Drug-induced rheumatic syndromes. Curr. Opin. Rheumatol. 15: 76-80 (2003).
Brombacher F, Kastelein RA, Alber G. Novel IL-12 family members shed light on the orchestration of Th1 responses. Trends Immunol. 24: 207-212 (2003). *
Bronner F. Calcium nutrition and metabolism. Dent. Clin. North Am. 47: 209-224 (2003).
Brooklyn T, Probert C. A Crohn's repertoire: T cell receptor gammadelta. Inflamm. Bowel Dis. 9: 213-214 (2003). *
Broome U. Autoimmune hepatitis and overlap syndromes. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 38-39. September 12 - 13 (2003). *
Broome U, Bergquist A. Hepatocellular carcinoma, cholangiocarcinoma, colon and pancreas carcinoma in patients with primary sclerosing cholangitis. Epidemiology and risk factors. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 89-90. October 15-16 (2003). *
Brophy S, Taylor G, Blake D, Calin A. The interrelationship between sex, susceptibility factors, and outcome in ankylosing spondylitis and its associated disorders including inflammatory bowel disease, psoriasis, and iritis. J. Rheumatol. 30: 2054-2058 (2003).
Brousseau ME. ATP-binding cassette transporter A1, fatty acids, and cholesterol absorption. Curr. Opin. Lipidol. 14: 35-40 (2003).
Brousseau ME. Statins, super-statins and cholesterol absorption inhibitors. IDrugs 6: 458-463 (2003).
Brown GR, Lee EL, Thiele DL. TNF enhances CD4+ T cell alloproliferation, IFN-gamma responses, and intestinal graft-versus-host disease by IL-12-independent mechanisms. J. Immunol. 170: 5082-5088 (2003). *
Brown KA, Moonka D. Liver transplantation. Curr. Opin. Gastroenterol. 19: 259-263 (2003).
Brown MA, Brophy S, Bradbury L, Hamersma J, Timms A, Laval S, Cardon L, Calin A, Wordsworth BP. Identification of major loci controlling clinical manifestations of ankylosing spondylitis. Arthritis Rheum. 48: 2234-2239 (2003). *
Brown RS Jr. Evaluation of the potential living donor. Transplant. Proc. 35: 915-916 (2003).
Brown RS Jr, Brenner DA. MELD and the practicing gastroenterologist. Gastroenterology 125: 1009 (2003). *
Brown RS Jr, Russo MW, Lai M, Shiffman ML, Richardson MC, Everhart JE, Hoofnagle JH. A survey of liver transplantation from living adult donors in the United States. N. Engl. J. Med. 348: 818-825 (2003). *
Browning J, Combes B, Mayo MJ. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. Am. J. Gastroenterol. 98: 2736-2741 (2003). *
Browning LM. n-3 Polyunsaturated fatty acids, inflammation and obesity-related disease. Proc. Nutr. Soc. 62: 447-453 (2003). *
Brtko J, Thalhamer J. Renaissance of the biologically active vitamin A derivatives: established and novel directed therapies for cancer and chemoprevention. Curr. Pharm. Des. 9: 2067-2077 (2003).
Bruewer M, Krieglstein CF, Utech M, Bode M, Rijcken E, Anthoni C, Laukoetter MG, Schuermann G, Senninger N. Is colonoscopy alone sufficient to screen for ulcerative colitis-associated colorectal carcinoma? World J. Surg. 27: 611-615 (2003). *
Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J. Immunol. 171: 6164-6172 (2003). *
Bruggraber SF, Leung PS, Amano K, Quan C, Kurth MJ, Nantz MH, Benson GD, Van de Water J, Luketic V, Roche TE, Ansari AA, Coppel RL, Gershwin ME. Autoreactivity to lipoate and a conjugated form of lipoate in primary biliary cirrhosis. Gastroenterology 125: 1705-1713 (2003). *
Bruix J. Hepatocellular carcinoma. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 31-33. October 17 - 19 (2003). *
Brummelkamp T, Nijman S, Dirac A, Bernards R. High throughput loss-of-function phenotypic screens in mammalian cells. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 52. October 20 - 21 (2003). *
Brune S, Kolsch H, Ptok U, Majores M, Schulz A, Schlosser R, Rao ML, Maier W, Heun R. Polymorphism in the peroxisome proliferator-activated receptor alpha gene influences the risk for Alzheimer's disease. J. Neural. Transm. 110: 1041-1050 (2003). *
Brunner M, Assandri R, Kletter K, Tschurlovits M, Corrado ME, Villa R, Eichler HG, Muller M. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment. Pharmacol. Ther. 17: 395-402 (2003). *
Brunner M, Greinwald R, Kletter K, Kvaternik H, Corrado ME, Eichler HG, Muller M. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment. Pharmacol. Ther. 17: 1163-1169 (2003). *
Brunt EM, Ramrakhiani S, Cordes BG, Neuschwander-Tetri BA, Janney CG, Bacon BR, Di Bisceglie AM. Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease. Mod. Pathol. 16: 49-56 (2003). *
Bryce NS, Schevzov G, Ferguson V, Percival JM, Lin JJ, Matsumura F, Bamburg JR, Jeffrey PL, Hardeman EC, Gunning P, Weinberger RP. Specification of actin filament function and molecular composition by tropomyosin isoforms. Mol. Biol. Cell 14: 1002-1016 (2003). *
Bubnova LN, Pavlova IE, Berkos MV, Solovyeva OI, Simanenkov VI. HLA II class polymorphism in patients with ulcerative colitis. Hum. Immunol. 64 (10 Suppl.): S149 (2003).
Bucheton B, Abel L, Kheir MM, Mirgani A, El-Safi SH, Chevillard C, Dessein A. Genetic control of visceral leishmaniasis in a Sudanese population: candidate gene testing indicates a linkage to the NRAMP1 region. Genes Immun. 4: 104-109 (2003). *
Buckel E, Uribe M, Brahm J, Silva G, Ferrario M, Godoy J, Segovia R, Ceresa S, Hunter B, Alegria S, Berwart F, Smok G, Herzog C, Santander T, Calabran L. Outcomes of orthotopic liver transplantation in Chile. Transplant. Proc. 35: 2509-2510 (2003). *
Bugawan TL, Mirel DB, Valdes AM, Panelo A, Pozzilli P, Erlich HA. Association and interaction of the IL4R, IL4, and IL13 loci with type 1 diabetes among Filipinos. Am. J. Hum. Genet. 72: 1505-1514 (2003). *
Bull AW. The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease. Arch. Pathol. Lab. Med. 127: 1121-1123 (2003). *
Bull TJ, McMinn EJ, Sidi-Boumedine K, Skull A, Durkin D, Neild P, Rhodes G,. Detection and verification of Mycobacterium avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn's disease. J. Clin. Microbiol. 41: 2915-2923 (2003). *
Bullen TF, Hershman MJ. Surgery for inflammatory bowel disease. Hosp. Med. 64: 719-723 (2003).
Bullen TF, Hershman MJ. Laparoscopic surgery for inflammatory bowel disease. Hosp. Med. 64: 724-727 (2003).
Buning C, Genschel J, Weltrich R, Lochs H, Schmidt H. The interleukin-25 gene located in the inflammatory bowel disease (IBD) 4 region: no association with inflammatory bowel disease. Eur. J. Immunogenet. 30: 329-333 (2003). *
Buning C, Ockenga J, Kruger S, Jurga J, Baier P, Dignass A, Vogel A, Strassburg C, Weltrich R, Genschel J, Lochs H, Schmidt H. The C/C(-13910) and G/G(-22018) genotypes for adult-type hypolactasia are not associated with inflammatory bowel disease. Scand. J. Gastroenterol. 38: 538-542 (2003). *
Burak KW, Angulo P, Lindor KD. Is there a role for liver biopsy in primary sclerosing cholangitis? Am. J. Gastroenterol. 98: 1155-1158 (2003). *
Burchill MA, Nardelli DT, England DM, DeCoster DJ, Christopherson JA, Callister SM, Schell RF. Inhibition of interleukin-17 prevents the development of arthritis in vaccinated mice challenged with Borrelia burgdorferi. Infect. Immun. 71: 3437-3442 (2003). *
Burgner D, Rockett K, Ackerman H, Hull J, Usen S, Pinder M, Kwiatkowski DP. Haplotypic relationship between SNP and microsatellite markers at the NOS2A locus in two populations. Genes Immun. 4: 506-514 (2003). *
Burke CA, Bauer WM, Lashner B. Chemoprevention of colorectal cancer: slow, steady progress. Cleve. Clin. J. Med. 70: 346-350 (2003). *
Burkhart CN, Gottwald L. Assessment of etiologic agents in acne pathogenesis. Skinmed. 2: 222-228 (2003).
Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J. Exp. Med. 197: 263-268 (2003). *
Burns TM. Neurosarcoidosis. Arch. Neurol. 60: 1166-1168 (2003).
Burns TM, Ryan MM, Darras B, Jones HR Jr. Current therapeutic strategies for patients with polyneuropathies secondary to inherited metabolic disorders. Mayo Clin. Proc. 78: 858-868 (2003). *
Burroughs AK. Is the use of albumin of value in cirrhosis? The case not so in favour, or is there an alternative? Dig. Liver Dis. 35: 664-667 (2003).
Burt RK, Marmont A, Arnold R, Heipe F, Firestein GS, Carrier E, Hahn B, Barr W, Oyama Y, Snowden J, Kalunian K, Traynor A. Development of a phase III trial of hematopoietic stem cell transplantation for systemic lupus erythematosus. Bone Marrow Transplant. 32 Suppl. 1: S49-S51 (2003).
Burt RK, Traynor A, Oyama Y, Craig R. High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood 101: 2064-2066 (2003). *
Burt RK, Traynor AE. SLE - hematopoietic stem cell transplantation for systemic lupus erythematosus. Arthritis Res. Ther. 5: 207-209 (2003). *
Butterworth RF. Pathogenesis of hepatic encephalopathy: new insights from neuroimaging and molecular studies. J. Hepatol. 39: 278-285 (2003). *
Butterworth RF. Molecular neurobiology of acute liver failure. Semin. Liver Dis. 23: 251-258 (2003).
Buzi F, Badolato R, Mazza C, Giliani S, Notarangelo LD, Radetti G, Plebani A, Notarangelo LD. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome: time to review diagnostic criteria? J. Clin. Endocrinol. Metab. 88: 3146-3148 (2003). *
Caballeria J. Current concepts in alcohol metabolism. Ann. Hepatol. 2: 60-68 (2003). *
Cabibi D, Licata A, Barresi E, Craxi A, Aragona F. Expression of cytokeratin 7 and 20 in pathological conditions of the bile tract. Pathol. Res. Pract. 199: 65-70 (2003).
Cabral VL, Miszputen SJ, Catapani WR. Anti-neutrophil cytoplasmic antibodies in Brazilian patients with inflammatory bowel disease. Hepatogastroenterology 50: 412-415 (2003).
Cabre E, Gassull MA. Nutritional and metabolic issues in inflammatory bowel disease. Curr. Opin. Clin. Nutr. Metab. Care 6: 569-576 (2003).
Cabrero A, Cubero M, Llaverias G, Jove M, Planavila A, Alegret M, Sanchez R, Laguna JC, Carrera MV. Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism 52: 652-657 (2003). *
Cadranel S, Gottrand F. Is upper gastro-intestinal endoscopy required for diagnosis and treatment of Helicobacter pylori infection in childhood? Pro and cons. Arch. Pediatr. 10: 256-259 (2003).
Cai Y, Dai T, Ao Y, Konishi T, Chuang KH, Lue Y, Chang C, Wan YJ. Cytochrome P450 genes are differentially expressed in female and male hepatocyte retinoid X receptor alpha-deficient mice. Endocrinology 144: 2311-2318 (2003). *
Caillat-Zucman S. Why mapping celiac disease susceptibility genes is so challenging: lessons from the CTLA-4 gene. J. Pediatr. Gastroenterol. Nutr. 37: 115-116 (2003). *
Caillier S, Barcellos LF, Baranzini SE, Swerdlin A, Lincoln RR, Steinman L, Martin E, Haines JL, Pericak-Vance M, Hauser SL, Oksenberg JR; Multiple Sclerosis Genetics Group. Osteopontin polymorphisms and disease course in multiple sclerosis. Genes Immun. 4: 312-315 (2003). *
Cakir M, Samanci N, Balci N, Balci MK. Musculoskeletal manifestations in patients with thyroid disease. Clin. Endocrinol. (Oxf.) 59: 162-167 (2003). *
Calabrese V, Butterfield DA, Stella AM. Nutritional antioxidants and the heme oxygenase pathway of stress tolerance: novel targets for neuroprotection in Alzheimer's disease. Ital. J. Biochem. 52: 177-181 (2003).
Calabrese V, Scapagnini G, Colombrita C, Ravagna A, Pennisi G, Giuffrida Stella AM, Galli F, Butterfield DA. Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids 25: 437-444 (2003). *
Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat. Rev. Immunol. 3: 791-800 (2003). *
Calder PC. Immunonutrition. BMJ 327: 117-118 (2003). *
Calder PC. Polyunsaturated fatty acids and cytokine profiles: a clue to the changing prevalence of atopy? Clin. Exp. Allergy 33: 412-415 (2003). *
Calder PC. n-3 Polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 38: 343-352 (2003).
Calder PC. New evidence in support of the cardiovascular benefit of long-chain n-3 fatty acids. Ital. Heart J. 4: 427-429 (2003).
Calder PC. Long-chain n-3 fatty acids and inflammation: potential application in surgical and trauma patients. Braz. J. Med. Biol. Res. 36: 433-446 (2003). *
Calder PC, Deckelbaum RJ. Fat as a physiological regulator: the news gets better. Curr. Opin. Clin. Nutr. Metab. Care 6: 127-131 (2003).
Calvo-Alen J, Reveille JD, Rodriguez-Valverde V, McGwin G Jr, Baethge BA, Friedman AW, Alarcon GS. Clinical, immunogenetic and outcome features of Hispanic systemic lupus erythematosus patients of different ethnic ancestry. Lupus 12: 377-385 (2003).
Campbell DJ, Debes GF, Johnston B, Wilson E, Butcher EC. Targeting T cell responses by selective chemokine receptor expression. Semin. Immunol. 15: 277-286 (2003). *
Campbell S, Ghosh S. Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant severe ulcerative colitis: the Edinburgh experience of outcome. Dig. Liver Dis. 35: 546-551 (2003).
Campos FG, Waitzberg DL, Teixeira MG, Mucerino DR, Kiss DR, Habr-Gama A. Pharmacological nutrition in inflammatory bowel diseases. Nutr. Hosp. 18: 57-64 (2003).
Canataroglu A, Tanriverdi K, Inal T, Seydaoglu G, Arslan D, Ozbek S, Baslamisli F. Methylenetetrahydrofolate reductase gene C677T mutation and plasma homocysteine level in Behcet's disease. Rheumatol. Int. 23: 236-240 (2003). *
Canbay A, Guicciardi ME, Higuchi H, Feldstein A, Bronk SF, Rydzewski R, Taniai M, Gores GJ. Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis. J. Clin. Invest. 112: 152-159 (2003). *
Cannon CL, Kowalski MP, Stopak KS, Pier GB. Pseudomonas aeruginosa-induced apoptosis is defective in respiratory epithelial cells expressing mutant cystic fibrosis transmembrane conductance regulator. Am. J. Respir. Cell. Mol. Biol. 29: 188-197 (2003). *
Cao L, Owsianik G, Jaspers M, Janssens A, Cuppens H, Cassiman JJ, Nilius B. Functional analysis of CFTR chloride channel activity in cells with elevated MDR1 expression. Biochem. Biophys. Res. Commun. 304: 248-252 (2003). *
Cappell MS. Gastrointestinal disorders during pregnancy. Preface. Gastroenterol. Clin. North Am. 32: xi-xiii (2003). *
Cappell MS. The fetal safety and clinical efficacy of gastrointestinal endoscopy during pregnancy. Gastroenterol. Clin. North Am. 32: 123-179 (2003). *
Cappell MS. Gastric and duodenal ulcers during pregnancy. Gastroenterol. Clin. North Am. 32: 263-308 (2003). *
Cappell MS. Colon cancer during pregnancy. Gastroenterol. Clin. North Am. 32: 341-383 (2003). *
Cappell MS, Friedel D. Abdominal pain during pregnancy. Gastroenterol. Clin. North Am. 32: 1-58 (2003). *
Caprilli R, Cottone M, Tonelli F, Sturniolo G, Castiglione F, Annese V, Papi C, Viscido A, Camma C, Corrao G, Latella G. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Aliment. Pharmacol. Ther. 17: 517-523 (2003). *
Caprilli R, Guagnozzi D. CARD 15 and Toll-like receptors: the link with Crohn's disease. Dig. Liver Dis. 35: 753-757 (2003).
Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 125: 89-97 (2003). *
Carcao MD, Blanchette VS, Wakefield CD, Stephens D, Ellis J, Matheson K, Denomme GA. Fcgamma receptor IIa and IIIa polymorphisms in childhood immune thrombocytopenic purpura. Br. J. Haematol. 120: 135-141 (2003).
Card T, Hubbard R, Logan RF. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 125: 1583-1590 (2003). *
Cardarelli G, Anatra GM. Hepcidin: a key peptide in iron metabolism. Minerva Med. 94: 135-139 (2003).
Cardenas A, Arroyo V. Hepatorenal syndrome. Ann. Hepatol. 2: 23-29 (2003). *
Cariati A, Puglisi R, Zaffarano R, Accarpio FT, Cetta F. Helicobacter pylori and the risk of benign and malignant biliary tract disease. Cancer 98: 656-657 (2003). *
Carini R, Albano E. Recent insights on the mechanisms of liver preconditioning. Gastroenterology 125: 1480-1491 (2003). *
Cario E. Toll-like receptors and intestinal defence: molecular basis and therapeutic implications. Expert Rev. Mol. Med. 5: 1-15 (2003).
Carithers RL Jr. Primary biliary cirrhosis: specific treatment. Clin. Liver Dis. 7: 923-939 (2003).
Carlson GL. Surgical management of intestinal failure. Proc. Nutr. Soc. 62: 711-718 (2003). *
Carlsson E, Bosaeus I, Nordgren S. What concerns subjects with inflammatory bowel disease and an ileostomy? Scand. J. Gastroenterol. 38: 978-984 (2003). *
Carlsson M, Eriksson L, Erwander I, Wieslander J, Segelmark M. Pseudomonas-induced lung damage in cystic fibrosis correlates to bactericidal-permeability increasing protein (BPI)-autoantibodies. Clin. Exp. Rheumatol. 21: S95-S100 (2003).
Carlton VE, Harris BZ, Puffenberger EG, Batta AK, Knisely AS, Robinson DL, Strauss KA, Shneider BL, Lim WA, Salen G, Morton DH, Bull LN. Complex inheritance of familial hypercholanemia with associated mutations in TJP2 and BAAT. Nat. Genet. 34: 91-96 (2003). *
Carreras E, Saiz A, Marin P, Martinez C, Rovira M, Villamor N, Aymerich M, Lozano M, Fernandez-Aviles F, Urbano-Izpizua A, Montserrat E, Graus F. CD34+ selected autologous peripheral blood stem cell transplantation for multiple sclerosis: report of toxicity and treatment results at one year of follow-up in 15 patients. Haematologica 88: 306-314 (2003). *
Carrier J, Medline A, Sohn KJ, Choi M, Martin R, Hwang SW, Kim YI. Effects of dietary folate on ulcerative colitis-associated colorectal carcinogenesis in the interleukin 2- and beta(2)-microglobulin-deficient mice. Cancer Epidemiol. Biomarkers Prev. 12: 1262-1267 (2003). *
Carrion F, Figueroa F, Martinez ME, Massardo L, Perez T, Foster C, Mancilla C, Neira O, Guzman L, Valenzuela V, Urrutia R, Carmona S, Figueroa M, Lubiano A, Wainstein E. Study of polymorphism of Fc gamma IIa receptors in Chilean patients with systemic lupus erythematosus. Rev. Med. Chil. 131: 11-18 (2003).
Carroccio A, Soresi M, Di Prima L, Montalto G. Screening for celiac disease in patients with chronic liver disease. Gastroenterology 125: 1289 (2003). *
Carson CF, Riley TV. Non-antibiotic therapies for infectious diseases. Commun. Dis. Intell. 27 Suppl.: S143-S146 (2003).
Carter JD, Valeriano J, Vasey FB. Crohn disease worsened by anakinra administration. J. Clin. Rheumatol. 9: 276-277 (2003).
Carter K, Bowen DJ, McCune CA, Worwood M. Haptoglobin type neither influences iron accumulation in normal subjects nor predicts clinical presentation in HFE C282Y haemochromatosis: phenotype and genotype analysis. Br. J. Haematol. 122: 326-332 (2003).
Carter LL, Carreno BM. Cytotoxic T-lymphocyte antigen-4 and programmed death-1 function as negative regulators of lymphocyte activation. Immunol. Res. 28: 49-59 (2003). *
Carty E, Rampton DS. Evaluation of new therapies for inflammatory bowel disease. Br. J. Clin. Pharmacol. 56: 351-361 (2003). *
Carvalho AT, Elia CC, de Souza HS, Elias PR, Pontes EL, Lukashok HP, de Freitas FC, Lapa e Silva JR. Immunohistochemical study of intestinal eosinophils in inflammatory bowel disease. J. Clin. Gastroenterol. 36: 120-125 (2003).
Casp CB, She JX, McCormack WT. Genes of the LMP/TAP cluster are associated with the human autoimmune disease vitiligo. Genes Immun. 4: 492-499 (2003). *
Caspi RR. Experimental autoimmune uveoretinitis in the rat and mouse. Curr. Protoc. Immunol. Chapter 15: Unit 15.6 (2003).
Castagnola E, Fioredda F. Prevention of life-threatening infections due to encapsulated bacteria in children with hyposplenia or asplenia: a brief review of current recommendations for practical purposes. Eur. J. Haematol. 71: 319-326 (2003). *
Castano G, Fernandez L, Mas R, Illnait J, Mesa M, Fernandez JC. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. Clin. Drug Investig. 23: 639-650 (2003).
Castano G, Viudez P, Riccitelli M, Sookoian S. A randomized study of losartan vs propranolol: Effects on hepatic and systemic hemodynamics in cirrhotic patients. Ann. Hepatol. 2: 36-40 (2003). *
Castiglione F, Rispo A, Di Girolamo E, Cozzolino A, Manguso F, Grassia R, Mazzacca G. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment. Pharmacol. Ther. 18: 1107-1112 (2003). *
Castillo S, Ramaiah B, Blum S, Remy P. The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology 125: 999 (2003). *
Castrillo A, Joseph SB, Marathe C, Mangelsdorf DJ, Tontonoz P. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J. Biol. Chem. 278: 10443-10449 (2003). *
Castrillo A, Joseph SB, Vaidya SA, Haberland M, Fogelman AM, Cheng G, Tontonoz P. Crosstalk between LXR and Toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell. 12: 805-816 (2003). *
Cat H, Sophani I, Lemann M, Modiglani R, Solue JC. Cyclosporin treatment of anal and perianal lesions associated with Crohn's disease. Turk. J. Gastroenterol. 14: 121-127 (2003). *
Cataldo F, Lio D, Marino V, Scola L, Crivello A, Corazza GR; Working Group of the SIGEP; Working Group of 'Club del Tenue'. Plasma cytokine profiles in patients with celiac disease and selective IgA deficiency. Pediatr. Allergy Immunol. 14: 320-324 (2003). *
Cataldo F, Lio D, Marino V, Scola L, Crivello A, Mule AM, Corazza GR; Groups of the SIGEP and "Club del Tenue". Cytokine genotyping (TNF and IL-10) in patients with celiac disease and selective IgA deficiency. Am. J. Gastroenterol. 98: 850-856 (2003). *
Caturelli E, Castellano L, Fusilli S, Palmentieri B, Niro GA, del Vecchio-Blanco C, Andriulli A, de Sio I. Coarse nodular US pattern in hepatic cirrhosis: risk for hepatocellular carcinoma. Radiology 226: 691-697 (2003). *
Cavaco I, Gil JP, Gil-Berglund E, Ribeiro V. CYP3A4 and MDR1 alleles in a Portuguese population. Clin. Chem. Lab. Med. 41: 1345-1350 (2003).
Cavaglieri CR, Nishiyama A, Fernandes LC, Curi R, Miles EA, Calder PC. Differential effects of short-chain fatty acids on proliferation and production of pro- and anti-inflammatory cytokines by cultured lymphocytes. Life Sci. 73: 1683-1690 (2003). *
Cavanaugh JA. IBD International Genetics Consortium: international cooperation making sense of complex disease. Inflamm. Bowel Dis. 9: 190-193 (2003). *
Cavanaugh JA, Adams KE, Quak EJ, Bryce ME, O'Callaghan NJ, Rodgers HJ, Magarry GR, Butler WJ, Eaden JA, Roberts-Thomson IC, Pavli P, Wilson SR, Callen DF. CARD15/NOD2 risk alleles in the development of Crohn's disease in the Australian population. Ann. Hum. Genet. 67: 35-41 (2003). *
Cave NJ. Chronic inflammatory disorders of the gastrointestinal tract of companion animals. N. Z. Vet. J. 51: 262-274 (2003).
Cavestro GM, Frulloni L, Neri TM, Seghini P, Nouvenne A, Zanetti A, Bovo P, Di Mario F, Okolicsanyi L, Cavallini G. Association of HLA-DRB1*0401 allele with chronic pancreatitis. Pancreas 26: 388-391 (2003).
Ceelie H, Spaargaren-Van Riel CC, De Jong M, Bertina RM, Vos HL. Functional characterization of transcription factor binding sites for HNF1-alpha, HNF3-beta (FOXA2), HNF4-alpha, Sp1 and Sp3 in the human prothrombin gene enhancer. J. Thromb. Haemost. 1: 1688-1698 (2003). *
Centers for Disease Control and Prevention (CDC). Hepatic toxicity possibly associated with kava-containing products - United States, Germany, and Switzerland, 1999-2002. JAMA 289: 36-37 (2003). *
Cerkauskiene R, Kaminskas A, Kaltenis P, Vitkus D. Influence of omega-3 fatty acids on lipid metabolism in children with steroid sensitive nephrotic syndrome. Medicina (Kaunas) 39 Suppl. 1: 82-87 (2003).
Cerwenka A, Lanier LL. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61: 335-343 (2003). *
Cezard JP, Nouaili N, Talbotec C, Hugot JP, Gobert JG, Schmitz J, Mougenot JF, Alberti C, Goulet O. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 36: 632-636 (2003). *
Chakir H, Campos-Neto A, Mojibian M, Webb JR. IL-12Rbeta2-deficient mice of a genetically resistant background are susceptible to Leishmania major infection and develop a parasite-specific Th2 immune response. Microbes Infect. 5: 241-249 (2003). *
Chakraborty A, Bremner AR, Moore I, Beattie RM. Coeliac disease and Crohn's disease: an association not to be forgotten. Hosp. Med. 64: 684-655 (2003).
Chalasani N, Crabb DW, Cummings OW, Kwo PY, Asghar A, Pandya PK, Considine RV. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am. J. Gastroenterol. 98: 2771-2776 (2003). *
Chalasani N, Deeg MA, Persohn S, Crabb DW. Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 98: 1849-1855 (2003). *
Chalasani N, Gorski JC, Asghar MS, Asghar A, Foresman B, Hall SD, Crabb DW. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology 37: 544-550 (2003). *
Chalon SA, Desager JP, Desante KA, Frye RF, Witcher J, Long AJ, Sauer JM, Golnez JL, Smith BP, Thomasson HR, Horsmans Y. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. Clin. Pharmacol. Ther. 73: 178-191 (2003). *
Chamaillard M, Girardin SE, Viala J, Philpott DJ. Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation. Cell. Microbiol. 5: 581-592 (2003). *
Chamaillard M, Hashimoto M, Horie Y, Masumoto J, Qiu S, Saab L, Ogura Y, Kawasaki A, Fukase K, Kusumoto S, Valvano MA, Foster SJ, Mak TW, Nunez G, Inohara N. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat. Immunol. 4: 702-707 (2003). *
Chamaillard M, Philpott D, Girardin SE, Zouali H, Lesage S, Chareyre F, Bui TH, Giovannini M, Zaehringer U, Penard-Lacronique V, Sansonetti PJ, Hugot JP, Thomas G. Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc. Natl. Acad. Sci. U.S.A. 100: 3455-3460 (2003). *
Chambers V, Sutherland L, Palmer K, Dalton A, Rigby AS, Sokol R, Pollitt R, Tanner S, Gleeson D. Haemochromatosis-associated HFE genotypes in English blood donors: age-related frequency and biochemical expression. J. Hepatol. 39: 925-931 (2003). *
Chan AT. Aspirin, non-steroidal anti-inflammatory drugs and colorectal neoplasia: future challenges in chemoprevention. Cancer Causes Control 14: 413-418 (2003). *
Chan C, Berthiaume F, Lee K, Yarmush ML. Metabolic flux analysis of cultured hepatocytes exposed to plasma. Biotechnol. Bioeng. 81: 33-49 (2003). *
Chan C, Berthiaume F, Lee K, Yarmush ML. Metabolic flux analysis of hepatocyte function in hormone- and amino acid-supplemented plasma. Metab. Eng. 5: 1-15 (2003). *
Chan C, Hwang D, Stephanopoulos GN, Yarmush ML, Stephanopoulos G. Application of multivariate analysis to optimize function of cultured hepatocytes. Biotechnol. Prog. 19: 580-598 (2003). *
Chan CW, Papatheodoridis GV, Goulis J, Burroughs AK. Ursodeoxycholic acid and histological progression in primary biliary cirrhosis. J. Hepatol. 39: 1094-1095 (2003). *
Chan E, Fonseca VA. Management of hyperhomocysteinemia. Metab. Syndr. Relat. Disord. 1: 159-170 (2003).
Chandran P, Satthaporn S, Robins A, Eremin O. Inflammatory bowel disease: dysfunction of GALT and gut bacterial flora (I). Surgeon 1: 63-75 (2003).
Chandran P, Satthaporn S, Robins A, Eremin O. Inflammatory bowel disease: dysfunction of GALT and gut bacterial flora (II). Surgeon 1: 125-136 (2003).
Chang G. Multidrug resistance ABC transporters. FEBS Lett. 555: 102-105 (2003). *
Chang TK, Bandiera SM, Chen J. Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab. Dispos. 31: 7-10 (2003). *
Chang YT, Tsai SF, Lee DD, Shiao YM, Huang CY, Liu HN, Wang WJ, Wong CK. A study of candidate genes for psoriasis near HLA-C in Chinese patients with psoriasis. Br. J. Dermatol. 148: 418-423 (2003). *
Chang YT, Tsai SF, Lin MW, Liu HN, Lee DD, Shiao YM, Chin PJ, Wang WJ. SPR1 gene near HLA-C is unlikely to be a psoriasis susceptibility gene. Exp. Dermatol. 12: 307-314 (2003). *
Chapman RW. The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17 (2003).
Chapman RW. To perform or not to perform liver biopsy: an alternative view. Gut 52: 1227 (2003). *
Chapman RW. Viruses, protozoans and drugs as etiological factors in primary sclerosing cholangitis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 73-74. October 15-16 (2003). *
Chapman RW. Medical treatment of primary sclerosing cholangitis with ursodeoxycholic acid. Dig. Liver Dis. 35: 306-308 (2003).
Charron M. Temporal correlation of the erythrocyte sedimentation rate with Tc-99m WBC uptake on children with inflammatory bowel diseases. Clin. Nucl. Med. 28: 905-907 (2003).
Charron M. Inflammatory bowel disease activity assessment with biologic markers and (99m)Tc-WBC scintigraphy: are there different trends in ileitis versus colitis? J. Nucl. Med. 44: 1586-1591 (2003). *
Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat. Rev. Immunol. 3: 123-132 (2003).
Chatterjee P, Franklin MR. Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab. Dispos. 31: 1391-1397 (2003). *
Chawla Y, Dhiman RK. Portal biliopathy: emerging management problems. Trop. Gastroenterol. 24: 165-166 (2003).
Chazouilleres O, Wendum D. Diseases of the intrahepatic bile duct: diagnosis and treatments. Gastroenterol. Clin. Biol. 27: 307-318 (2003).
Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S. The incidence and management of infusion reactions to infliximab: a large center experience. Am. J. Gastroenterol. 98: 1315-1324 (2003). *
Cheikh I, Maamouri N, Chouaib S, Chaabouni H, Ouerghi H, Ben Ammar A. Association of celiac disease and Crohn's disease. A case report. Tunis. Med. 81: 969-971 (2003).
Cheikh I, Said Y, Chaabouni H, Ouerghi H, Ben Ammar A. Primary biliary cirrhosis and autoimmune hepatitis overlap syndrome: therapeutic features in 5 patients. Ann. Med. Interne. (Paris) 154: 7-11 (2003).
Chen C, Gulati P, French SW. Pathologic quiz case: a patient with acquired immunodeficiency syndrome and an unusual biliary infection. Arch. Pathol. Lab. Med. 127: 243-244 (2003). *
Chen C, Staudinger JL, Klaassen CD. Nuclear receptor, pregnane X receptor, is required for induction of UDP-glucuronosyltranferases in mouse liver by pregnenolone-16 alpha-carbonitrile. Drug Metab. Dispos. 31: 908-915 (2003). *
Chen F, Ma L, Dawson PA, Sinal CJ, Sehayek E, Gonzalez FJ, Breslow J, Ananthanarayanan M, Shneider BL. Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. J. Biol. Chem. 278: 19909-19916 (2003). *
Chen GG, Xu H, Lee JF, Subramaniam M, Leung KL, Wang SH, Chan UP, Spelsberg TC. 15-Hydroxy-eicosatetraenoic acid arrests growth of colorectal cancer cells via a peroxisome proliferator-activated receptor gamma-dependent pathway. Int. J. Cancer 107: 837-843 (2003). *
Chen JM, Le Marechal C, Lucas D, Raguenes O, Ferec C. "Loss of function" mutations in the cationic trypsinogen gene (PRSS1) may act as a protective factor against pancreatitis. Mol. Genet. Metab. 79: 67-70 (2003). *
Chen MJ, Chu CH, Lin SC, Shih SC, Wang TE. Eosinophilic gastroenteritis: clinical experience with 15 patients. World J. Gastroenterol. 9: 2813-2816 (2003). *
Chen P, Soares AM, Lima AA, Gamble MV, Schorling JB, Conway M, Barrett LJ, Blaner WS, Guerrant RL. Association of vitamin A and zinc status with altered intestinal permeability: analyses of cohort data from northeastern Brazil. J. Health Popul. Nutr. 21: 309-315 (2003).
Chen R, Rabinovitch PS, Crispin DA, Emond MJ, Koprowicz KM, Bronner MP, Brentnall TA. DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am. J. Pathol. 162: 665-672 (2003). *
Chen S, Harisinghani MG, Wittenberg J. Small bowel CT fat density target sign in chronic radiation enteritis. Australas. Radiol. 47: 450-452 (2003).
Chen W, Chiang JY. Regulation of human sterol 27-hydroxylase gene (CYP27A1) by bile acids and hepatocyte nuclear factor 4alpha (HNF4alpha). Gene 313: 71-82 (2003). *
Chen W, Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 2: CD003626 (2003). *
Chen W, Harp JA, Harmsen AG. Cryptosporidium parvum infection in gene-targeted B cell-deficient mice. J. Parasitol. 89: 391-393 (2003).
Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198: 1875-1886 (2003). *
Chen W, Li D, Cannan RJ, Stubbs RS. Common presence of Helicobacter DNA in the gallbladder of patients with gallstone diseases and controls. Dig. Liver Dis. 35: 237-243 (2003).
Chen XM, Huang BQ, Splinter PL, Cao H, Zhu G, McNiven MA, LaRusso NF. Cryptosporidium parvum invasion of biliary epithelia requires host cell tyrosine phosphorylation of cortactin via c-Src. Gastroenterology 125: 216-228 (2003). *
Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-D-glucuronide) by ABCG2: effects of acquired mutations at R482 on methotrexate transport. Cancer Res. 63: 4048-4054 (2003). *
Cheng F, Wang HW, Cuenca A, Huang M, Ghansah T, Brayer J, Kerr WG, Takeda K, Akira S, Schoenberger SP, Yu H, Jove R, Sotomayor EM. A critical role for Stat3 signaling in immune tolerance. Immunity 19: 425-436 (2003). *
Cheng JB, Jacquemin E, Gerhardt M, Nazer H, Cresteil D, Heubi JE, Setchell KD, Russell DW. Molecular genetics of 3beta-hydroxy-Delta5-C27-steroid oxidoreductase deficiency in 16 patients with loss of bile acid synthesis and liver disease. J. Clin. Endocrinol. Metab. 88: 1833-1841 (2003). *
Cheng S, Clancy CJ, Checkley MA, Handfield M, Hillman JD, Progulske-Fox A, Lewin AS, Fidel PL, Nguyen MH. Identification of Candida albicans genes induced during thrush offers insight into pathogenesis. Mol. Microbiol. 48: 1275-1288 (2003). *
Cheng VC, Lo CM, Lau GK. Current issues and treatment of fulminant hepatic failure including transplantation in Hong Kong and the Far East. Semin. Liver Dis. 23: 239-250 (2003).
Cherayil BJ. How not to get bugged by bugs: mechanisms of cellular tolerance to microorganisms. Curr. Opin. Gastroenterol. 19: 572-577 (2003).
Chernova MN, Jiang L, Shmukler BE, Schweinfest CW, Blanco P, Freedman SD, Stewart AK, Alper SL. Acute regulation of the SLC26A3 congenital chloride diarrhoea anion exchanger (DRA) expressed in Xenopus oocytes. J. Physiol. 549: 3-19 (2003). *
Cherrington NJ, Slitt AL, Maher JM, Zhang XX, Zhang J, Huang W, Wan YJ, Moore DD, Klaassen CD. Induction of multidrug resistance protein 3 (mrp3) in vivo is independent of constitutive androstane receptor. Drug Metab. Dispos. 31: 1315-1319 (2003). *
Chetri K, Choudhuri G. Role of trace elements in hepatic encephalopathy: zinc and manganese. Indian J. Gastroenterol. 22 Suppl. 2: S28-S30 (2003).
Cheung B, Yan J, Smith SA, Nguyen T, Lee M, Kavallaris M, Norris MD, Haber M, Marshall GM. Growth inhibitory retinoid effects after recruitment of retinoid X receptor beta to the retinoic acid receptor beta promoter. Int. J. Cancer 105: 856-867 (2003). *
Cheung C, Akiyama TE, Kudo G, Gonzalez FJ. Hepatic expression of cytochrome P450s in hepatocyte nuclear factor 1-alpha (HNF1alpha)-deficient mice. Biochem. Pharmacol. 66: 2011-2020 (2003). *
Cheung O, Regueiro MD. Inflammatory bowel disease emergencies. Gastroenterol. Clin. North Am. 32: 1269-1288 (2003).
Chew SS, Kerdic RI, Yang JL, Shi EC, Newstead GL, Douglas PR. Functional outcome and quality of life after ileal pouch-anal anastomosis in children and adults. ANZ J. Surg. 73: 983-987 (2003). *
Chew SS, Ngo TQ, Douglas PR, Newstead GL, Selby W, Solomon MJ. Cholecystectomy in patients with Crohn's ileitis. Dis. Colon Rectum 46: 1484-1488 (2003).
Chi CH, Lin CY, Sheu BS, Yang HB, Huang AH, Wu JJ. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. Aliment. Pharmacol. Ther. 18: 347-353 (2003). *
Chi ZC, Ma SZ. Rheumatologic manifestations of hepatic diseases. Hepatobiliary Pancreat. Dis. Int. 2: 32-37 (2003). *
Chiang JY. Bile acid regulation of hepatic physiology: III. Bile acids and nuclear receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G349-G356 (2003). *
Chignard N, Mergey M, Veissiere D, Poupon R, Capeau J, Parc R, Paul A, Housset C. Bile salts potentiate adenylyl cyclase activity and cAMP-regulated secretion in human gallbladder epithelium. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G205-G212 (2003). *
Chikanza IC, Kozaci D, Chernajovsky Y. The molecular and cellular basis of corticosteroid resistance. J. Endocrinol. 179: 301-310 (2003). *
Chikoteev SP, Tovarshinov AI, Plekhanov AN, Lepekhova SA. Transplantation of isolated hepatocytes in hepatic failure. Klin. Med. (Mosk.) 81: 11-15 (2003).
Chikuma S, Bluestone JA. CTLA-4 and tolerance: the biochemical point of view. Immunol. Res. 28: 241-253 (2003). *
Child NJ, Yang IA, Pulletz MC, de Courcy-Golder K, Andrews AL, Pappachan VJ, Holloway JW. Polymorphisms in Toll-like receptor 4 and the systemic inflammatory response syndrome. Biochem. Soc. Trans. 31: 652-653 (2003). *
Chin RK, Lo JC, Kim O, Blink SE, Christiansen PA, Peterson P, Wang Y, Ware C, Fu YX. Lymphotoxin pathway directs thymic Aire expression. Nat. Immunol. 4: 1121-11237 (2003). *
Chinetti G, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors and inflammation: from basic science to clinical applications. Int. J. Obes. Relat. Metab. Disord. 27 Suppl. 3: S41-S45 (2003).
Ching DW, McClintock A, Beswick F. Successful treatment with low-dose thalidomide in a patient with both Behcet's disease and complex regional pain syndrome type I: case report. J. Clin. Rheumatol. 9: 96-98 (2003).
Chistiakov DA. Thyroid-stimulating hormone receptor and its role in Graves' disease. Mol. Genet. Metab. 80: 377-388 (2003). *
Chistiakov DA, Turakulov RI. CTLA-4 and its role in autoimmune thyroid disease. J. Mol. Endocrinol. 31: 21-36 (2003). *
Chiu CC, Huang SY, Shen WW, Su KP. Omega-3 fatty acids for depression in pregnancy. Am. J. Psychiatry 160: 385 (2003). *
Cho JH. Significant role of genetics in IBD: the NOD2 gene. Rev. Gastroenterol. Disord. 3 Suppl. 1: S18-S22 (2003). *
Cho MC, Lee HS, Kim JH, Choe YK, Hong JT, Paik SG, Yoon do Y. A simple ELISA for screening ligands of peroxisome proliferator-activated receptor-gamma. J. Biochem. Mol. Biol. 36: 207-213 (2003). *
Choi SW, Bangaru BS, Wu CD, Finlay JL. Gastrointestinal involvement in disseminated Langerhans cell histiocytosis (LCH) with durable complete response to 2-chlorodeoxyadenosine and high-dose cytarabine. J. Pediatr. Hematol. Oncol. 25: 503-506 (2003).
Choi YH, Im EO, Suh H, Jin Y, Yoo YH, Kim ND. Apoptosis and modulation of cell cycle control by synthetic derivatives of ursodeoxycholic acid and chenodeoxycholic acid in human prostate cancer cells. Cancer Lett. 199: 157-167 (2003). *
Chopin-Delannoy S, Thenot S, Delaunay F, Buisine E, Begue A, Duterque-Coquillaud M, Laudet V. A specific and unusual nuclear localization signal in the DNA binding domain of the Rev-erb orphan receptors. J. Mol. Endocrinol. 30: 197-211 (2003). *
Choudhuri S, Cherrington NJ, Li N, Klaassen CD. Constitutive expression of various xenobiotic and endobiotic transporter mRNAs in the choroid plexus of rats. Drug Metab. Dispos. 31: 1337-1345 (2003). *
Choudhury J, Sanyal AJ. Treatment of ascites. Curr. Treat. Options Gastroenterol. 6: 481-491 (2003).
Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci. 6: 33-66 (2003). *
Chow JY, Carlstrom K, Barrett KE. Growth hormone reduces chloride secretion in human colonic epithelial cells via EGF receptor and extracellular regulated kinase. Gastroenterology 125: 1114-1124 (2003). *
Christakos S, Barletta F, Huening M, Dhawan P, Liu Y, Porta A, Peng X. Vitamin D target proteins: function and regulation. J. Cell. Biochem. 88: 238-244 (2003). *
Christakos S, Dhawan P, Liu Y, Peng X, Porta A. New insights into the mechanisms of vitamin D action. J. Cell. Biochem. 88: 695-705 (2003). *
Christensen E. Prognosis of untreated primary sclerosing cholangitis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 63. October 15-16 (2003). *
Christensen T, Moller-Larsen A. Human endogenous retroviruses and disease? Ugeskr. Laeger. 165: 556-561 (2003).
Chrobak P. Control of T cell responses, tolerance and autoimmunity by regulatory T cells: current concepts. Acta Medica (Hradec Kralove) 46: 131-137 (2003).
Chu SH, Lee-Kang J, Lee KH, Lee K. Roles of reactive oxygen species, NF-kappaB, and peroxiredoxins in glycochenodeoxycholic acid-induced rat hepatocytes death. Pharmacology 69: 12-19 (2003).
Chung CC, Tsang WW, Kwok SY, Li MK. Laparoscopy and its current role in the management of colorectal disease. Colorectal Dis. 5: 528-543 (2003). *
Chung HT, Kim LH, Park BL, Lee JH, Park HS, Choi BW, Hong SJ, Chae SC, Kim JJ, Park CS, Shin HD. Association analysis of novel TBX21 variants with asthma phenotypes. Hum. Mutat. 22: 257 (2003). *
Chung SW, Kang BY, Kim TS. Inhibition of interleukin-4 production in CD4+ T cells by peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands: involvement of physical association between PPAR-gamma and the nuclear factor of activated T cells transcription factor. Mol. Pharmacol. 64: 1169-1179 (2003). *
Chung YC, Chang YF. Significance of inflammatory cytokines in the progression of colorectal cancer. Hepatogastroenterology 50: 1910-1913 (2003).
Church RD, Fleshman JW, McLeod HL. Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br. J. Surg. 90: 1055-1067 (2003). *
Ciccocioppo R, Di Sabatino A, Ara C, Biagi F, Perilli M, Amicosante G, Cifone MG, Corazza GR. Gliadin and tissue transglutaminase complexes in normal and coeliac duodenal mucosa. Clin. Exp. Immunol. 134: 516-524 (2003). *
Ciorba MA, Prakash C. Wireless capsule endoscopy in the diagnosis of small bowel Crohn's disease. Inflamm. Bowel Dis. 9: 276 (2003). *
Clabby ML, Robison TA, Quigley HF, Wilson DB, Kelly DP. Retinoid X receptor alpha represses GATA-4-mediated transcription via a retinoid-dependent interaction with the cardiac-enriched repressor FOG-2. J. Biol. Chem. 278: 5760-5767 (2003). *
Clancy R, Borody T, Ren Z, Pang G. Can the response to eradication therapy in Helicobacter pylori infection be predicted? Can. J. Gastroenterol. 17 Suppl. B: 58B-61B (2003).
Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol. 98: 960-967 (2003). *
Clark MP, Benjamin E, Alusi G. A rare case of Crohn's disease in head and neck surgery. J. Laryngol. Otol. 117: 146-147 (2003).
Clark-Curtiss JE, Haydel SE. Molecular genetics of Mycobacterium tuberculosis pathogenesis. Annu. Rev. Microbiol. 57: 517-549 (2003). *
Classen JB, Classen DC. Clustering of cases of type 1 diabetes mellitus occurring 2-4 years after vaccination is consistent with clustering after infections and progression to type 1 diabetes mellitus in autoantibody positive individuals. J. Pediatr. Endocrinol. Metab. 16: 495-508 (2003).
Claudel T, Inoue Y, Barbier O, Duran-Sandoval D, Kosykh V, Fruchart J, Fruchart JC, Gonzalez FJ, Staels B. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology 125: 544-555 (2003). *
Clavien PA. Organ preservation. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 111. October 17 - 19 (2003). *
Clough JD. The promise of molecular biology: efficacy, safety, wallet depletion. Cleve. Clin. J. Med. 70: 584 (2003).
Clough JD. A matter of privacy. Cleve. Clin. J. Med. 70: 166 (2003).
Coeffier M, Marion R, Ducrotte P, Dechelotte P. Modulating effect of glutamine on IL-1beta-induced cytokine production by human gut. Clin. Nutr. 22: 407-413 (2003).
Coghlan MJ, Jacobson PB, Lane B, Nakane M, Lin CW, Elmore SW, Kym PR, Luly JR, Carter GW, Turner R, Tyree CM, Hu J, Elgort M, Rosen J, Miner JN. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol. Endocrinol. 17: 860-869 (2003). *
Cohen RD. The mesalamine wars heat up-enter balsalazide. Gastroenterology 124: 574-575 (2003). *
Cohen RD. Infliximab at 5 years - tweaking the recipe for success? Gastroenterology 125: 1902-1903 (2003). *
Cohen RD. IBD indirect costs: the sleeping giant? Gastroenterology 125: 982-984 (2003). *
Cohn JA. Motion - genetic testing is useful in the diagnosis of nonhereditary pancreatic conditions: arguments against the motion. Can. J. Gastroenterol. 17: 53-55 (2003).
Cohran VC, Heubi JE. Treatment of pediatric cholestatic liver disease. Curr. Treat. Options Gastroenterol. 6: 403-415 (2003).
Colecchia A, Sandri L, Staniscia T, Vestito A, Capodicasa S, Portincasa P, Mazzella G, Roda E, Festi D. Gallbladder motility and functional gastrointestinal disorders. Dig. Liver Dis. 35 Suppl. 3: S30-S34 (2003).
Coleman FT, Mueschenborn S, Meluleni G, Ray C, Carey VJ, Vargas SO, Cannon CL, Ausubel FM, Pier GB. Hypersusceptibility of cystic fibrosis mice to chronic Pseudomonas aeruginosa oropharyngeal colonization and lung infection. Proc. Natl. Acad. Sci. U.S.A. 100: 1949-1954 (2003). *
Colin A, Reggers J, Castronovo V, Ansseau M. Lipids, depression and suicide. Encephale 29: 49-58 (2003).
Colle I, Van Vlierberghe H. Diagnosis and therapeutic problems of primary sclerosing cholangitis. Acta Gastroenterol. Belg. 66: 155-159 (2003).
Colle I, Van Vlierberghe H, Pattyn P, Troisi R, Vogelaers D, de Hemptinne B, De Vos M. Cholestasis as presenting symptom of portal cavernoma. Hepatol. Res. 25: 32-37 (2003). *
Collin P, Reunala T. Recognition and management of the cutaneous manifestations of celiac disease: a guide for dermatologists. Am. J. Clin. Dermatol. 4: 13-20 (2003).
Collins JE, Heward JM, Carr-Smith J, Daykin J, Franklyn JA, Gough SC. Association of a rare thyroglobulin gene microsatellite variant with autoimmune thyroid disease. J. Clin. Endocrinol. Metab. 88: 5039-5042 (2003). *
Collins M, Whitters MJ, Young DA. IL-21 and IL-21 receptor: a new cytokine pathway modulates innate and adaptive immunity. Immunol. Res. 28: 131-140 (2003). *
Colombel JF. The CARD15 (also known as NOD2) gene in Crohn's disease: are there implications for current clinical practice? Clin. Gastroenterol. Hepatol. 1: 5-9 (2003). *
Colombel JF, Ricart E, Loftus EV, Tremaine WJ, Young-Fadok T, Dozois EJ, Wolff BG, Devine R, Pemberton JH, Sandborn WJ. Management of Crohn's disease of the ileoanal pouch with infliximab. Am. J. Gastroenterol. 98: 2239-2244 (2003). *
Colombo M, Sangiovanni A. Etiology, natural history and treatment of hepatocellular carcinoma. Antiviral Res. 60: 145-150 (2003). *
Colonna M. TREMs in the immune system and beyond. Nat. Rev. Immunol. 3: 445-453 (2003). *
Colucci F, Caligiuri MA, Di Santo JP. What does it take to make a natural killer? Nat. Rev. Immunol. 3: 413-425 (2003). *
Cong Y, Konrad A, Iqbal N, Elson CO. Probiotics and immune regulation of inflammatory bowel diseases. Curr. Drug Targets Inflamm. Allergy 2: 145-154 (2003).
Conti F, Morelon E, Calmus Y. Immunosuppressive therapy in liver transplantation. J. Hepatol. 39: 664-678 (2003). *
Conti P, Kempuraj D, Frydas S, Kandere K, Boucher W, Letourneau R, Madhappan B, Sagimoto K, Christodoulou S, Theoharides TC. IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26. Immunol. Lett. 88: 171-174 (2003).
Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur. J. Immunol. 33: 125-134 (2003). *
Cook DN, Hollingsworth JW Jr, Schwartz DA. Toll-like receptors and the genetics of innate immunity. Curr. Opin. Allergy Clin. Immunol. 3: 523-529 (2003).
Coppola N, De Stefano G, Marrocco C, Scarano F, Scolastico C, Tarantino L, Rossi G, Battaglia M, Onofrio M, D'Aniello F, Pisapia R, Sagnelli C, Sagnelli E, Piccinino F, Giorgio A, Filippini P. Helicobacter spp. and liver diseases. Infez. Med. 11: 201-207 (2003).
Cordoba-Rodriguez R, Frucht DM. IL-23 and IL-27: new members of the growing family of IL-12-related cytokines with important implications for therapeutics. Expert Opin. Biol. Ther. 3: 715-723 (2003).
Coremans G, Dockx S, Wyndaele J, Hendrickx A. Do anal fistulas in Crohn's disease behave differently and defy Goodsall's rule more frequently than fistulas that are cryptoglandular in origin? Am. J. Gastroenterol. 98: 2732-2735 (2003). *
Corpechot C. Primary biliary cirrhosis. Gastroenterol. Clin. Biol. 27: 320-324 (2003).
Corpechot C, Carrat F, Bahr A, Poupon RE, Poupon R. The impact of ursodeoxycholic acid (UDCA) therapy with or without liver transplantation (OLT) on long-term survival in primary biliary cirrhosis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 51. October 15-16 (2003). *
Corpechot C, Chazouilleres O. Primary biliary cirrhosis. Primary sclerosing cholangitis. Gastroenterol. Clin. Biol. 27: 325-332 (2003).
Correa PA, Molina JF, Pinto LF, Arcos-Burgos M, Herrera M, Anaya JM. TAP1 and TAP2 polymorphisms analysis in northwestern Colombian patients with systemic lupus erythematosus. Ann. Rheum. Dis. 62: 363-365 (2003). *
Cosma CL, Sherman DR, Ramakrishnan L. The secret lives of the pathogenic mycobacteria. Annu. Rev. Microbiol. 57: 641-676 (2003). *
Costa AM, Tuchweber B, Lamireau T, Yousef IM, Balabaud C, Rosenbaum J, Desmouliere A. Role of apoptosis in the remodeling of cholestatic liver injury following release of the mechanical stress. Virchows Arch. 442: 372-380 (2003). *
Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, Sterpi C, Marchi S, Maltinti G. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig. Liver Dis. 35: 642-647 (2003).
Costantino G, Macchiarulo A, Entrena-Guadix A, Camaioni E, Pellicciari R. Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR). Bioorg. Med. Chem. Lett. 13: 1865-1868 (2003). *
Costello JC, Halverson PB. A new era in rheumatoid arthritis treatment. WMJ 102: 29-33 (2003).
Costet P, Lalanne F, Gerbod-Giannone MC, Molina JR, Fu X, Lund EG, Gudas LJ, Tall AR. Retinoic acid receptor-mediated induction of ABCA1 in macrophages. Mol. Cell. Biol. 23: 7756-7766 (2003). *
Cottone M, Marrone C, Casa A, Oliva L, Orlando A, Calabrese E, Martorana G, Pagliaro L. Familial occurrence of inflammatory bowel disease in celiac disease. Inflamm. Bowel Dis. 9: 321-323 (2003). *
Cottone M, Orlando A, Viscido A, Calabrese E, Camma C, Casa A. Review article: prevention of postsurgical relapse and recurrence in Crohn's disease. Aliment. Pharmacol. Ther. 17 Suppl. 2: 38-42 (2003).
Coulter-Mackie MB, Gagnier L. Spectrum of mutations in the arylsulfatase A gene in a Canadian DNA collection including two novel frameshift mutations, a new missense mutation (C488R) and an MLD mutation (R84Q) in cis with a pseudodeficiency allele. Mol. Genet. Metab. 79: 91-98 (2003). *
Cournu-Rebeix I, Genin E, Lesca G, Azoulay-Cayla A, Tubridy N, Noe E, Clanet M, Edan G, Clerget-Darpoux F, Semana G, Fontaine B. Intercellular adhesion molecule-1: a protective haplotype against multiple sclerosis. Genes Immun. 4: 518-523 (2003). *
Court FG, Wemyss-Holden SA, Dennison AR, Maddern GJ. Bioartificial liver support devices: historical perspectives. ANZ J. Surg. 73: 739-748 (2003). *
Coverdale SA, Field J, Farrell GC. How reversible is hepatic functional impairment in autoimmune hepatitis? J. Gastroenterol. Hepatol. 18: 371-375 (2003). *
Craig RM, Traynor A, Oyama Y, Burt RK. Hematopoietic stem cell transplantation for severe Crohn's disease. Bone Marrow Transplant. 32 Suppl. 1: S57-S59 (2003). *
Cranendonk RJ, Kodde CJ, Chipeta D, Zijlstra EE, Sluiters JF. Cryptosporidium parvum and Isospora belli infections among patients with and without diarrhoea. East Afr. Med. J. 80: 398-401 (2003).
Crawford CL. The schizophrenic career of a "monster drug". Pediatrics 111: 712 (2003). *
Crawford MA, Golfetto I, Ghebremeskel K, Min Y, Moodley T, Poston L, Phylactos A, Cunnane S, Schmidt W. The potential role for arachidonic and docosahexaenoic acids in protection against some central nervous system injuries in preterm infants. Lipids 38: 303-315 (2003).
Crawford NP, Colliver DW, Galandiuk S. Tumor markers and colorectal cancer: utility in management. J. Surg. Oncol. 84: 239-248 (2003).
Crilly A, Hamilton J, Clark CJ, Jardine A, Madhok R. Analysis of the 5' flanking region of the interleukin 10 gene in patients with systemic sclerosis. Rheumatology (Oxford) 42: 1295-1298 (2003). *
Crispe IN. Hepatic T cells and liver tolerance. Nat. Rev. Immunol. 3: 51-62 (2003). *
Crocenzi FA, Mottino AD, Cao J, Veggi LM, Pozzi EJ, Vore M, Coleman R, Roma MG. Estradiol-17beta-D-glucuronide induces endocytic internalization of Bsep in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 285: G449-G459 (2003). *
Crocenzi FA, Mottino AD, Sanchez Pozzi EJ, Pellegrino JM, Rodriguez Garay EA, Milkiewicz P, Vore M, Coleman R, Roma MG. Impaired localisation and transport function of canalicular Bsep in taurolithocholate induced cholestasis in the rat. Gut 52: 1170-1177 (2003). *
Crocenzi FA, Sanchez Pozzi EJ, Pellegrino JM, Rodriguez Garay EA, Mottino AD, Roma MG. Preventive effect of silymarin against taurolithocholate-induced cholestasis in the rat. Biochem. Pharmacol. 66: 355-364 (2003). *
Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3: 609-620 (2003). *
Croker BP, Gilkeson G, Morel L. Genetic interactions between susceptibility loci reveal epistatic pathogenic networks in murine lupus. Genes Immun. 4: 575-585 (2003). *
Cron RQ. CD154 transcriptional regulation in primary human CD4 T cells. Immunol. Res. 27: 185-202 (2003). *
Croog VJ, Ullman TA, Itzkowitz SH. Chemoprevention of colorectal cancer in ulcerative colitis. Int. J. Colorectal Dis. 18: 392-400 (2003). *
Croquet V, Fort J, Oberti F, Roquelaure Y, Ben Bouali AK, Pilette C, Cales P. 1,1,1-Trichloroethane-induced chronic active hepatitis. Gastroenterol. Clin. Biol. 27: 120-122 (2003).
Cross RK, Wilson KT. Nitric oxide in inflammatory bowel disease. Inflamm. Bowel Dis. 9: 179-189 (2003). *
Croucher PJ, Mascheretti S, Foelsch UR, Hampe J, Schreiber S. Lack of association between the C3435T MDR1 gene polymorphism and inflammatory bowel disease in two independent Northern European populations. Gastroenterology 125: 1919-1920 (2003). *
Croucher PJ, Mascheretti S, Hampe J, Huse K, Frenzel H, Stoll M, Lu T, Nikolaus S, Yang SK, Krawczak M, Kim WH, Schreiber S. Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur. J. Hum. Genet. 11: 6-16 (2003). *
Crowley-Weber CL, Dvorakova K, Crowley C, Bernstein H, Bernstein C, Garewal H, Payne CM. Nicotine increases oxidative stress, activates NF-kappaB and GRP78, induces apoptosis and sensitizes cells to genotoxic/xenobiotic stresses by a multiple stress inducer, deoxycholate: relevance to colon carcinogenesis. Chem. Biol. Interact. 145: 53-66 (2003). *
Crowson AN, Mihm MC Jr, Magro CM. Cutaneous vasculitis: a review. J. Cutan. Pathol. 30: 161-173 (2003). *
Crowson AN, Nuovo GJ, Mihm MC Jr, Magro C. Cutaneous manifestations of Crohn's disease, its spectrum, and its pathogenesis: intracellular consensus bacterial 16S rRNA is associated with the gastrointestinal but not the cutaneous manifestations of Crohn's disease. Hum. Pathol. 34: 1185-1192 (2003). *
Csepregi A, Obermayer-Straub P, Kneip S, Kayser A, Loges S, Schmidt E, Nemesanszky E, Szalay F, Manns MP, Strassburg CP. Characterization of a lipoyl domain-independent B-cell autoepitope on the human branched-chain acyltransferase in primary biliary cirrhosis and overlap syndrome with autoimmune hepatitis. Clin. Dev. Immunol. 10: 173-181 (2003). *
Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748 (2003). *
Cucca F, Contu D, Zavattari P, Murru D. Correlation between major histocompatibility complex (MHC)-class II and type 1 diabetes. Minerva Endocrinol. 28: 111-122 (2003).
Cuenca J, Cuchacovich M, Perez C, Ferreira L, Aguirre A, Schiattino I, Soto L, Cruzat A, Salazar-Onfray F, Aguillon JC. The -308 polymorphism in the tumour necrosis factor (TNF) gene promoter region and ex vivo lipopolysaccharide-induced TNF expression and cytotoxic activity in Chilean patients with rheumatoid arthritis. Rheumatology (Oxford) 42: 308-313 (2003). *
Cui B, Abe M, Hidata S, Nakanishi S, Matsuura B, Michitaka K, Yamamoto K, Horiike N, Onji M. Autoimmune hepatitis associated with Graves' disease. Intern. Med. 42: 331-335 (2003). *
Cui J, Huang L, Zhao A, Lew JL, Yu J, Sahoo S, Meinke PT, Royo I, Pelaez F, Wright SD. Guggulsterone is a farnesoid X receptor antagonist in coactivator association assays but acts to enhance transcription of bile salt export pump. J. Biol. Chem. 278: 10214-10220 (2003). *
Cui R, He J, Zhang F, Wang B, Ding H, Shen H, Li Y, Chen X. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br. J. Cancer 88: 1878-1882 (2003). *
Cui Y, Konig J, Nies AT, Pfannschmidt M, Hergt M, Franke WW, Alt W, Moll R, Keppler D. Detection of the human organic anion transporters SLC21A6 (OATP2) and SLC21A8 (OATP8) in liver and hepatocellular carcinoma. Lab. Invest. 83: 527-538 (2003).
Cukovic-Cavka S. Primary biliary cirrhosis. Acta Med. Croatica 57: 221-225 (2003).
Cullen LM, Prat L, Cox DW. Genetic variation in the promoter and 5' UTR of the copper transporter, ATP7B, in patients with Wilson disease. Clin. Genet. 64: 429-432 (2003). *
Cullen M, Malasky M, Harding A, Carrington M. High-density map of short tandem repeats across the human major histocompatibility complex. Immunogenetics 54: 900-910 (2003). *
Cullen S, Chapman R. Primary sclerosing cholangitis. Autoimmun. Rev. 2: 305-312 (2003).
Cummings JH, Macfarlane GT, Macfarlane S. Intestinal bacteria and ulcerative colitis. Curr. Issues Intest. Microbiol. 4: 9-20 (2003).
Cunliffe RN. alpha-Defensins in the gastrointestinal tract. Mol. Immunol. 40: 463-467 (2003). *
Cunningham S, McColm JR, Mallinson A, Boyd I, Marshall TG. Duration of effect of intravenous antibiotics on spirometry and sputum cytokines in children with cystic fibrosis. Pediatr. Pulmonol. 36: 43-48 (2003).
Curley SA. CHAPTER 99. Diagnosis and Management of Biliary Tract Cancer. (http://www.cancer.org/downloads/PUB/DOCS/SECTION29/99.pdf) SECTION 29. Neoplasms of the Alimentary Canal. pp. 1423-1430 (2003). *
Cuzzocrea S. Emerging biotherapies for inflammatory bowel disease. Expert Opin. Emerg. Drugs 8: 339-347 (2003).
Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. Br. J. Pharmacol. 140: 366-376 (2003). *
Czaja AJ. The autoimmune hepatitis/hepatitis C overlap syndrome: does it exist? Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 42-43. October 15-16 (2003). *
Czaja AJ. Autoimmune liver disease. Curr. Opin. Gastroenterol. 19: 232-242 (2003). *
Czaja AJ, Carpenter HA. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int. 23: 116-123 (2003). *
Czaja AJ, Norman GL. Autoantibodies in the diagnosis and management of liver disease. J. Clin. Gastroenterol. 37: 315-329 (2003).
Czaja AJ, Shums Z, Binder WL, Lewis SJ, Nelson VJ, Norman GL. Frequency and significance of antibodies to chromatin in autoimmune hepatitis. Dig. Dis. Sci. 48: 1658-1664 (2003). *
Czarneski J, Rassa JC, Ross SR. Mouse mammary tumor virus and the immune system. Immunol. Res. 27: 469-480 (2003).
Czuczejko J, Zachara BA, Staubach-Topczewska E, Halota W, Kedziora J. Selenium, glutathione and glutathione peroxidases in blood of patients with chronic liver diseases. Acta Biochim. Pol. 50: 1147-1154 (2003). *
D'Eredita G, Ferrarese F, Cecere V, Fabiano G. Factors affecting prognosis in patients with short bowel syndrome. G. Chir. 24: 302-304 (2003).
D'Haens G. Anti-TNF therapy for Crohn's disease. Curr. Pharm. Des. 9: 289-294 (2003).
D'Haens GR. Infliximab as disease-modifying therapy. Eur. J. Gastroenterol. Hepatol. 15: 233-237 (2003). *
Da Silva AM, Maciel RM, Da Silva MR, Toledo SR, De Carvalho MB, Cerutti JM. A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 88: 5438-5443 (2003). *
Dabeva MD, Shafritz DA. Hepatic stem cells and liver repopulation. Semin. Liver Dis. 23: 349-362 (2003).
Dafnis G, Blomqvist P, Granath F, Pahlman L, Ekbom A. Colorectal cancer detection by colonoscopy in a Swedish county, 1979-95. Scand. J. Gastroenterol. 38: 1059-1067 (2003). *
Dahlan Y, Smith L, Simmonds D, Jewell LD, Wanless I, Heathcote EJ, Bain VG. Pediatric-onset primary biliary cirrhosis. Gastroenterology 125: 1476-1479 (2003). *
Dai T, Wu Y, Leng AS, Ao Y, Robel RC, Lu SC, French SW, Wan YJ. RXRalpha-regulated liver SAMe and GSH levels influence susceptibility to alcohol-induced hepatotoxicity. Exp. Mol. Pathol. 75: 194-200 (2003). *
Daikh BE, Ryan CK, Schwartz RH. Montelukast reduces peripheral blood eosinophilia but not tissue eosinophilia or symptoms in a patient with eosinophilic gastroenteritis and esophageal stricture. Ann. Allergy Asthma Immunol. 90: 23-27 (2003).
Daimon Y, Yamanishi K, Murakami Y, Kirishima T, Ito Y, Minami M, Okanoue T. Novel single nucleotide polymorphisms of the cytokeratin 19 pseudogene are associated with primary biliary cirrhosis. Hepatol. Res. 25: 281-286 (2003).
Dalby-Payne JR, O'Loughlin EV, Gunning P. Polarization of specific tropomyosin isoforms in gastrointestinal epithelial cells and their impact on CFTR at the apical surface. Mol. Biol. Cell 14: 4365-4375 (2003). *
Dalwadi H, Wei B, Schrage M, Spicher K, Su TT, Birnbaumer L, Rawlings DJ, Braun J. B cell developmental requirement for the Galphai2 gene. J. Immunol. 170: 1707-1715 (2003). *
Danalioglu A, Kaymakoglu S, Mungan Z, Karaca C, Demir K, Durakoglu Z, Besisik F, Boztas G, Cakaloglu Y, Okyen A. Cyclosporin for severe ulcerative colitis attacks. Hepatogastroenterology 50 Suppl. 2: ccxcviii-ccc (2003).
Danby FW. Night blindness, vitamin A deficiency, and isotretinoin psychotoxicity. Dermatol. Online J. 9: 30 (2003). *
Danelli P, Bartolucci C, Sampietro GM, Panizzo V, Sartani A, Maconi G, Parente E, Taschieri AM. Surgical options in the treatment of perianal Crohn's disease. Ann. Ital. Chir. 74: 635-640 (2003).
Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, Fiocchi C. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 52: 1435-1441 (2003). *
Dardon A, Corona R, Mendez-Sanchez N. Hepatocellular carcinoma not associated with virus B and C and alcohol. Ann. Hepatol. 2: 46 (2003). *
Das UN, Ramos EJ, Meguid MM. Metabolic alterations during inflammation and its modulation by central actions of omega-3 fatty acids. Curr. Opin. Clin. Nutr. Metab. Care 6: 413-419 (2003).
Dascher CC, Brenner MB. CD1 antigen presentation and infectious disease. Contrib. Microbiol. 10: 164-182 (2003).
Dattner AM. From medical herbalism to phytotherapy in dermatology: back to the future. Dermatol. Ther. 16: 106-113 (2003).
Davari HR, Malekhossini SA, Salahi HA, Bahador A, Saberifirozi M, Geramizadeh B, Lahsaee SM, Khosravi MB, Imanieh MH, Bagheri MH. Outcome of mucormycosis in liver transplantation: four cases and a review of literature. Exp. Clin. Transplant. 1: 147-152 (2003).
Davidson BL. Hepatic diseases - hitting the target with inhibitory RNAs. N. Engl. J. Med. 349: 2357-2359 (2003). *
Davies DB. The impact of PELD on OPTN liver allocation: preliminary results. Clin. Transpl. 2003: 13-20 (2003).
Davies TF, Greenberg D, Tomer Y. The genetics of the autoimmune thyroid diseases. Ann. Endocrinol. (Paris) 64: 28-30 (2003).
Davies YK, Cox KM, Abdullah BA, Terry AB, Cox KL. Oral vancomycin: treatment of primary sclerosing cholangitis in children. J. Pediatr. Gastroenterol. Nutr. 37: 345-346 (2003). *
Davis JC Jr, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, Kivitz A, Fleischmann R, Inman R, Tsuji W; Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 48: 3230-3236 (2003). *
Davis KG, Wertin TM, Schriver JP. The use of simvastatin for the prevention of gallstones in the lithogenic prairie dog model. Obes. Surg. 13: 865-868 (2003).
Dawson PA, Haywood J, Craddock AL, Wilson M, Tietjen M, Kluckman K, Maeda N, Parks JS. Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. J. Biol. Chem. 278: 33920-33927 (2003). *
Day CP. Alcoholic steatohepatitis (ASH). Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 85-86. October 17 - 19 (2003). *
Day RM, Mitchell TJ, Knight SC, Forbes A. Regulation of epithelial syndecan-1 expression by inflammatory cytokines. Cytokine 21: 224-233 (2003). *
De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev. 24: 488-522 (2003). *
De Fabiani E, Mitro N, Gilardi F, Caruso D, Galli G, Crestani M. Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle. J. Biol. Chem. 278: 39124-39132 (2003). *
de Franchis R. Evaluation and follow-up of patients with cirrhosis and oesophageal varices. J. Hepatol. 38: 361-363 (2003). *
de Freitas Junior S, Bustorff-Silva JM, Castro e Silva Junior O, Jorge Gde L, Leonardi LS. Retinyl-palmitate reduces liver fibrosis induced by biliary obstruction in rats. Hepatogastroenterology 50: 146-150 (2003).
de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin. Diagn. Lab. Immunol. 10: 133-139 (2003). *
de Jong DJ, Derijks LJ, Naber AH, Hooymans PM, Mulder CJ. Safety of thiopurines in the treatment of inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 239: 69-72 (2003). *
de Jong DJ, Franke B, Naber AH, Willemen JJ, Heister AJ, Brunner HG, de Kovel CG, Hol FA. No evidence for involvement of IL-4R and CD11B from the IBD1 region and STAT6 in the IBD2 region in Crohn's disease. Eur. J. Hum. Genet. 11: 884-887 (2003). *
de Jong DJ, van der Logt EM, van Schaik A, Roelofs HM, Peters WH, Naber TH. Genetic polymorphisms in biotransformation enzymes in Crohn's disease: association with microsomal epoxide hydrolase. Gut 52: 547-551 (2003). *
De Lange T, Moum BA, Tholfsen JK, Larsen S, Aabakken L. Standardization and quality of endoscopy text reports in ulcerative colitis. Endoscopy 35: 835-840 (2003).
De las Heras D, Fernandez J, Gines P, Cardenas A, Ortega R, Navasa M, Barbera JA, Calahorra B, Guevara M, Bataller R, Jimenez W, Arroyo V, Rodes J. Increased carbon monoxide production in patients with cirrhosis with and without spontaneous bacterial peritonitis. Hepatology 38: 452-459 (2003). *
De Miguel S, Jover JA, Vadillo C, Judez E, Loza E, Fernandez-Gutierrez B. B cell activation in rheumatoid arthritis patients under infliximab treatment. Clin. Exp. Rheumatol. 21: 726-732 (2003).
de Oca J, Sanchez-Santos R, Rague JM, Biondo S, Pares D, Osorio A, del Rio C, Jaurrieta E. Long-term results of ileal pouch-anal anastomosis in Crohn's disease. Inflamm. Bowel Dis. 9: 171-175 (2003). *
de Oca J, Vilar L, Castellote J, Sanchez Santos R, Pares D, Biondo S, Osorio A, del Rio C, Jaurrieta E, Marti Rague J. Immunodulation with tacrolimus (FK506): results of a prospective, open-label, non-controlled trial in patients with inflammatory bowel disease. Rev. Esp. Enferm. Dig. 95: 465-470, 459-464 (2003).
de Raucourt E, Barbier C, Sinda P, Dib M, Peltier JY, Ternisien C. High-dose intravenous immunoglobulin treatment in two patients with acquired factor V inhibitors. Am. J. Hematol. 74: 187-190 (2003). *
De Rosa FG, Shaz D, Campagna AC, Dellaripa PE, Khettry U, Craven DE. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect. Control Hosp. Epidemiol. 24: 477-482 (2003). *
de Silva AD, Mylonaki M, Rampton DS. Oral iron therapy in inflammatory bowel disease: usage, tolerance, and efficacy. Inflamm. Bowel Dis. 9: 316-320 (2003). *
de Silva HA, Saparamadu PA, Thabrew MI, Pathmeswaran A, Fonseka MM, de Silva HJ. Liv.52 in alcoholic liver disease: a prospective, controlled trial. J. Ethnopharmacol. 84: 47-50 (2003).
De Tommaso AM, Santos DS, Novaes P, Arieta CE, Hessel G. Steroid-induced cataracts in patients with autoimmune hepatitis. Acta Gastroenterol. Latinoam. 33: 93-97 (2003).
de Villartay JP, Fischer A, Durandy A. The mechanisms of immune diversification and their disorders. Nat. Rev. Immunol. 3: 962-972 (2003). *
de Villiers WJ. Crohn's disease and IL-10 therapy: promise regained. Inflamm. Bowel Dis. 9: 210-211 (2003). *
De Vizia B, Raia V, Spano C, Pavlidis C, Coruzzo A, Alessio M. Effect of an 8-month treatment with omega-3 fatty acids (eicosapentaenoic and docosahexaenoic) in patients with cystic fibrosis. JPEN J. Parenter. Enteral Nutr. 27: 52-57 (2003). *
De Vries EG, Timmer T, Mulder NH, Van Geelen CM, Van Der Graaf WT, Spierings DC, De Hooge MN, Gietema JA, De Jong S. Modulation of death receptor pathways in oncology. Drugs Today (Barc.) 39 Suppl. C: 95-109 (2003).
De Wachter E, Malfroot A, De Schutter I, Vanbesien J, De Schepper J. Inhaled budesonide induced Cushing's syndrome in cystic fibrosis patients, due to drug inhibition of cytochrome P450. J. Cyst. Fibros. 2: 72-75 (2003).
Debler J, Schiemann U, Seybold U, Mussack T, Landauer N, Ladurner R, Gross M. Heat-shock protein HSP70-2 genotypes in patients with Crohn's disease: a more severe clinical course with intestinal complications in presence of the PstI-polymorphism. Eur. J. Med. Res. 8: 120-124 (2003).
Dehmer C, Greinwald R, Loffler J, Grotz W, Wolf L, Hagmann HB, Schneider W, Kreisel W; German Salofalk Study Group. No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases. Int. J. Colorectal Dis. 18: 406-412 (2003). *
Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment. Pharmacol. Ther. 18: 1113-1120 (2003). *
Del Castillo IC, Alvarez JG, Freedman SD, Ollero M, Claros L, Song JC, Yoo J, Matthews JB. Docosahexaenoic acid selectively augments muscarinic stimulation of epithelial Cl- secretion. J. Surg. Res. 110: 338-343 (2003). *
Del Zotto B, Mumolo G, Pronio AM, Montesani C, Tersigni R, Boirivant M. TGF-beta1 production in inflammatory bowel disease: differing production patterns in Crohn's disease and ulcerative colitis. Clin. Exp. Immunol. 134: 120-126 (2003). *
Delacourt C. Inflammation and cystic fibrosis. Arch. Pediatr. 10 Suppl. 2: 338s-341s (2003).
Delaney BC, Moayyedi P, Forman D. Initial management strategies for dyspepsia. Cochrane Database Syst. Rev. 2: CD001961 (2003). *
DeLeve LD. Vascular liver diseases. Curr. Gastroenterol. Rep. 5: 63-70 (2003).
Delgado J, Delgado B, Sztarkier I, Cagnano E, Sperber AD, Fich A. Presentation of Crohn's disease as metastatic cutaneous non-caseating granulomatous lesions. Isr. Med. Assoc. J. 5: 897-898 (2003). *
Delgado M, Abad C, Martinez C, Juarranz MG, Leceta J, Ganea D, Gomariz RP. PACAP in immunity and inflammation. Ann. N. Y. Acad. Sci. 992: 141-157 (2003). *
Demenais F, Kanninen T, Lindgren CM, Wiltshire S, Gaget S, Dandrieux C, Almgren P, Sjögren M, Hattersley A, Dina C, Tuomi T, McCarthy MI, Froguel P, Groop LC. A meta-analysis of four European genome screens (GIFT Consortium) shows evidence for a novel region on chromosome 17p11.2-q22 linked to type 2 diabetes. Hum. Mol. Genet. 12: 1865-1873 (2003). *
Dempsey PW, Vaidya SA, Cheng G. The art of war: innate and adaptive immune responses. Cell. Mol. Life Sci. 60: 2604-2621 (2003). *
Deng L, Ding W, Granstein RD. Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells. J. Invest. Dermatol. 121: 1060-1065 (2003). *
Denis M, Bissonnette R, Haidar B, Krimbou L, Bouvier M, Genest J. Expression, regulation, and activity of ABCA1 in human cell lines. Mol. Genet. Metab. 78: 265-274 (2003). *
Denk H. Alcoholic hepatitis and Mallory bodies. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 46. October 17 - 19 (2003). *
Deodhar NS. Epidemiological perspective of domestic and personal hygiene in India. Int. J. Environ. Health Res. 13 Suppl. 1: S47-S56 (2003).
Deplancke B, Finster K, Graham WV, Collier CT, Thurmond JE, Gaskins HR. Gastrointestinal and microbial responses to sulfate-supplemented drinking water in mice. Exp. Biol. Med. (Maywood) 228: 424-433 (2003). *
Derijks LJ, de Jong DJ, Gilissen LP, Engels LG, Hooymans PM, Jansen JB, Mulder CJ. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur. J. Gastroenterol. Hepatol. 15: 63-67 (2003).
Descamps V, Mahe E, Houhou N, Abramowitz L, Rozenberg F, Ranger-Rogez S, Crickx B. Drug-induced hypersensitivity syndrome associated with Epstein-Barr virus infection. Br. J. Dermatol. 148: 1032-1034 (2003). *
Deshmukh R, Franco K. Talking to patients about St. John's wort. Cleve. Clin. J. Med. 70: 985-989 (2003).
Desideri G, Croce G, Tucci M, Passacquale G, Broccoletti S, Valeri L, Santucci A, Ferri C. Effects of bezafibrate and simvastatin on endothelial activation and lipid peroxidation in hypercholesterolemia: evidence of different vascular protection by different lipid-lowering treatments. J. Clin. Endocrinol. Metab. 88: 5341-5437 (2003). *
Desiderio S, Yoo JY. A genome-wide analysis of the acute-phase response and its regulation by Stat3beta. Ann. N. Y. Acad. Sci. 987: 280-284 (2003). *
Desjardins M. ER-mediated phagocytosis: a new membrane for new functions. Nat. Rev. Immunol. 3: 280-291 (2003).
Desmet VJ. Classification of chronic hepatitis. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 44-45. October 17 - 19 (2003). *
Desmet VJ. Histology of autoimmune cholestatic liver diseases. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 25-26. October 15-16 (2003). *
Desreumaux P, Colombel JF. Intestinal flora and Crohn's disease. Ann. Pharm. Fr. 61: 276-281 (2003).
DeStefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, Shinefield HR, Mullooly JP, Likosky W, Chen RT; Vaccine Safety Datalink Research Group, National Immunization Program, Centers for Disease Control and Prevention. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch. Neurol. 60: 504-509 (2003). *
Detkova Z, Kupcova V, Prikazska M, Turecky L, Weissova S, Jahnova E. Different patterns of serum interleukin 10 response to treatment with anti-tumor necrosis factor alpha antibody (infliximab) in Crohn's disease. Physiol. Res. 52: 95-100 (2003). *
Deurloo DT, van Berkel MA, van Esch BC, Hofhuis F, Nijkamp FP, Oosterwegel MA, van Oosterhout AJ. CD28/CTLA4 double deficient mice demonstrate crucial role for B7 co-stimulation in the induction of allergic lower airways disease. Clin. Exp. Allergy 33: 1297-1304 (2003). *
Devaney J, Maher M, Smith T, Houghton JA, Glennon M. HFE alleles in an Irish cystic fibrosis population. Genet. Test. 7: 155-158 (2003).
Devine DA. Antimicrobial peptides in defence of the oral and respiratory tracts. Mol. Immunol. 40: 431-443 (2003). *
Dhillon NK, Mudryj M. Cyclin E overexpression enhances cytokine-mediated apoptosis in MCF7 breast cancer cells. Genes Immun. 4: 336-342 (2003). *
Di Campli C, Gasbarrini G, Gasbarrini A. Review article: a medicine based on cell transplantation - is there a future for treating liver diseases? Aliment. Pharmacol. Ther. 18: 473-480 (2003). *
Di Campli C, Nestola M, Piscaglia AC, Santoliquido A, Gasbarrini G, Pola P, Gasbarrini A. Cell-based therapy for liver diseases. Eur. Rev. Med. Pharmacol. Sci. 7: 41-44 (2003).
Di Marco R, Mangano K, Quattrocchi C, Musumeci R, Speciale AM, Papaccio G, Buschard K, Bendtzen K, Nicoletti F. Curative effects of sodium fusidate on the development of dinitrobenzenesulfonic acid-induced colitis in rats. Clin. Immunol. 109: 266-271 (2003). *
Di Sabatino A, Ciccocioppo R, Luinetti O, Ricevuti L, Morera R, Cifone MG, Solcia E, Corazza GR. Increased enterocyte apoptosis in inflamed areas of Crohn's disease. Dis. Colon Rectum 46: 1498-1507 (2003).
Di Sario A, Bendia E, Taffetani S, Marzioni M, Candelaresi C, Pigini P, Schindler U, Kleemann HW, Trozzi L, Macarri G, Benedetti A. Selective Na+/H+ exchange inhibition by cariporide reduces liver fibrosis in the rat. Hepatology 37: 256-266 (2003). *
Diamanti A, Papadatou B, Knafelz D, Gambarara M, Ferretti F, Castro M. Complications of infliximab therapy in children and adolescents affected by Crohn's disease. Am. J. Gastroenterol. 98: 2812-2813 (2003). *
Diculescu M, Ciocirlan M, Ciocirlan M, Pitigoi D, Becheanu G, Croitoru A, Spanache S. Folic acid and sulfasalazine for colorectal carcinoma chemoprevention in patients with ulcerative colitis: the old and new evidence. Rom. J. Gastroenterol. 12: 283-286 (2003).
Didziapetris R, Japertas P, Avdeef A, Petrauskas A. Classification analysis of P-glycoprotein substrate specificity. J. Drug Target. 11: 391-406 (2003).
Dieleman LA, Goerres MS, Arends A, Sprengers D, Torrice C, Hoentjen F, Grenther WB, Sartor RB. Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 52: 370-376 (2003). *
Dienes HP. Histopathology of overlap syndromes in the liver. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 44-45. October 15-16 (2003). *
Dierkes J, Westphal S, Luley C. Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management. Drug Saf. 26: 81-91 (2003).
Dieterich W, Esslinger B, Schuppan D. Pathomechanisms in celiac disease. Int. Arch. Allergy Immunol. 132: 98-108 (2003).
Dietrich CG, Geier A, Oude Elferink RP. ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut 52: 1788-1795 (2003). *
Dietrich W, Erbguth F. Neurological complications of inflammatory intestinal diseases. Fortschr. Neurol. Psychiatr. 71: 406-414 (2003).
DiGiovanna JJ, Robinson-Bostom L. Ichthyosis: etiology, diagnosis, and management. Am. J. Clin. Dermatol. 4: 81-95 (2003).
Dijkstra G, Hospers GA, Kleibeuker JH. Gene therapy with interleukin 10 in Crohn's disease: too early yet. Ned. Tijdschr. Geneeskd. 147: 2153-2156 (2003).
Dikopoulos N, Weidenbach H, Adler G, Schmid RM. Lipopolysaccharide represses cholesterol 7-alpha hydroxylase and induces binding activity to the bile acid response element II. Eur. J. Clin. Invest. 33: 58-64 (2003). *
Dimicoli S, Bensoussan D, Latger-Cannard V, Straczek J, Antunes L, Mainard L, Dao A, Barbe F, Araujo C, Clement L, Feugier P, Lecompte T, Stoltz JF, Bordigoni P. Complete recovery from Cryptosporidium parvum infection with gastroenteritis and sclerosing cholangitis after successful bone marrow transplantation in two brothers with X-linked hyper-IgM syndrome. Bone Marrow Transplant. 32: 733-737 (2003). *
Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine 21 Suppl. 2: S24-S34 (2003). *
Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu. Rev. Pharmacol. Toxicol. 43: 149-173 (2003). *
Ding Y, Chen D, Tarcsafalvi A, Su R, Qin L, Bromberg JS. Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses. J. Immunol. 170: 1383-1391 (2003). *
Ding YL, Tan LL, Deng W. Clinical analysis of intrahepatic cholestasis during pregnancy in 150 patients. Hunan Yi Ke Da Xue Xue Bao 28: 645-647 (2003).
Dionne S, Laberge S, Deslandres C, Seidman EG. Modulation of cytokine release from colonic explants by bacterial antigens in inflammatory bowel disease. Clin. Exp. Immunol. 133: 108-114 (2003). *
Direskeneli H, Saruhan-Direskeneli G. The role of heat shock proteins in Behcet's disease. Clin. Exp. Rheumatol. 21: S44-S48 (2003).
Distante S, Elmberg M, Foss Haug KB, Ovstebo R, Berg JP, Kierulf P, Hultcrantz R, Bell H. Tumour necrosis factor alpha and its promoter polymorphisms' role in the phenotypic expression of hemochromatosis. Scand. J. Gastroenterol. 38: 871-877 (2003). *
Ditschkowski M, Einsele H, Schwerdtfeger R, Bunjes D, Trenschel R, Beelen DW, Elmaagacli AH. Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation. Transplantation 75: 1745-1747 (2003).
Dittmar M, Kahaly GJ. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J. Clin. Endocrinol. Metab. 88: 2983-2992 (2003). *
Dittrich S, de Mattos AA, Becker M, Goncaves DM, Cheinquer H. Role of hepatic hemodynamic study in the evaluation of patients with cirrhosis. Hepatogastroenterology 50: 2052-2056 (2003).
Djouadi F, Bonnefont JP, Thuillier L, Droin V, Khadom N, Munnich A, Bastin J. Correction of fatty acid oxidation in carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate. Pediatr. Res. 54: 446-451 (2003). *
Dobbin CJ, Moriarty C, Bye PT. Granulomatous diseases in a patient with cystic fibrosis. J. Cyst. Fibros. 2: 35-37 (2003).
Dobrovolskaia MA, Medvedev AE, Thomas KE, Cuesta N, Toshchakov V, Ren T, Cody MJ, Michalek SM, Rice NR, Vogel SN. Induction of in vitro reprogramming by Toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR "homotolerance" versus "heterotolerance" on NF-kappa B signaling pathway components. J. Immunol. 170: 508-519 (2003). *
Dode C, Cuisset L, Delpech M, Grateau G. TNFRSF1A-associated periodic syndrome (TRAPS), Muckle-Wells syndrome (MWS) and renal amyloidosis. J. Nephrol. 16: 435-437 (2003).
Dolan M, Lindberg G. The Inflammatory Bowel Disease Act: Congress considers landmark legislation focused exclusively on inflammatory bowel disease. Inflamm. Bowel Dis. 9: 59-60 (2003). *
Dommels YE, Haring MM, Keestra NG, Alink GM, van Bladeren PJ, van Ommen B. The role of cyclooxygenase in n-6 and n-3 polyunsaturated fatty acid mediated effects on cell proliferation, PGE(2) synthesis and cytotoxicity in human colorectal carcinoma cell lines. Carcinogenesis 24: 385-392 (2003). *
Donadiue J. Langerhans' cell histiocytosis. Orphanet Encyclopedia, May 2003, p 1-8 (http://www.orpha.net/data/patho/GB/uk-LCH.pdf) (2003). *
Donaldson P. HLA system and other genetic markers in PSC. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 71-72. October 15-16 (2003). *
Donaldson PT. Immunogenetics in liver diseases. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 23-24. September 12 - 13 (2003). *
Dong WG, Liu SP, Yu BP, Wu DF, Luo HS, Yu JP. Ameliorative effects of sodium ferulate on experimental colitis and their mechanisms in rats. World J. Gastroenterol. 9: 2533-2538 (2003). *
Doria C, Doyle HR, Mandala L, Marino IR, Caruana G, Gruttadauria S, Lauro A, Magnone M, Scotti Foglieni C, Lamonaca V, Scott VL. Changes in serum electrolytes during treatment of patients in liver failure with molecular adsorbent recirculating system. Int. J. Artif. Organs 26: 918-923 (2003).
Dowds TA, Masumoto J, Chen FF, Ogura Y, Inohara N, Nunez G. Regulation of cryopyrin/Pypaf1 signaling by pyrin, the familial Mediterranean fever gene product. Biochem. Biophys. Res. Commun. 302: 575-580 (2003). *
Downes M, Verdecia MA, Roecker AJ, Hughes R, Hogenesch JB, Kast-Woelbern HR, Bowman ME, Ferrer JL, Anisfeld AM, Edwards PA, Rosenfeld JM, Alvarez JG, Noel JP, Nicolaou KC, Evans RM. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. Mol. Cell 11: 1079-1092 (2003). *
Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22: 7340-7358 (2003). *
Dragnev KH, Petty WJ, Dmitrovsky E. Retinoid targets in cancer therapy and chemoprevention. Cancer Biol. Ther. 2: S150-S156 (2003).
Drancourt M, Jacomo V, Lepidi H, Lechevallier E, Grisoni V, Coulange C, Ragni E, Alasia C, Dussol B, Berland Y, Raoult D. Attempted isolation of Nanobacterium sp. microorganisms from upper urinary tract stones. J. Clin. Microbiol. 41: 368-372 (2003). *
Dray X, Marteau P, Bienvenu T, Dusser D, Hubert D. Discussion on genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology 125: 1286 (2003). *
Dresch C, Xavier R, Brenol JC, Nardi NB, Chies JA. Analysis of two T-cell receptor BV gene segment polymorphisms in caucasoid Brazilian patients with rheumatoid arthritis. Immunol. Lett. 90: 77-80 (2003).
Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, Fromm MF. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin. Pharmacol. Ther. 73: 223-231 (2003). *
Drewe E, McDermott EM, Powell PT, Isaacs JD, Powell RJ. Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS)… Rheumatology (Oxford) 42: 235-239 (2003). *
Drewe E, Zaitoun AM, Walker DA. Case 11-2003: ulcerative colitis and primary sclerosing cholangitis in a 14-year-old boy. N. Engl. J. Med. 349: 1482 (2003).
Drisko JA, Giles CK, Bischoff BJ. Probiotics in health maintenance and disease prevention. Altern. Med. Rev. 8: 143-155 (2003). *
Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J. Cutan. Med. Surg. 7: 382-386 (2003). *
du Bois RM, Goh N, McGrath D, Cullinan P. Is there a role for microorganisms in the pathogenesis of sarcoidosis? J. Intern. Med. 253: 4-17 (2003). *
Du Y, Zhang QY, Ruan LR, Liang CC, Li QR, He W. The relationship between abnormal apoptosis and Fas expression of thymocytes from patients with myasthenia gravis. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 19: 450-453 (2003).
Duan HO, Simpson-Haidaris PJ. Functional analysis of interleukin 6 response elements (IL-6REs) on the human gamma-fibrinogen promoter: binding of hepatic Stat3 correlates negatively with transactivation potential of type II IL-6REs. J. Biol. Chem. 278: 41270-41281 (2003). *
Dubaniewicz A, Dubaniewicz A. Cholangiocarcinoma - bile ducts cancer. Wiad. Lek. 56: 57-60 (2003).
Dubaniewicz A, Szczerkowska Z, Hoppe A. Comparative analysis of HLA class I antigens in pulmonary sarcoidosis and tuberculosis in the same ethnic group. Mayo Clin. Proc. 78: 436-442 (2003). *
Dubey AP, Banerjee S. Measles, mumps, rubella (MMR) vaccine. Indian J. Pediatr. 70: 579-584 (2003).
Dubinsky MC. Optimizing immunomodulator therapy for inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 506-511 (2003).
Dubinsky MC. Monitoring of AZA/6-MP treatment in children with IBD is necessary. Inflamm. Bowel Dis. 9: 386-388 (2003). *
Dubinsky MC, Fleshner PP. Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes. Curr. Treat. Options Gastroenterol. 6: 183-200 (2003).
Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125: 298-303 (2003). *
Dubois RN. Will an aspirin a day keep the endoscope away? Gastroenterology 125: 612-614 (2003). *
Dubuquoy L, Jansson EA, Deeb S, Rakotobe S, Karoui M, Colombel JF, Auwerx J, Pettersson S, Desreumaux P. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 124: 1265-1276 (2003). *
Duclos P. Safety of immunisation and adverse events following vaccination against hepatitis B. Expert Opin. Drug Saf. 2: 225-231 (2003).
Duclos-Vallee JC, Sebagh M, Rifai K, Johanet C, Ballot E, Guettier C, Karam V, Hurtova M, Feray C, Reynes M, Bismuth H, Samuel D. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence. Gut 52: 893-897 (2003). *
Duerr RH. Update on the genetics of inflammatory bowel disease. J. Clin. Gastroenterol. 37: 358-367 (2003).
Duggal P, An P, Beaty TH, Strathdee SA, Farzadegan H, Markham RB, Johnson L, O'Brien SJ, Vlahov D, Winkler CA. Genetic influence of CXCR6 chemokine receptor alleles on PCP-mediated AIDS progression among African Americans. Genes Immun. 4: 245-250 (2003). *
Duhamel GE, Stryker CJ, Lu G, Wong VJ, Tarara RP. Colonic spirochetosis of colony-raised rhesus macaques associated with Brachyspira and Helicobacter. Anaerobe 9: 45-55 (2003).
Dumoutier L, Lejeune D, Hor S, Fickenscher H, Renauld JC. Cloning of a new type II cytokine receptor activating signal transducer and activator of transcription (STAT)1, STAT2 and STAT3. Biochem. J. 370: 391-396 (2003). *
Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T, Everson GT, Kam I. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl. 9: 463-468 (2003). *
Dunn DS, Inoko H, Kulski JK. Dimorphic Alu element located between the TFIIH and CDSN genes within the major histocompatibility complex. Electrophoresis 24: 2740-2748 (2003). *
Dunne A, Ejdeback M, Ludidi PL, O'Neill LA, Gay NJ. Structural complementarity of Toll/interleukin-1 receptor domains in Toll-like receptors and the adaptors Mal and MyD88. J. Biol. Chem. 278: 41443-41451 (2003). *
Dunnwald M, Zuberi AR, Stephens K, Le R, Sundberg JP, Fleckman P, Dale BA. The ichq mutant mouse, a model for the human skin disorder harlequin ichthyosis: mapping, keratinocyte culture, and consideration of candidate genes involved in epidermal growth regulation. Exp. Dermatol. 12: 245-254 (2003). *
Dunstan JA, Mori TA, Barden A, Beilin LJ, Taylor AL, Holt PG, Prescott SL. Maternal fish oil supplementation in pregnancy reduces interleukin-13 levels in cord blood of infants at high risk of atopy. Clin. Exp. Allergy 33: 442-448 (2003). *
Dunstan JA, Mori TA, Barden A, Beilin LJ, Taylor AL, Holt PG, Prescott SL. Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: a randomized, controlled trial. J. Allergy Clin. Immunol. 112: 1178-1184 (2003). *
Durazzo M, Premoli A, Fagoonee S, Pellicano R. Overlap syndromes of autoimmune hepatitis: what is known so far. Dig. Dis. Sci. 48: 423-430 (2003). *
Dussault I, Beard R, Lin M, Hollister K, Chen J, Xiao JH, Chandraratna R, Forman BM. Identification of gene-selective modulators of the bile acid receptor FXR. J. Biol. Chem. 278: 7027-7033 (2003). *
Dussault I, Yoo HD, Lin M, Wang E, Fan M, Batta AK, Salen G, Erickson SK, Forman BM. Identification of an endogenous ligand that activates pregnane X receptor-mediated sterol clearance. Proc. Natl. Acad. Sci. U.S.A. 100: 833-838 (2003). *
Duvic M, Norris D, Christiano A, Hordinsky M, Price V. Alopecia areata registry: an overview. J. Investig. Dermatol. Symp. Proc. 8: 219-221 (2003). *
Duymaz-Tozkir J, Gul A, Uyar FA, Ozbek U, Saruhan-Direskeneli G. Tumour necrosis factor-alpha gene promoter region -308 and -376 G-->A polymorphisms in Behcet's disease. Clin. Exp. Rheumatol. 21: S15-S18 (2003).
Dvorak Z, Modriansky M, Pichard-Garcia L, Balaguer P, Vilarem MJ, Ulrichova J, Maurel P, Pascussi JM. Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol. Pharmacol. 64: 160-169 (2003). *
Dziarski R. Recognition of bacterial peptidoglycan by the innate immune system. Cell. Mol. Life Sci. 60: 1793-1804 (2003). *
Dziarski R, Platt KA, Gelius E, Steiner H, Gupta D. Defect in neutrophil killing and increased susceptibility to infection with nonpathogenic gram-positive bacteria in peptidoglycan recognition protein-S (PGRP-S)-deficient mice. Blood 102: 689-697 (2003). *
Eaden J. Review article: the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 18 Suppl. 2: 15-21 (2003). *
Eberl G, Littman DR. The role of the nuclear hormone receptor RORgammat in the development of lymph nodes and Peyer's patches. Immunol. Rev. 195: 81-90 (2003). *
Edmond LM, Hopkins MJ, Magee EA, Cummings JH. The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria. Inflamm. Bowel Dis. 9: 10-17 (2003). *
Edwards G. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J. 2 Suppl. 1: S8 (2003). *
Efferth T. Adenosine triphosphate-binding cassette transporter genes in ageing and age-related diseases. Ageing Res. Rev. 2: 11-24 (2003).
Efrati O, Barak A, Modan-Moses D, Augarten A, Vilozni D, Katznelson D, Szeinberg A, Yahav J, Bujanover Y. Liver cirrhosis and portal hypertension in cystic fibrosis. Eur. J. Gastroenterol. Hepatol. 15: 1073-1078 (2003).
Ehlin AG, Montgomery SM, Ekbom A, Pounder RE, Wakefield AJ. Prevalence of gastrointestinal diseases in two British national birth cohorts. Gut 52: 1117-1121 (2003). *
Einarsdottir E, Soderstrom I, Lofgren-Burstrom A, Haraldsson S, Nilsson-Ardnor S, Penha-Goncalves C, Lind L, Holmgren G, Holmberg M, Asplund K, Holmberg D. The CTLA4 region as a general autoimmunity factor: an extended pedigree provides evidence for synergy with the HLA locus in the etiology of type 1 diabetes mellitus, Hashimoto's thyroiditis and Graves' disease. Eur. J. Hum. Genet. 11: 81-84 (2003). *
Eisen DP, Minchinton RM. Impact of mannose-binding lectin on susceptibility to infectious diseases. Clin. Infect. Dis. 37: 1496-1505 (2003). *
Ekbom A. Paratuberculosis and Crohn's disease - possible linkage? Acta Vet. Scand. 44: 267-268 (2003).
Eknoyan G. On testing for proteinuria: time for a methodical approach. Cleve. Clin. J. Med. 70: 493, 496-497, 501 (2003).
El-Sayed LH, Ghoneim HM, El-Sayed MH, Deimian SR, Adam AN, Abou Rawash SN, Abou Rawash NM, Ursos P. Immunological abnormalities in workers exposed to pollutants at an Egyptian copper company. Immunopharmacol. Immunotoxicol. 25: 473-490 (2003).
El-Tawil AM. Zinc deficiency in men with Crohn's disease may contribute to poor sperm function and male infertility. Andrologia 35: 337-341 (2003).
El-Youssef M. Wilson disease. Mayo Clin. Proc. 78: 1126-1136 (2003). *
Elamiri A, Perwaiz S, Tuchweber B, Yousef IM. Effect of mdr2 mutation with combined tandem disruption of canalicular glycoprotein transporters by cyclosporine A on bile formation in mice. Pharmacol. Res. 48: 467-472 (2003). *
Elices MJ. Natalizumab. Elan/Biogen. Curr. Opin. Investig. Drugs 4: 1354-1362 (2003).
Eliopoulos AG, Caamano JH, Flavell J, Reynolds GM, Murray PG, Poyet JL, Young LS. Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-kappaB2 to p52 via an IKKgamma/NEMO-independent signalling pathway. Oncogene 22: 7557-7569 (2003). *
Elkin PL. Primer on medical genomics. Part V: Bioinformatics. Mayo Clin. Proc. 78: 57-64 (2003). *
Ellingson JL, Cheville JC, Brees D, Miller JM, Cheville NF. Absence of Mycobacterium avium subspecies paratuberculosis components from Crohn's disease intestinal biopsy tissues. Clin. Med. Res. 1: 217-226 (2003). *
Elliott DE, Li J, Blum A, Metwali A, Qadir K, Urban JF, Weinstock JV. Exposure to schistosome eggs protects mice from TNBS-induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G385-G391 (2003). *
Ellis E, Axelson M, Abrahamsson A, Eggertsen G, Thorne A, Nowak G, Ericzon BG, Bjorkhem I, Einarsson C. Feedback regulation of bile acid synthesis in primary human hepatocytes: evidence that CDCA is the strongest inhibitor. Hepatology 38: 930-938 (2003). *
Ellis HJ, Pollock EL, Engel W, Fraser JS, Rosen-Bronson S, Wieser H, Ciclitira PJ. Investigation of the putative immunodominant T cell epitopes in coeliac disease. Gut 52: 212-217 (2003). *
Elmberg M, Hultcrantz R, Ekbom A, Brandt L, Olsson S, Olsson R, Lindgren S, Loof L, Stal P, Wallerstedt S, Almer S, Sandberg-Gertzen H, Askling J. Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology 125: 1733-1741 (2003). *
Eloranta ML, Hakli T, Hiltunen M, Helisalmi S, Punnonen K, Heinonen S. Association of single nucleotide polymorphisms of the bile salt export pump gene with intrahepatic cholestasis of pregnancy. Scand. J. Gastroenterol. 38: 648-652 (2003). *
Elsner HA, Baengeroth K, Blasczyk R. The nature of introns 4-6 suggests reduced lineage specificity in HLA-B alleles. Genes Immun. 4: 391-401 (2003). *
Elson CO, Sartor RB, Targan SR, Sandborn WJ. Challenges in IBD research: updating the scientific agendas. Inflamm. Bowel Dis. 9: 137-153 (2003). *
Emerson SD, Palermo R, Liu CM, Tilley JW, Chen L, Danho W, Madison VS, Greeley DN, Ju G, Fry DC. NMR characterization of interleukin-2 in complexes with the IL-2Ralpha receptor component, and with low molecular weight compounds that inhibit the IL-2/IL-Ralpha interaction. Protein Sci. 12: 811-822 (2003). *
Emery P, Seto Y. Role of biologics in early arthritis. Clin. Exp. Rheumatol. 21 (5 Suppl. 31): S191-S194 (2003).
Eng B, Nakamura LN, O'Reilly N, Schokman N, Nowaczyk MM, Krivit W, Waye JS. Identification of nine novel arylsulfatase a (ARSA) gene mutations in patients with metachromatic leukodystrophy (MLD). Hum. Mutat. 22: 418-419 (2003). *
Engel P, Eck MJ, Terhorst C. The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat. Rev. Immunol. 3: 813-821 (2003). *
Enghard P, Riemekasten G. Regulatory T cells - a possible promising target in the treatment of autoimmune diseases. Z. Rheumatol. 62: 355-360 (2003).
Engler S, Elsing C, Flechtenmacher C, Theilmann L, Stremmel W, Stiehl A. Progressive sclerosing cholangitis after septic shock: a new variant of vanishing bile duct disorders. Gut 52: 688-693 (2003). *
Enns R, Eloubeidi MA, Mergener K, Jowell PS, Branch MS, Baillie J. Predictors of successful clinical and laboratory outcomes in patients with primary sclerosing cholangitis undergoing endoscopic retrograde cholangiopancreatography. Can. J. Gastroenterol. 17: 243-248 (2003).
Ensenauer RE, Reinke SS, Ackerman MJ, Tester DJ, Whiteman DA, Tefferi A. Primer on medical genomics. Part VIII: Essentials of medical genetics for the practicing physician. Mayo Clin. Proc. 78: 846-857 (2003). *
Eraly SA, Hamilton BA, Nigam SK. Organic anion and cation transporters occur in pairs of similar and similarly expressed genes. Biochem. Biophys. Res. Commun. 300: 333-342 (2003). *
Erdman SE, Poutahidis T, Tomczak M, Rogers AB, Cormier K, Plank B, Horwitz BH, Fox JG. CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am. J. Pathol. 162: 691-702 (2003). *
Erdman SE, Rao VP, Poutahidis T, Ihrig MM, Ge Z, Feng Y, Tomczak M, Rogers AB, Horwitz BH, Fox JG. CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res. 63: 6042-6050 (2003). *
Eren M, Saltik-Temizel IN, Demir H. Esophagogastroduodenoscopy in childhood inflammatory bowel disease. Indian J. Gastroenterol. 22: 236-237 (2003).
Erickson SK, Lear SR, Deane S, Dubrac S, Huling SL, Nguyen L, Bollineni JS, Shefer S, Hyogo H, Cohen DE, Shneider B, Sehayek E, Ananthanarayanan M, Balasubramaniyan N, Suchy FJ, Batta AK, Salen G. Hypercholesterolemia and changes in lipid and bile acid metabolism in male and female cyp7A1-deficient mice. J. Lipid Res. 44: 1001-1009 (2003). *
Eriksson A, Shafazand M, Jennische E, Lange S. Effect of antisecretory factor in ulcerative colitis on histological and laborative outcome: a short period clinical trial. Scand. J. Gastroenterol. 38: 1045-1049 (2003). *
Eriksson A, Shafazand M, Jennische E, Lonnroth I, Lange S. Antisecretory factor-induced regression of Crohn's disease in a weak responder to conventional pharmacological treatment. Inflamm. Bowel Dis. 9: 398-400 (2003). *
Erridge C, Stewart J, Poxton IR. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J. Exp. Med. 197: 1787-1791 (2003). *
Ertekin V, Selimoglu MA, Orbak Z. An unusual combination of relapsing and cholestatic hepatitis A in childhood. Yonsei. Med. J. 44: 939-942 (2003). *
Escher JC, Taminiau JA, Nieuwenhuis EE, Buller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm. Bowel Dis. 9: 34-58 (2003). *
Eskandari F, Webster JI, Sternberg EM. Neural immune pathways and their connection to inflammatory diseases. Arthritis Res. Ther. 5: 251-265 (2003). *
Estes JD, Stolpman D, Olyaei A, Corless CL, Ham JM, Schwartz JM, Orloff SL. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch. Surg. 138: 852-858 (2003). *
Estiarte R, Juan J, Colome E, Artes M, Jimenez FJ. Drug utilization study in patients with Crohn's disease in Spain. Eur. J. Gastroenterol. Hepatol. 15: 355-362 (2003).
Etchegaray JP, Lee C, Wade PA, Reppert SM. Rhythmic histone acetylation underlies transcription in the mammalian circadian clock. Nature 421: 177-182 (2003). *
Etzioni A. Immune deficiency and autoimmunity. Autoimmun. Rev. 2: 364-369 (2003).
Evans LT, Kim WR, Poterucha JJ, Kamath PS. Spontaneous bacterial peritonitis in asymptomatic outpatients with cirrhotic ascites. Hepatology 37: 897-901 (2003). *
Evans WE. Pharmacogenomics: marshalling the human genome to individualise drug therapy. Gut 52 Suppl. 2: ii10-ii18 (2003). *
Everson GT, Trotter JF, Kugelmas M, Forman L. Immunosuppression in liver transplantation. Minerva Chir. 58: 725-740 (2003).
Ezaki T, Watanabe M, Inoue N, Kanai T, Ogata H, Iwao Y, Ishii H, Hibi T. A specific genetic alteration on chromosome 6 in ulcerative colitis-associated colorectal cancers. Cancer Res. 63: 3747-3749 (2003). *
Ezekowitz RA. Role of the mannose-binding lectin in innate immunity. J. Infect. Dis. 187 Suppl. 2: S335-S339 (2003). *
Faber KN, Muller M, Jansen PL. Drug transport proteins in the liver. Adv. Drug Deliv. Rev. 55: 107-124 (2003). *
Fagarasan S, Honjo T. Intestinal IgA synthesis: regulation of front-line body defences. Nat. Rev. Immunol. 3: 63-72 (2003).
Fahlgren A, Hammarstrom S, Danielsson A, Hammarstrom ML. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis. Clin. Exp. Immunol. 131: 90-101 (2003). *
Fain PR, Gowan K, LaBerge GS, Alkhateeb A, Stetler GL, Talbert J, Bennett DC, Spritz RA. A genomewide screen for generalized vitiligo: confirmation of AIS1 on chromosome 1p31 and evidence for additional susceptibility loci. Am. J. Hum. Genet. 72: 1560-1564 (2003). *
Falk Symposium No 134 + Falk Workshop (Berlin, Germany), June 12-14, 2003 (http://www.falkfoundation.com/pdf/FSK134e.pdf). New Findings on Pathogenesis and Progress in Management of Inflammatory Bowel Diseases. Falk Congress Short Reports (2003). *
Falkowska-Podstawka M, Wernicki A. Heat shock proteins in health and disease. Pol. J. Vet. Sci. 6: 61-70 (2003).
Falkowski O, An HJ, Ianus IA, Chiriboga L, Yee H, West AB, Theise ND. Regeneration of hepatocyte 'buds' in cirrhosis from intrabiliary stem cells. J. Hepatol. 39: 357-364 (2003). *
Fallarino F, Grohmann U, Hwang KW, Orabona C, Vacca C, Bianchi R, Belladonna ML, Fioretti MC, Alegre ML, Puccetti P. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4: 1206-1212 (2003). *
Fallone CA, Tran S, Semret M, Discepola F, Behr M, Barkun AN. Helicobacter DNA in bile: correlation with hepato-biliary diseases. Aliment. Pharmacol. Ther. 17: 453-458 (2003). *
Falorni A. Immunologic and genetic aspects of latent autoimmune diabetes in the adult. Minerva Endocrinol. 28: 297-312 (2003).
Famularo G, Mosca L, Minisola G, Trinchieri V, De Simone C. Probiotic lactobacilli: a new perspective for the treatment of inflammatory bowel disease. Curr. Pharm. Des. 9: 1973-1980 (2003).
Fan LY, Zhong RQ, Tu XQ, Zhu Y, Gong CL, Zhou L, Zhao ZX, Ralph F, Thomas P. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune liver diseases on Chinese. Zhonghua Yi Xue Za Zhi 83: 1852-1855 (2003).
Fan YY, Spencer TE, Wang N, Moyer MP, Chapkin RS. Chemopreventive n-3 fatty acids activate RXRalpha in colonocytes. Carcinogenesis 24: 1541-1548 (2003). *
Fantry L. Gastrointestinal infections in the immunocompromised host. Curr. Opin. Gastroenterol. 19: 37-41 (2003).
Farnier M, Salko T, Isaacsohn JL, Troendle AJ, Dejager S, Gonasun L. Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil). Am. J. Cardiol. 92: 794-797 (2003). *
Farrell RJ. Epidermal growth factor for ulcerative colitis. N. Engl. J. Med. 349: 395-397 (2003). *
Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J. Endocrinol. 178: 339-346 (2003). *
Fasano A. Celiac disease - how to handle a clinical chameleon. N. Engl. J. Med. 348: 2568-2570 (2003). *
Fassas A, Kazis A. High-dose immunosuppression and autologous hematopoietic stem cell rescue for severe multiple sclerosis. J. Hematother. Stem Cell Res. 12: 701-711 (2003).
Fatma OS, Sarper DA, Dilek E, Emel OA, Semra A, Dilek KS, Mahmut C. HLA-DRB1 association in Turkish psoriasis vulgaris patients. Swiss Med. Wkly. 133: 541-543 (2003). *
Faust D, Menge F, Armbruster FP, Lembcke B, Stein J. Increased serum bone sialoprotein concentrations in patients with Crohn's disease. Z. Gastroenterol. 41: 243-247 (2003).
Fausto N, Campbell JS. The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech. Dev. 120: 117-130 (2003). *
Favre C, Gerard A, Clauzier E, Pontarotti P, Olive D, Nunes JA. DOK4 and DOK5: new dok-related genes expressed in human T cells. Genes Immun. 4: 40-45 (2003). *
Fdez-Morera JL, Rodrigo L, Lopez-Vazquez A, Rodero SR, Martinez-Borra J, Nino P, Gonzalez S, Lopez-Larrea C. MHC class I chain-related gene A transmembrane polymorphism modulates the extension of ulcerative colitis. Hum. Immunol. 64: 816-822 (2003).
Feagan BG. Maintenance therapy for inflammatory bowel disease. Am. J. Gastroenterol. 98: S6-S17 (2003). *
Feferman T, Im SH, Fuchs S, Souroujon MC. Breakage of tolerance to hidden cytoplasmic epitopes of the acetylcholine receptor in experimental autoimmune myasthenia gravis. J. Neuroimmunol. 140: 153-158 (2003).
Feghali-Bostwick C, Medsger TA Jr, Wright TM. Analysis of systemic sclerosis in twins reveals low concordance for disease and high concordance for the presence of antinuclear antibodies. Arthritis Rheum. 48: 1956-1963 (2003). *
Feher J, Lengyel G. A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). J. Int. Med. Res. 31: 537-551 (2003).
Feld J, Heathcote E. Epidemiology of autoimmune liver disease. J. Gastroenterol. Hepatol. 18: 1118-1128 (2003). *
Felderbauer P, Hoffmann P, Einwachter H, Bulut K, Ansorge N, Schmitz F, Schmidt WE. A novel mutation of the calcium sensing receptor gene is associated with chronic pancreatitis in a family with heterozygous SPINK1 mutations. BMC Gastroenterol. 3: 34 (2003). *
Feldmann H, Jones S, Klenk HD, Schnittler HJ. Ebola virus: from discovery to vaccine. Nat. Rev. Immunol. 3: 677-685 (2003).
Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD, Gores GJ. Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125: 437-443 (2003). *
Feldstein AE, Canbay A, Guicciardi ME, Higuchi H, Bronk SF, Gores GJ. Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice. J. Hepatol. 39: 978-983 (2003). *
Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 38: 210-217 (2003). *
Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol. Int. 23: 61-66 (2003). *
Felldin M, Friman S, Olausson M, Backman L, Castedal M, Larsson B, Henriksson BA, Siewert-Delle A. Liver dialysis using MARS in acute hepatic failure. Promising results in a pilot setting. Lakartidningen 100: 3836-3838, 3841 (2003).
Fellermann K, Luhmann D, Stange EF. Is there still a role for cyclosporine in the treatment of inflammatory bowel disease? Con argument. Inflamm. Bowel Dis. 9: 198-201 (2003). *
Fellermann K, Wehkamp J, Herrlinger KR, Stange EF. Crohn's disease: a defensin deficiency syndrome? Eur. J. Gastroenterol. Hepatol. 15: 627-634 (2003). *
Felley C, Michetti P. Engineered lymphocytes to treat dinitrobenzene sulphonic acid colitis in mice. Eur. J. Gastroenterol. Hepatol. 15: 1253-1255 (2003).
Fenwick SW, Toogood GJ, Lodge JP, Hull MA. The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology 125: 716-729 (2003). *
Ferenci P. How to identify the genetic basis of gastrointestinal and liver diseases? Gut 52 Suppl. 2: ii6-ii9 (2003). *
Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, Schilsky M, Cox D, Berr F. Diagnosis and phenotypic classification of Wilson disease. Liver Int. 23: 139-142 (2003). *
Fernandes J, Reshef A, Patton L, Ayuso R, Reese G, Lehrer SB. Immunoglobulin E antibody reactivity to the major shrimp allergen, tropomyosin, in unexposed Orthodox Jews. Clin. Exp. Allergy 33: 956-961 (2003). *
Fernandez MI, Pedron T, Tournebize R, Olivo-Marin JC, Sansonetti PJ, Phalipon A. Anti-inflammatory role for intracellular dimeric immunoglobulin A by neutralization of lipopolysaccharide in epithelial cells. Immunity 18: 739-749 (2003). *
Fernandez P, Guillen MI, Gomar F, Alcaraz MJ. Expression of heme oxygenase-1 and regulation by cytokines in human osteoarthritic chondrocytes. Biochem. Pharmacol. 66: 2049-2052 (2003). *
Fernandez-Aguilar JL, Bondia Navarro JA, Santoyo Santoyo J, Suarez-Munoz MA, Perez-Daga A, Ramirez Plaza C, Mera Velasco S, de la Fuente Perucho A. Calibrated portacaval H-graft shunt in variceal hemorrhage. Long-term results. Hepatogastroenterology 50: 2000-2004 (2003).
Fernandez-Checa JC. Alcohol-induced liver disease: when fat and oxidative stress meet. Ann. Hepatol. 2: 69-75 (2003). *
Fernandez-Real JM, Broch M, Vendrell J, Ricart W. Insulin resistance, inflammation, and serum fatty acid composition. Diabetes Care 26: 1362-1368 (2003). *
Fernandez-Vozmediano JM, Armario-Hita JC, Gonzalez-Cabrerizo A. Sjogren-Larsson syndrome: treatment with topical calcipotriol. Pediatr. Dermatol. 20: 179-180 (2003). *
Ferrandez A, Prescott S, Burt RW. COX-2 and colorectal cancer. Curr. Pharm. Des. 9: 2229-2251 (2003).
Ferreira MA. Cytokine expression in allergic inflammation: systematic review of in vivo challenge studies. Mediators Inflamm. 12: 259-267 (2003). *
Ferreiros-Vidal I, Amarelo J, Barros F, Carracedo A, Gomez-Reino JJ, Gonzalez A. Lack of association of ankylosing spondylitis with the most common NOD2 susceptibility alleles to Crohn's disease. J. Rheumatol. 30: 102-104 (2003).
Ferreiros-Vidal I, Barros F, Pablos JL, Carracedo A, Gomez-Reino JJ, Gonzalez A. CARD15/NOD2 analysis in rheumatoid arthritis susceptibility. Rheumatology (Oxford) 42: 1380-1382 (2003). *
Ferreiros-Vidal I, Garcia-Meijide J, Carreira P, Barros F, Carracedo A, Gomez-Reino JJ, Gonzalez A. The three most common CARD15 mutations associated with Crohn's disease and the chromosome 16 susceptibility locus for systemic lupus erythematosus. Rheumatology (Oxford) 42: 570-574 (2003). *
Ferrier L, Mazelin L, Cenac N, Desreumaux P, Janin A, Emilie D, Colombel JF, Garcia-Villar R, Fioramonti J, Bueno L. Stress-induced disruption of colonic epithelial barrier: role of interferon-gamma and myosin light chain kinase in mice. Gastroenterology 125: 795-804 (2003). *
Fickert P, Trauner M, Fuchsbichler A, Stumptner C, Zatloukal K, Denk H. Mallory body formation in primary biliary cirrhosis is associated with increased amounts and abnormal phosphorylation and ubiquitination of cytokeratins. J. Hepatol. 38: 387-394 (2003). *
Fidder HH, Olschwang S, Avidan B, Zouali H, Lang A, Bardan E, Picard O, Bar-Meir S, Colombel JF, Chowers Y. Association between mutations in the CARD15 (NOD2) gene and Crohn's disease in Israeli Jewish patients. Am. J. Med. Genet. 121A: 240-244 (2003). *
Field AC, Bloch MF, Bellon B. Neonatal tolerance to a Th2-mediated autoimmune disease generates CD8+ Tc1 regulatory cells. J. Autoimmun. 21: 201-212 (2003).
Field EA, Allan RB. Oral ulceration - aetiopathogenesis, clinical diagnosis and management in the gastrointestinal clinic. Aliment. Pharmacol. Ther. 18: 949-962 (2003). *
Filippi J, Eyraud E, Al-Jaouni R, Schneider SM, Hebuterne X. Food intake and micronutrient status in patients with Crohn's disease. Clin. Nutr. 22: S34 (2003). *
Filippone A, Ambrosini R, Fuschi M, Marinelli T, Pinto D, Maggialetti A. Clinical impact of MR cholangiopancreatography in patients with biliary disease. Radiol. Med. (Torino) 105: 27-35 (2003).
Finesilver AG. Newer approaches to the treatment of rheumatoid arthritis. WMJ 102: 34-37 (2003).
Fink MP. Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness. Curr. Opin. Crit. Care 9: 143-151 (2003).
Finn OJ. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3: 630-641 (2003). *
Fiocchi C. More answers and more questions in inflammatory bowel disease. Curr. Opin. Gastroenterol. 19: 325-326 (2003).
Fioramonti J, Theodorou V, Bueno L. Probiotics: what are they? What are their effects on gut physiology? Best Pract. Res. Clin. Gastroenterol. 17: 711-724 (2003).
Fiorucci S, Antonelli E, Brancaleone V, Sanpaolo L, Orlandi S, Distrutti E, Acuto G, Clerici C, Baldoni M, Del Soldato P, Morelli A. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J. Hepatol. 39: 932-939 (2003). *
Fiorucci S, Antonelli E, Morelli A. Nitric oxide and portal hypertension: a nitric oxide-releasing derivative of ursodeoxycholic acid that selectively releases nitric oxide in the liver. Dig. Liver Dis. 35 Suppl. 2: S61-S69 (2003).
Firneisz G, Zehavi I, Vermes C, Hanyecz A, Frieman JA, Glant TT. Identification and quantification of disease-related gene clusters. Bioinformatics 19: 1781-1786 (2003). *
Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice. J. Biol. Chem. 278: 27997-28004 (2003). *
Fisher SA, Lanchbury JS, Lewis CM. Meta-analysis of four rheumatoid arthritis genome-wide linkage studies: confirmation of a susceptibility locus on chromosome 16. Arthritis Rheum. 48: 1200-1206 (2003). *
Fisher SA, Moody A, Mirza MM, Cuthbert AP, Hampe J, Macpherson A, Sanderson J, Forbes A, Mansfield J, Schreiber S, Lewis CM, Mathew CG. Genetic variation at the chromosome 16 chemokine gene cluster: development of a strategy for association studies in complex disease. Ann. Hum. Genet. 67: 377-390 (2003). *
Fiszenson-Albala F, Auzerie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, Descamps V. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br. J. Dermatol. 149: 1018-1022 (2003). *
Flanders KC, Burmester JK. Medical applications of transforming growth factor-beta. Clin. Med. Res. 1: 13-20 (2003). *
Fleischmann R, Shealy D. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis. Mol. Intervent. 3: 310-318 (2003). *
Fleming KA. Histology and brush cytology for diagnosis of bile duct carcinoma in primary sclerosing cholangitis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 92. October 15-16 (2003). *
Floch MH. Probiotics, irritable bowel syndrome, and inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 6: 283-288 (2003).
Flodstrom-Tullberg M. Viral infections: their elusive role in regulating susceptibility to autoimmune disease. Microbes Infect. 5: 911-921 (2003). *
Floreani A. Preventative therapy in primary biliary cirrhosis. Clin. Liver Dis. 7: 911-921 (2003).
Floreani A, Baragiotta A, Guido M. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: a cause of resistance to ursodeoxycholic treatment. Dig. Liver Dis. 35: 128-129 (2003).
Floreani A, Baragiotta A, Leone MG, Baldo V, Naccarato R. Primary biliary cirrhosis and hepatitis C virus infection. Am. J. Gastroenterol. 98: 2757-2762 (2003). *
Flores-Villanueva PO, Hendel H, Caillat-Zucman S, Rappaport J, Burgos-Tiburcio A, Bertin-Maghit S, Ruiz-Morales JA, Teran ME, Rodriguez-Tafur J, Zagury JF. Associations of MHC ancestral haplotypes with resistance/susceptibility to AIDS disease development. J. Immunol. 170: 1925-1929 (2003). *
Flori L, Kumulungui B, Aucan C, Esnault C, Traoré AS, Fumoux F, Rihet P. Linkage and association between Plasmodium falciparum blood infection levels and chromosome 5q31-q33. Genes Immun. 4: 265-268 (2003). *
Flourie B, Moussata D, Nancey S, Bonvoisin S, Benahmed M, Descos L. Cancer and inflammatory bowel diseases. Gastroenterol. Clin. Biol. 27: S104-S111 (2003).
Flynn M. Noninfectious liver disorders: adult autoimmune hepatitis. Nurse Pract. 28: 28-31 (2003).
Fociani P, Carsana L, Zerbi P, Ferri A, Sampietro GM, Vago G. Histopathological differential diagnosis in inflammatory bowel diseases. Ann. Ital. Chir. 74: 641-649 (2003).
Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, Roth J. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52: 847-853 (2003). *
Fofi C, Nicoletti MC, Onetti-Muda A, Giulio S. Focal segmental glomerulosclerosis with IgA deposits in a patient with ulcerative colitis. G. Ital. Nefrol. 20: 641-644 (2003).
Fogden E, Neuberger J. Alternative medicines and the liver. Liver Int. 23: 213-220 (2003). *
Fogel EL, Sherman S, Park SH, McHenry L, Lehman GA. Therapeutic biliary endoscopy. Endoscopy 35: 156-163 (2003).
Folwaczny C, Glas J, Torok HP. Crohn's disease: an immunodeficiency? Eur. J. Gastroenterol. Hepatol. 15: 621-626 (2003). *
Folwaczny M, Glas J, Torok HP, Fricke K, Folwaczny C. Prevalence of the chemokine receptor CCR5-Delta32 gene mutation in periodontal disease. Clin. Immunol. 109: 325-329 (2003). *
Fonarow GC. Aggressive treatment of atherosclerosis: the time is now. Cleve. Clin. J. Med. 70: 431-434, 437438, 440 (2003).
Fontana S, Moratto D, Mangal S, De Francesco M, Vermi W, Ferrari S, Facchetti F, Kutukculer N, Fiorini C, Duse M, Das PK, Notarangelo LD, Plebani A, Badolato R. Functional defects of dendritic cells in patients with CD40 deficiency. Blood 102: 4099-4106 (2003). *
Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4: 330-336 (2003). *
Forbes A, Cartwright A, Marchant S, McIntyre P, Newton M. Review article: oral, modified-release mesalazine formulations - proprietary versus generic. Aliment. Pharmacol. Ther. 17: 1207-1214 (2003). *
Forbes JR, Gros P. Iron, manganese, and cobalt transport by Nramp1 (Slc11a1) and Nramp2 (Slc11a2) expressed at the plasma membrane. Blood 102: 1884-1892 (2003). *
Forchielli ML, Walker WA. Nutritional factors contributing to the development of cholestasis during total parenteral nutrition. Adv. Pediatr. 50: 245-267 (2003).
Forestier M, Banninger R, Reichen J, Solioz M. Betaine homocysteine methyltransferase: gene cloning and expression analysis in rat liver cirrhosis. Biochim. Biophys. Acta 1638: 29-34 (2003). *
Fornoni A, Lenz O, Striker LJ, Striker GE. Glucose induces clonal selection and reversible dinucleotide repeat expansion in mesangial cells isolated from glomerulosclerosis-prone mice. Diabetes 52: 2594-2602 (2003). *
Foroncewicz B, Mucha K, Paczek L, Oldakowska-Jedynak U, Gornicka B, Zieniewicz K, Nyckowski P, Krawczyk M. Anti-CD25 and tacrolimus therapy may not prevent early primary biliary cirrhosis recurrence after liver transplantation: two case reports. Transplant. Proc. 35: 2310-2312 (2003). *
Forrest CM, Gould SR, Darlington LG, Stone TW. Levels of purine, kynurenine and lipid peroxidation products in patients with inflammatory bowel disease. Adv. Exp. Med. Biol. 527: 395-400 (2003).
Fortuna VA, Martucci RB, Trugo LC, Borojevic R. Hepatic stellate cells uptake of retinol associated with retinol-binding protein or with bovine serum albumin. J. Cell. Biochem. 90: 792-805 (2003).
Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH, Bryan M, Budzinski JW, Ramputh A, Arnason JT. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 10: 334-342 (2003).
Foster CS. Diagnosis and treatment of juvenile idiopathic arthritis-associated uveitis. Curr. Opin. Ophthalmol. 14: 395-398 (2003).
Foster JE, Gott K, Schuyler MR, Kozak W, Tesfaigzi Y. LPS-induced neutrophilic inflammation and Bcl-2 expression in metaplastic mucous cells. Am. J. Physiol. Lung Cell Mol. Physiol. 285: L405-L414 (2003). *
Foster RA, Zander DS, Mergo PJ, Valentine JF. Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations. Inflamm. Bowel Dis. 9: 308-315 (2003). *
Foussat A, Cottrez F, Brun V, Fournier N, Breittmayer JP, Groux H. A comparative study between T regulatory type 1 and CD4(+)CD25(+) T cells in the control of inflammation. J. Immunol. 171: 5018-5026 (2003). *
Fox IJ. Hepatocyte transplantation: clinical aspects. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 37. October 20 - 21 (2003). *
Franca AV, Valerio HM, Trevisan M, Escanhoela C, Seva-Pereira T, Zucoloto S, Martinelli A, Soares EC. Fine needle aspiration biopsy for improving the diagnostic accuracy of cut needle biopsy of focal liver lesions. Acta Cytol. 47: 332-336 (2003).
Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 124: 9-17 (2003). *
Francis GA, Fayard E, Picard F, Auwerx J. Nuclear receptors and the control of metabolism. Annu. Rev. Physiol. 65: 261-311 (2003). *
Frangolias DD, Ruan J, Wilcox PJ, Davidson AG, Wong LT, Berthiaume Y, Hennessey R, Freitag A, Pedder L, Corey M, Sweezey N, Zielenski J, Tullis E, Sandford AJ. Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease. Am. J. Respir. Cell. Mol. Biol. 29: 390-396 (2003). *
Frank C, Gonzalez MM, Oinonen C, Dunlop TW, Carlberg C. Characterization of DNA complexes formed by the nuclear receptor constitutive androstane receptor. J. Biol. Chem. 278: 43299-43310 (2003). *
Franklin GM, Nelson L. Environmental risk factors in multiple sclerosis: causes, triggers, and patient autonomy. Neurology 61: 1032-1034 (2003).
Fraser JS, Engel W, Ellis HJ, Moodie SJ, Pollock EL, Wieser H, Ciclitira PJ. Coeliac disease: in vivo toxicity of the putative immunodominant epitope. Gut 52: 1698-1702 (2003). *
Frauendorf E, von Goessel H, May E, Marker-Hermann E. HLA-B27-restricted T cells from patients with ankylosing spondylitis recognize peptides from B*2705 that are similar to bacteria-derived peptides. Clin. Exp. Immunol. 134: 351-359 (2003). *
Frazer DM, Anderson GJ. The orchestration of body iron intake: how and where do enterocytes receive their cues? Blood Cells Mol. Dis. 30: 288-297 (2003). *
Freeman HJ. Natural history and clinical behavior of Crohn's disease extending beyond two decades. J. Clin. Gastroenterol. 37: 216-219 (2003).
Freeman HJ. Temporal and geographic evolution of longstanding Crohn's disease over more than 50 years. Can. J. Gastroenterol. 17: 696-700 (2003).
Freeman ML. Understanding risk factors and avoiding complications with endoscopic retrograde cholangiopancreatography. Curr. Gastroenterol. Rep. 5: 145-153 (2003).
Freeman ML, Sielaff TD. A modern approach to malignant hilar biliary obstruction. Rev. Gastroenterol. Disord. 3: 187-201 (2003). *
Freeman RB. MELD/PELD: one year later. Transplant. Proc. 35: 2425-2427 (2003). *
Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA 289: 2554-2559 (2003). *
Freitas M, Tavan E, Cayuela C, Diop L, Sapin C, Trugnan G. Host-pathogens cross-talk. Indigenous bacteria and probiotics also play the game. Biol. Cell 95: 503-506 (2003). *
Fridell JA, Bond GJ, Mazariegos GV, Orenstein DM, Jain A, Sindhi R, Finder JD, Molmenti E, Reyes J. Liver transplantation in children with cystic fibrosis: a long-term longitudinal review of a single center's experience. J. Pediatr. Surg. 38: 1152-1156 (2003).
Friedewald SM, Molmenti EP, DeJong MR, Hamper UM. Vascular and nonvascular complications of liver transplants: sonographic evaluation and correlation with other imaging modalities and findings at surgery and pathology. Ultrasound Q. 19: 71-85 (2003).
Friedman S, Odze RD, Farraye FA. Management of neoplastic polyps in inflammatory bowel disease. Inflamm. Bowel Dis. 9: 260-266 (2003). *
Friedman SL. Hepatic fibrogenesis. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 24. October 20 - 21 (2003). *
Friedman SL. Liver fibrosis - from bench to bedside. J. Hepatol. 38 Suppl. 1: S38-S53 (2003). *
Friedman SL. Hepatic stellate cell biology and fibrosis - from Hans Popper to the present. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 76-77. October 17 - 19 (2003). *
Friedrich M, Sterry W, Asadullah K. Novel developments in the systemic treatment of psoriasis. J. Dtsch. Dermatol. Ges. 1: 12-21 (2003).
Friedrich RE, Heiland M, El-Moawen A, Dogan A, Von Schrenck T, Loning T. Oral lichen planus in patients with chronic liver diseases. Infection 31: 383-386 (2003).
Frieri M. Identification of masqueraders of autoimmune disease in the office. Allergy Asthma Proc. 24: 421-429 (2003).
Frilling A. Standards of visceral organ procurement. Zentralbl. Chir. 128: 804-815 (2003).
Froicu M, Weaver V, Wynn TA, McDowell MA, Welsh JE, Cantorna MT. A crucial role for the vitamin D receptor in experimental inflammatory bowel diseases. Mol. Endocrinol. 17: 2386-2392 (2003). *
Fruhwirth M, Janecke AR, Muller T, Carlton VE, Kronenberg F, Offner F, Knisely AS, Geleff S, Song EJ, Simma B, Konigsrainer A, Margreiter R, van der Hagen CB, Eiklid K, Aagenaes O, Bull L, Ellemunter H. Evidence for genetic heterogeneity in lymphedema-cholestasis syndrome. J. Pediatr. 142: 441-447 (2003). *
Frulloni L, Castellani C, Bovo P, Vaona B, Calore B, Liani C, Mastella G, Cavallini G. Natural history of pancreatitis associated with cystic fibrosis gene mutations. Dig. Liver Dis. 35: 179-185 (2003).
Fryer J, Pellar S, Ormond D, Koffron A, Abecassis M. Mortality in candidates waiting for combined liver-intestine transplants exceeds that for other candidates waiting for liver transplants. Liver Transpl. 9: 748-753 (2003). *
Fu T, Kashireddy P, Borensztajn J. The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. Biochem. J. 373: 941-947 (2003). *
Fuchs M. Bile acid regulation of hepatic physiology: III. Regulation of bile acid synthesis: past progress and future challenges. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G551-G557 (2003). *
Fuchtenbusch M, Vogel A, Achenbach P, Gummer M, Ziegler AG, Albert E, Standl E, Manns MP. Lupus-like panniculitis in a patient with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). Exp. Clin. Endocrinol. Diabetes 111: 288-293 (2003).
Fuentealba IC, Aburto EM. Animal models of copper-associated liver disease. Comp. Hepatol. 2: 5 (2003). *
Fujii K, Miyashita T, Omata T, Kobayashi K, Takanashi J, Kouchi K, Yamada M, Kohno Y. Gorlin syndrome with ulcerative colitis in a Japanese girl. Am. J. Med. Genet. A. 121A: 65-68 (2003).
Fujii S, Fujimori T, Chiba T, Terano A. Efficacy of surveillance and molecular markers for detection of ulcerative colitis-associated colorectal neoplasia. J. Gastroenterol. 38: 1117-1125 (2003). *
Fujii T, Shiba M, Takatera H. A case of ammonium urate urolithiasis with Crohn's disease. Hinyokika. Kiyo. 49: 615-617 (2003).
Fujimoto J. Reversal of liver cirrhosis by hepatocyte growth factor. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 41. October 20 - 21 (2003). *
Fujinaga J, Loiselle FB, Casey JR. Transport activity of chimaeric AE2-AE3 chloride/bicarbonate anion exchange proteins. Biochem. J. 371: 687-696 (2003). *
Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52: 65-70 (2003). *
Fujiwara Y, Yokoyama M, Sawada R, Seyama Y, Ishii M, Tsutsumi S, Aburatani H, Hanaka S, Itakura H, Matsumoto A. Analysis of the comprehensive effects of polyunsaturated fatty acid on mRNA expression using a gene chip. J. Nutr. Sci. Vitaminol. (Tokyo) 49: 125-132 (2003).
Fukuhara C, Tosini G. Peripheral circadian oscillators and their rhythmic regulation. Front. Biosci. 8: d642-d651 (2003).
Fukushima K, Yonezawa H, Fiocchi C. Inflammatory bowel disease-associated gene expression in intestinal epithelial cells by differential cDNA screening and mRNA display. Inflamm. Bowel Dis. 9: 290-301 (2003). *
Fuller SJ, Kumar P, Weltman M, Wiley JS. Autoimmune hemolysis associated with primary biliary cirrhosis responding to ursodeoxycholic acid as sole treatment. Am. J. Hematol. 72: 31-33 (2003). *
Fulop T Jr, Larbi A, Dupuis G, Pawelec G. Ageing, autoimmunity and arthritis: perturbations of TCR signal transduction pathways with ageing - a biochemical paradigm for the ageing immune system. Arthritis Res. Ther. 5: 290-302 (2003). *
Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, Fischkoff SA, Chartash EK. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. 30: 2563-2571 (2003).
Fuss IJ. Cytokine network in inflammatory bowel disease. Curr. Drug Targets Inflamm. Allergy 2: 101-112 (2003).
Gaiva MH, Couto RC, Oyama LM, Couto GE, Silveira VL, Ribeiro EB, Nascimento CM. Diets rich in polyunsaturated fatty acids: effect on hepatic metabolism in rats. Nutrition 19: 144-149 (2003). *
Gallati S. Genetics of cystic fibrosis. Semin. Respir. Crit. Care Med. 24: 629-638 (2003).
Galle PR, Schuchmann M, Strand D, Strand S. Fas (CD95) mediated apoptosis in liver disease. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 18. October 20 - 21 (2003). *
Galman C, Ostlund-Lindqvist AM, Bjorquist A, Schreyer S, Svensson L, Angelin B, Rudling M. Pharmacological interference with intestinal bile acid transport reduces plasma cholesterol in LDL receptor/apoE deficiency. FASEB J. 17: 265-267 (2003). *
Galvani AP, Slatkin M. Evaluating plague and smallpox as historical selective pressures for the CCR5-Delta 32 HIV-resistance allele. Proc. Natl. Acad. Sci. U.S.A. 100: 15276-15279 (2003). *
Galvao Da Silva AP, Jacysyn JF, De Almeida Abrahamsohn I. Resistant mice lacking interleukin-12 become susceptible to Trypanosoma cruzi infection but fail to mount a T helper type 2 response. Immunology 108: 230-237 (2003). *
Galvez J, Garrido M, Rodriguez-Cabezas ME, Ramis I, de Medina FS, Merlos M, Zarzuelo A. The intestinal anti-inflammatory activity of UR-12746S on reactivated experimental colitis is mediated through downregulation of cytokine production. Inflamm. Bowel Dis. 9: 363-371 (2003). *
Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr. Opin. Rheumatol. 15: 430-435 (2003).
Game X, Malavaud B, Alric L, Mouzin M, Sarramon JP, Rischmann P. Infliximab treatment of Crohn disease ileovesical fistula. Scand. J. Gastroenterol. 38: 1097-1098 (2003). *
Gammell P, O'Driscoll L, Clynes M. Characterisation of BHK-21 cells engineered to secrete human insulin. Cytotechnology 41: 11-21 (2003). *
Gan SI, Beck PL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am. J. Gastroenterol. 98: 2363-2371 (2003). *
Gant TW, Baus PR, Clothier B, Riley J, Davies R, Judah DJ, Edwards RE, George E, Greaves P, Smith AG. Gene expression profiles associated with inflammation, fibrosis, and cholestasis in mouse liver after griseofulvin. EHP Toxicogenomics 111: 37-43 (2003).
Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102: 783-788 (2003). *
Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat. Rev. Immunol. 3: 710-720 (2003). *
Gao J, Lin Y, Qiu C, Liu Y, Ma Y, Liu Y. Association between HLA-DQA1, -DQB1 gene polymorphisms and susceptibility to asthma in northern Chinese subjects. Chin. Med. J. (Engl.) 116: 1078-1082 (2003).
Garbo GM, Vicente MG, Fingar V, Kessel D. Effects of ursodeoxycholic acid on photodynamic therapy in a murine tumor model. Photochem. Photobiol. 78: 407-410 (2003).
Garchon HJ. Genetics of autoimmune myasthenia gravis, a model for antibody-mediated autoimmunity in man. J. Autoimmun. 21: 105-110 (2003).
Garcia AL, Ruhl R, Herz U, Koebnick C, Schweigert FJ, Worm M. Retinoid- and carotenoid-enriched diets influence the ontogenesis of the immune system in mice. Immunology 110: 180-187 (2003). *
Garcia C, Biller BM, Klibanski A. The role of the clinical laboratory in the diagnosis of Cushing syndrome. Am. J. Clin. Pathol. 120: S38-S45 (2003).
Garcia Cuerpo E. Nanobacteria and urinary system lithiasis. Arch. Esp. Urol. 56: 191-192 (2003).
Garcia Herola A, Nos P, Hinijosa J, Hoyos M, Moles J, Carmona E, Puig N, Sanchez-Cuenca J, Ponce J, Berenguer J. HLA antigens and anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease. Rev. Esp. Enferm. Dig. 95: 755-759 (2003).
Garcia-Leiva J, Rios-Vaca A, Torre-Delgadillo A. Antibodies and physiopathogeny of autoimmune hepatitis. Rev. Invest. Clin. 55: 577-582 (2003).
Garcia-Perez MA, Paz-Artal E, Corell A, Moreno A, Lopez-Goyanes A, Garcia-Martin F, Vazquez R, Pacho A, Romo E, Allende LM. Mutations of CD40 ligand in two patients with hyper-IgM syndrome. Immunobiology 207: 285-294 (2003).
Garcia-Porrua C, Gonzalez-Gay MA. Successful response to infliximab in a patient with undifferentiated spondyloarthropathy coexisting with polyarteritis nodosa-like cutaneous vasculitis. Clin. Exp. Rheumatol. 21 (6 Suppl. 32): S138 (2003).
Garcia-Ramos G, Tellez-Zenteno JF, Zapata-Zuniga M, Yamamoto-Furusho JK, Ruiz-Morales JA, Villarreal-Garza C, Vargas-Alarcon G, Estanol B, Llorente L, Granados J. HLA class II genotypes in Mexican Mestizo patients with myasthenia gravis. Eur. J. Neurol. 10: 707-710 (2003). *
Garcia-Tsao G. Portal hypertension. Curr. Opin. Gastroenterol. 19: 250-258 (2003).
Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect. Dis. 3: 148-155 (2003).
Garg S, Mehta S, Dormans JP. An atypical presentation of Langerhans cell histiocytosis of the cervical spine in a child. Spine 28: E445-E448 (2003).
Garred P, Larsen F, Madsen HO, Koch C. Mannose-binding lectin deficiency - revisited. Mol. Immunol. 40: 73-84 (2003). *
Garrido Serrano A, Guerrero Igea F. Atypical endoscopic appearance in ulcerative colitis. Rev. Esp. Enferm. Dig. 95: 664-665 (2003).
Gasbarrini A, Carloni E, Gasbarrini G, Menard A. Helicobacter pylori and extragastric diseases - other Helicobacters. Helicobacter 8 Suppl. 1: 68-76 (2003).
Gasbarrini G, Mingrone G, Giancaterini A, De Gaetano A, Scarfone A, Capristo E, Calvani M, Caso V, Greco AV. Effects of propionyl-L-carnitine topical irrigation in distal ulcerative colitis: a preliminary report. Hepatogastroenterology 50: 1385-1389 (2003).
Gasche C, Alizadeh BZ, Pena AS. Genotype-phenotype correlations: how many disorders constitute inflammatory bowel disease? Eur. J. Gastroenterol. Hepatol. 15: 599-606 (2003). *
Gassull MA. Nutrition and inflammatory bowel disease: its relation to pathophysiology, outcome and therapy. Dig. Dis. 21: 220-227 (2003).
Gause A, Schnabel A. Rheumatology 2003-part I: research news concerning pathogenesis, epidemiology, diagnosis, and therapy of chronic inflammatory joint diseases. Med. Klin. (Munich) 98: 523-533 (2003).
Gause WC, Urban JF, Stadecker MJ. The immune response to parasitic helminths: insights from murine models. Trends Immunol. 24: 269-277 (2003). *
Gawenis LR, Franklin CL, Simpson JE, Palmer BA, Walker NM, Wiggins TM, Clarke LL. cAMP inhibition of murine intestinal Na/H exchange requires CFTR-mediated cell shrinkage of villus epithelium. Gastroenterology 125: 1148-1163 (2003). *
Gaya DR, Thorburn D, Oien KA, Morris AJ, Stanley AJ. Hepatic granulomas: a 10 year single centre experience. J. Clin. Pathol. 56: 850-853 (2003). *
Gearry R, Barclay M, Gardiner S, Zhang M. 6-Thioguanine nucleotides and thiopurine methyltransferase activity: important factors determining response to treatment and incidence of adverse effects from azathioprine and 6-MP. N. Z. Med. J. 116: U531 (2003). *
Gearry RB, Barclay ML, Burt MJ, Collett JA, Chapman BA, Roberts RL, Kennedy MA. Thiopurine S-methyltransferase (TPMT) genotype does not predict adverse drug reactions to thiopurine drugs in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 18: 395-400 (2003). *
Geboes K, De Hertogh G. Indeterminate colitis. Inflamm. Bowel Dis. 9: 324-331 (2003). *
Geha RS, Jabara HH, Brodeur SR. The regulation of immunoglobulin E class-switch recombination. Nat. Rev. Immunol. 3: 721-732 (2003). *
Gehrke SG, Kulaksiz H, Herrmann T, Riedel HD, Bents K, Veltkamp C, Stremmel W. Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron. Blood 102: 371-376 (2003). *
Geier A, Dietrich CG, Gerloff T, Haendly J, Kullak-Ublick GA, Stieger B, Meier PJ, Matern S, Gartung C. Regulation of basolateral organic anion transporters in ethinylestradiol-induced cholestasis in the rat. Biochim. Biophys. Acta 1609: 87-94 (2003). *
Geier A, Dietrich CG, Voigt S, Kim SK, Gerloff T, Kullak-Ublick GA, Lorenzen J, Matern S, Gartung C. Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology 38: 345-354 (2003). *
Geier A, Gartung C, Dietrich CG, Lammert F, Wasmuth HE, Matern S. Diagnosis of cholestatic disorders. Med. Klin. (Munich) 98: 499-509 (2003).
Geier A, Gartung C, Dietrich CG, Wasmuth HE, Reinartz P, Matern S. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J. Gastroenterol. 9: 2681-2685 (2003). *
Geier A, Mertens PR, Gerloff T, Dietrich CG, En-Nia A, Kullak-Ublick GA, Karpen SJ, Matern S, Gartung C. Constitutive rat multidrug-resistance protein 2 gene transcription is down-regulated by Y-box protein 1. Biochem. Biophys. Res. Commun. 309: 612-618 (2003). *
Geier MR, Geier DA, Zahalsky AC. A review of hepatitis B vaccination. Expert Opin. Drug Saf. 2: 113-122 (2003).
Geissler M. DNA-based immunotherapy. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 43. October 20 - 21 (2003). *
Geissmann F, Revy P, Brousse N, Lepelletier Y, Folli C, Durandy A, Chambon P, Dy M. Retinoids regulate survival and antigen presentation by immature dendritic cells. J. Exp. Med. 198: 623-634 (2003). *
Gendrot C, Bacq Y, Brechot MC, Lansac J, Andres C. A second heterozygous MDR3 nonsense mutation associated with intrahepatic cholestasis of pregnancy. J. Med. Genet. 40: e32 (2003). *
Gene E, Calvet X, Azagra R, Gisbert JP. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment. Pharmacol. Ther. 17: 1137-1143 (2003). *
Gentzsch M, Cui L, Mengos A, Chang XB, Chen JH, Riordan JR. The PDZ-binding chloride channel ClC-3B localizes to the Golgi and associates with cystic fibrosis transmembrane conductance regulator-interacting PDZ proteins. J. Biol. Chem. 278: 6440-6449 (2003). *
Georgiades E, Behan WM, Kilduff LP, Hadjicharalambous M, Mackie EE, Wilson J, Ward SA, Pitsiladis YP. Chronic fatigue syndrome: new evidence for a central fatigue disorder. Clin. Sci. (Lond.) 105: 213-218 (2003). *
Gerhauser C, Klimo K, Heiss E, Neumann I, Gamal-Eldeen A, Knauft J, Liu GY, Sitthimonchai S, Frank N. Mechanism-based in vitro screening of potential cancer chemopreventive agents. Mutat. Res. 523-524: 163-172 (2003).
German JB, Roberts MA, Watkins SM. Genomics and metabolomics as markers for the interaction of diet and health: lessons from lipids. J. Nutr. 133: 2078S-2083S (2003). *
Gerner EW, Ignatenko NA, Besselsen DG. Preclinical models for chemoprevention of colon cancer. Recent Results Cancer Res. 163: 58-71 (2003).
Gershwin ME, Van de Water J, Leung P, Ansari AA, Coppel RL. The pathobiology and the cause of primary biliary cirrhosis. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 36-37. September 12 - 13 (2003). *
Gershwin ME, Van de WaterJ, Leung P, Ansari AA, Coppel RL. Primary biliary cirrhosis: from induction through destruction. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 18. October 15-16 (2003). *
Geubel AP, Sempoux C, Rahier J. Bile duct disorders. Clin. Liver Dis. 7: 295-309 (2003).
Gewirtz AT. Intestinal epithelial Toll-like receptors: to protect. And serve? Curr. Pharm. Des. 9: 1-5 (2003).
Gezer S. Antiphospholipid syndrome. Dis. Mon. 49: 696-741 (2003).
Ghanchi FD, Rembacken BJ. Inflammatory bowel disease and the eye. Surv. Ophthalmol. 48: 663-676 (2003). *
Gharagozlou P, Demirci H, David Clark J, Lameh J. Activity of opioid ligands in cells expressing cloned mu opioid receptors. BMC Pharmacol. 3: 1 (2003). *
Gheorghe L, Gheorghe C, Badea M, Vadan R, Parvulescu I, Toader C, Tugui L, Papuc O, Ionescu R, Preda C, Calin I, Diculescu M. Infliximab for Crohn's disease in clinical practice: the experience of a single center in Romania. Rom. J. Gastroenterol. 12: 7-13 (2003).
Ghirardi M, Di Fabio F, Mariani PP, Nascimbeni R, Salerni B. Surgery in severe ulcerative colitis: our experience. Ann. Ital. Chir. 74: 543-546 (2003).
Ghoreschi K, Mrowietz U, Rocken M. A molecule solves psoriasis? Systemic therapies for psoriasis inducing interleukin 4 and Th2 responses. J. Mol. Med. 81: 471-480 (2003). *
Ghoreschi K, Rocken M. Immunopathogenesis of psoriasis. J. Dtsch. Dermatol. Ges. 1: 524-532 (2003).
Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, van der Zee R, Biedermann T, Prinz J, Mack M, Mrowietz U, Christophers E, Schlondorff D, Plewig G, Sander CA, Rocken M. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9: 40-46 (2003). *
Ghosh S. Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab. Expert Opin. Biol. Ther. 3: 995-1000 (2003).
Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S; Natalizumab Pan-European Study Group. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348: 24-32 (2003). *
Giallourakis C, Stoll M, Miller K, Hampe J, Lander ES, Daly MJ, Schreiber S, Rioux JD. IBD5 is a general risk factor for inflammatory bowel disease: replication of association with Crohn disease and identification of a novel association with ulcerative colitis. Am. J. Hum. Genet. 73: 205-211 (2003). *
Giannini E, Botta F, Testa R. Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. Gastroenterology 125: 993-994 (2003). *
Gibert M, Balandraud N, Touinssi M, Mercier P, Roudier J, Reviron D. Functional categorization of HLA-DRB1 alleles in rheumatoid arthritis: the protective effect. Hum. Immunol. 64: 930-935 (2003).
Giedraitis V, Modin H, Callander M, Landtblom AM, Fossdal R, Stefansson K, Hillert J, Gulcher J. Genome-wide TDT analysis in a localized population with a high prevalence of multiple sclerosis indicates the importance of a region on chromosome 14q. Genes Immun. 4: 559-563 (2003). *
Gil A. Is eicosapentaenoic acid useful in the treatment of ulcerative colitis in children? J. Pediatr. Gastroenterol. Nutr. 37: 536-537 (2003). *
Gilde AJ, Van Bilsen M. Peroxisome proliferator-activated receptors (PPARS): regulators of gene expression in heart and skeletal muscle. Acta Physiol. Scand. 178: 425-434 (2003). *
Gines P. Refractory ascites and hepatorenal syndrome. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 97-98. October 17 - 19 (2003). *
Gionchetti P, Amadini C, Rizzello F, Venturi A, Poggioli G, Campieri M. Diagnosis and treatment of pouchitis. Best Pract. Res. Clin. Gastroenterol. 17: 75-87 (2003).
Gionchetti P, Rizzello F, Habal F, Morselli C, Amadini C, Romagnoli R, Campieri M. Standard treatment of ulcerative colitis. Dig. Dis. 21: 157-167 (2003).
Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, Vitali B, Poggioli G, Miglioli M, Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124: 1202-1209 (2003). *
Giovannucci E, Chen J, Smith-Warner SA, Rimm EB, Fuchs CS, Palomeque C, Willett WC, Hunter DJ. Methylenetetrahydrofolate reductase, alcohol dehydrogenase, diet, and risk of colorectal adenomas. Cancer Epidemiol. Biomarkers Prev. 12: 970-979 (2003). *
Girardin F, Rentsch KM, Schwab MA, Maggiorini M, Pauli-Magnus C, Kullak-Ublick GA, Meier PJ, Fattinger K. Pharmacokinetics of high doses of intramuscular and oral heroin in narcotic addicts. Clin. Pharmacol. Ther. 74: 341-352 (2003). *
Girardin SE, Boneca IG, Carneiro LA, Antignac A, Jehanno M, Viala J, Tedin K, Taha MK, Labigne A, Zahringer U, Coyle AJ, DiStefano PS, Bertin J, Sansonetti PJ, Philpott DJ. Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science 300: 1584-1587 (2003). *
Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278: 8869-8872 (2003). *
Girardin SE, Hugot JP, Sansonetti PJ. Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. Trends Immunol. 24: 652-658 (2003). *
Girardin SE, Travassos LH, Herve M, Blanot D, Boneca IG, Philpott DJ, Sansonetti PJ, Mengin-Lecreulx D. Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2. J. Biol. Chem. 278: 41702-41708 (2003). *
Gisbert JP, Ducons J, Gomollon F, Dominguez-Munoz JE, Borda F, Mino G, Jimenez I, Vazquez MA, Santolaria S, Gallego S, Iglesias J, Pastor G, Hervas A, Pajares JM. Validation of the 13C-urea breath test for the initial diagnosis of Helicobacter pylori infection and to confirm eradication after treatment. Rev. Esp. Enferm. Dig. 95: 121-126 (2003).
Gisbert JP, Gonzalez-Guijarro L, Cara C, Pajares JM, Moreno-Otero R. Thiopurine methyltransferase activity in patients with autoimmune hepatitis. Med. Clin. (Barc.) 121: 481-484 (2003).
Gisbert JP, Jones EA, Pajares JM, Moreno-Otero R. Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)? Aliment. Pharmacol. Ther. 17: 17-27 (2003). *
Gisbert JP, Luna M, Mate J, Gonzalez-Guijarro L, Cara C, Pajares JM. Thiopurine methyltransferase activity and myelosuppression in inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Med. Clin. (Barc.) 121: 1-5 (2003).
Gisbert JP, Pajares JM. Attitude facing a patient suffering from Helicobacter pylori infection resistant to a triple therapy. Rev. Esp. Enferm. Dig. 95: 220-228 (2003).
Gisbert JP, Pajares JM. Helicobacter pylori infection and perforated peptic ulcer prevalence of the infection and role of antimicrobial treatment. Helicobacter 8: 159-167 (2003).
Gisler SM, Pribanic S, Bacic D, Forrer P, Gantenbein A, Sabourin LA, Tsuji A, Zhao ZS, Manser E, Biber J, Murer H. PDZK1: I. A major scaffolder in brush borders of proximal tubular cells. Kidney Int. 64: 1733-1745 (2003). *
Gitlin JD. Wilson disease. Gastroenterology 125: 1868-1877 (2003). *
Gladman DD, Farewell VT, Pellett F, Schentag C, Rahman P. HLA is a candidate region for psoriatic arthritis. Evidence for excessive HLA sharing in sibling pairs. Hum. Immunol. 64: 887-889 (2003).
Glas J, Torok HP, Simperl C, Konig A, Martin K, Schmidt F, Schaefer M, Schiemann U, Folwaczny C. The Delta 32 mutation of the chemokine-receptor 5 gene neither is correlated with chronic hepatitis C nor does it predict response to therapy with interferon-alpha and ribavirin. Clin. Immunol. 108: 46-50 (2003). *
Glas J, Torok HP, Unterhuber H, Radlmayr M, Folwaczny C. The -295T-to-C promoter polymorphism of the IL-16 gene is associated with Crohn's disease. Clin. Immunol. 106: 197-200 (2003). *
Glaser S, Alvaro D, Roskams T, Phinizy JL, Stoica G, Francis H, Ueno Y, Barbaro B, Marzioni M, Mauldin J, Rashid S, Mancino MG, LeSage G, Alpini G. Dopaminergic inhibition of secretin-stimulated choleresis by increased PKC-gamma expression and decrease of PKA activity. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G683-G694 (2003). *
Glaser S, Alvaro D, Ueno Y, Francis H, Marzioni M, Phinizy JL, Baumann B, Mancino MG, Venter J, LeSage G, Alpini G. Gastrin reverses established cholangiocyte proliferation and enhanced secretin-stimulated ductal secretion of BDL rats by activation of apoptosis through increased expression of Ca2+- dependent PKC isoforms. Liver Int. 23: 78-88 (2003). *
Glehen O, Mithieux F, Traverse-Glehen A, Isaac S, Bienvenu J, Francois Y, Chung R, Gilly FN. Enteral immunotherapy in the treatment of chronic enterocolitis in interleukin-10-deficient mice. Hepatogastroenterology 50: 670-675 (2003).
Glossop JR, Nixon NB, Dawes PT, Hassell AB, Mattey DL. No association of polymorphisms in the tumor necrosis factor receptor I and receptor II genes with disease severity in rheumatoid arthritis. J. Rheumatol. 30: 1406-1409 (2003).
Godard B, Ten Kate L, Evers-Kiebooms G, Ayme S. Population genetic screening programmes: principles, techniques, practices, and policies. Eur. J. Hum. Genet. 11 Suppl. 2: S49-S87 (2003). *
Goedecke V, Crane AM, Jaakkola E, Kaluza W, Laiho K, Weeks DE, Wilson J, Kauppi M, Kaarela K, Tuomilehto J, Wordsworth BP, Brown MA. Interleukin 10 polymorphisms in ankylosing spondylitis. Genes Immun. 4: 74-76 (2003). *
Goel A, Chang DK, Ricciardiello L, Gasche C, Boland CR. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clin. Cancer Res. 9: 383-390 (2003). *
Goel A, Christian CL. Gastric antral vascular ectasia (watermelon stomach) in a patient with Sjogren's syndrome. J. Rheumatol. 30: 1090-1092 (2003).
Goering PL. The road to elucidating the mechanism of manganese-bilirubin-induced cholestasis. Toxicol. Sci. 73: 216-219 (2003). *
Goerres MS, Meijer JWR, Wahab PJ, Kerckhaert JAM, Groenen PJTA, Van Krieken JHJM, Mulder CJJ. Azathioprine and prednisone combination therapy in refractory Coeliac disease. Aliment. Pharmacol. Ther. 18: 487-494 (2003). *
Goertz B, Fassbender WJ, Williams JC, Marzeion AM, Bretzel RG, Stracke H, Berliner MN. Vitamin D receptor genotypes are not associated with rheumatoid arthritis or biochemical parameters of bone turnover in German RA patients. Clin. Exp. Rheumatol. 21: 333-339 (2003).
Goetz M, Lehr HA, Neurath MF, Galle PR, Orth T. Long-term evaluation of a rat model of chronic cholangitis resembling human primary sclerosing cholangitis. Scand. J. Immunol. 58: 533-540 (2003). *
Goffe B, Cather JC. Etanercept: an overview. J. Am. Acad. Dermatol. 49: S105-S111 (2003).
Goh J, O'Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment. Pharmacol. Ther. 17: 307-320 (2003). *
Goh NS, McDonald CE, MacGregor DP, Pretto JJ, Brodie GN. Successful treatment of Langerhans cell histiocytosis with 2-chlorodeoxyadenosine. Respirology 8: 91-94 (2003).
Gohar S, Desai D, Joshi A, Bhaduri A, Deshpande R, Balkrishna C, Chawla M, Rodrigues C, Joshi VR. Autoimmune hepatitis: a study of 50 patients. Indian J. Gastroenterol. 22: 140-142 (2003). *
Goicovich E, Molina C, Perez P, Aguilera S, Fernandez J, Olea N, Alliende C, Leyton C, Romo R, Leyton L, Gonzalez MJ. Enhanced degradation of proteins of the basal lamina and stroma by matrix metalloproteinases from the salivary glands of Sjogren's syndrome patients: correlation with reduced structural integrity of acini and ducts. Arthritis Rheum. 48: 2573-2584 (2003). *
Goldstein ES, Rubin PH. Endoscopic therapy for inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 6: 237-243 (2003).
Goldstein JT, Dobrzyn A, Clagett-Dame M, Pike JW, DeLuca HF. Isolation and characterization of unsaturated fatty acids as natural ligands for the retinoid-X receptor. Arch. Biochem. Biophys. 420: 185-193 (2003). *
Gollan JL. Morbus Wilson. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 91-92. October 17 - 19 (2003). *
Gollnick H. Current concepts of the pathogenesis of acne: implications for drug treatment. Drugs 63: 1579-1596 (2003).
Golovnova EV, Il'chenko LIu, Tsaregorodtseva TM, Serova TI, Gudkova RV, Shepeleva SD, Tkachev VD. Primary biliary cirrhosis: 12-year experience in observation. Ter. Arkh. 75: 26-30 (2003).
Golpe R, Mateos A, Perez-Valcarcel J, Lapena JA, Garcia-Figueiras R, Blanco J. Multiple pulmonary nodules in a patient with Crohn's disease. Respiration 70: 306-309 (2003). *
Gomez-Lira M, Bonamini D, Castellani C, Unis L, Cavallini G, Assael BM, Pignatti PF. Mutations in the SPINK1 gene in idiopathic pancreatitis Italian patients. Eur. J. Hum. Genet. 11: 543-546 (2003). *
Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 48: 2122-2127 (2003). *
Gommerman JL, Browning JL. Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat. Rev. Immunol. 3: 642-655 (2003). *
Gonzalez S, Martinez-Borra J, Lopez-Larrea C. Cloning and characterization of human complement component C7 promoter. Genes Immun. 4: 54-59 (2003). *
Gonzalez S, Rodrigo L, Martinez-Borra J, Lopez-Vazquez A, Fuentes D, Nino P, Cadahia V, Saro C, Dieguez MA, Lopez-Larrea C. TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's patients with fistulizing disease. Am. J. Gastroenterol. 98: 1101-1016 (2003). *
Gonzalez-Buitrago JM, Gonzalez C, Hernando M, Carrasco R, Sanchez A, Navajo JA, Papisch W. Antibodies to centromere antigens measured by an automated enzyme immunoassay. Clin. Chim. Acta 328: 135-138 (2003). *
Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE. Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin. Arthritis Rheum. 33: 38-48 (2003). *
Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog. Biophys. Mol. Biol. 81: 1-44 (2003). *
Goodwin B, Gauthier KC, Umetani M, Watson MA, Lochansky MI, Collins JL, Leitersdorf E, Mangelsdorf DJ, Kliewer SA, Repa JJ. Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. Proc. Natl. Acad. Sci. U.S.A. 100: 223-228 (2003). *
Goodwin B, Watson MA, Kim H, Miao J, Kemper JK, Kliewer SA. Differential regulation of rat and human CYP7A1 by the nuclear oxysterol receptor liver X receptor-alpha. Mol. Endocrinol. 17: 386-394 (2003). *
Goossens D, Jonkers D, Stobberingh E, van den Bogaard A, Russel M, Stockbrugger R. Probiotics in gastroenterology: indications and future perspectives. Scand. J. Gastroenterol. Suppl. 239: 15-23 (2003). *
Gopal DV, Corless CL, Rabkin JM, Olyaei AJ, Rosen HR. Graft failure from severe recurrent primary sclerosing cholangitis following orthotopic liver transplantation. J. Clin. Gastroenterol. 37: 344-347 (2003).
Gopal DV, Pfau PR, Lucey MR. Endoscopic management of biliary complications after orthotopic liver transplantation. Curr. Treat. Options Gastroenterol. 6: 509-515 (2003).
Gordon JN, Goggin PM. Thalidomide and its derivatives: emerging from the wilderness. Postgrad. Med. J. 79: 127-132 (2003). *
Gordon JN, MacDonald TT. Biological therapy in Crohn's disease. Hosp. Med. 64: 708-712 (2003).
Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 3: 23-35 (2003).
Gore JI, Surawicz C. Severe acute diarrhea. Gastroenterol. Clin. North Am. 32: 1249-1267 (2003).
Gores GJ. Apoptosis and liver diseases. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 25. September 12 - 13 (2003). *
Gores GJ. Cholangiocarcinoma: preventing invasion as anti-cancer strategy. J. Hepatol. 38: 671-673 (2003). *
Gores GJ. A spotlight on cholangiocarcinoma. Gastroenterology 125: 1536-1538 (2003). *
Gorman C, Leandro M, Isenberg D. B cell depletion in autoimmune disease. Arthritis Res. Ther. 5 Suppl. 4: S17-S21 (2003). *
Gostout BS, Poland GA, Calhoun ES, Sohni YR, Giuntoli RL 2nd, McGovern RM, Sloan JA, Cha SS, Persing DH. TAP1, TAP2, and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol. Oncol. 88: 326-332 (2003).
Goto K, Sugiyama K, Sugiura T, Ando T, Mizutani F, Terabe K, Ban K, Togari H. Bile salt export pump gene mutations in two Japanese patients with progressive familial intrahepatic cholestasis. J. Pediatr. Gastroenterol. Nutr. 36: 647-650 (2003). *
Gottenberg JE, Busson M, Loiseau P, Cohen-Solal J, Lepage V, Charron D, Sibilia J, Mariette X. In primary Sjogren's syndrome, HLA class II is associated exclusively with autoantibody production and spreading of the autoimmune response. Arthritis Rheum. 48: 2240-2245 (2003). *
Gottlieb AB. Infliximab for psoriasis. J. Am. Acad. Dermatol. 49: S112-S117 (2003).
Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. 139: 1627-1632 (2003). *
Gotto AM Jr. Risks and benefits of continued aggressive statin therapy. Clin. Cardiol. 26: III3-III12 (2003).
Gould HJ, Sutton BJ, Beavil AJ, Beavil RL, McCloskey N, Coker HA, Fear D, Smurthwaite L. The biology of IGE and the basis of allergic disease. Annu. Rev. Immunol. 21: 579-628 (2003). *
Graefe SE, Meyer BS, Muller-Myhsok B, Rüschendorf F, Drosten C, Laue T, Steeg C, Nürnberg P, Fleischer B. Murine susceptibility to Chagas' disease maps to chromosomes 5 and 17. Genes Immun. 4: 321-325 (2003). *
Graf GA, Yu L, Li WP, Gerard R, Tuma PL, Cohen JC, Hobbs HH. ABCG5 and ABCG8 are obligate heterodimers for protein trafficking and biliary cholesterol excretion. J. Biol. Chem. 278: 48275-48282 (2003). *
Graf J, Webb A, Davis J. The use of topical tacrolimus (FK506/protopic) in cutaneous manifestations of autoimmune diseases. J. Clin. Rheumatol. 9: 310-315 (2003).
Grahnquist L, Chapman SC, Hvidsten S, Murphy MS. Evaluation of 99mTc-HMPAO leukocyte scintigraphy in the investigation of pediatric inflammatory bowel disease. J. Pediatr. 143: 48-53 (2003). *
Grammer AC, Lipsky PE. B cell abnormalities in systemic lupus erythematosus. Arthritis Res. Ther. 5 Suppl. 4: S22-S27 (2003). *
Granato A, Gores G, Vilei MT, Tolando R, Ferraresso C, Muraca M. Bilirubin inhibits bile acid induced apoptosis in rat hepatocytes. Gut 52: 1774-1778 (2003). *
Granel B, Philip N, Serratrice J, Ene N, Grateau G, Dode C, Cuisset L, Disdier P, Berbis P, Delpech M, Weiller PJ. CIAS1 mutation in a patient with overlap between Muckle-Wells and chronic infantile neurological cutaneous and articular syndromes. Dermatology 206: 257-259 (2003).
Grant WB, Strange RC, Garland CF. Sunshine is good medicine. The health benefits of ultraviolet-B induced vitamin D production. J. Cosmet. Dermatol. 2: 86-98 (2003).
Granucci F, Zanoni I, Feau S, Ricciardi-Castagnoli P. Dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity. EMBO J. 22: 2546-2551 (2003). *
Granvil CP, Yu AM, Elizondo G, Akiyama TE, Cheung C, Feigenbaum L, Krausz KW, Gonzalez FJ. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab. Dispos. 31: 548-558 (2003). *
Gras M, van Kemenade FJ, van Maarsseveen AC, Alberts C. Sarcoidosis: immunopathogenesis and the potential of immunotherapy. Ned. Tijdschr. Geneeskd. 147: 150-155 (2003).
Grasset L, Guy C, Ollagnier M. Cyclines and acne: pay attention to adverse drug reactions! A recent literature review. Rev. Med. Interne. 24: 305-316 (2003).
Grattagliano I, Giudetti AM, Grattagliano V, Palmieri VO, Gnoni GV, Lapadula G, Palasciano G, Vendemiale G. Structural and oxidative modifications of erythrocyte ghosts in patients with primary biliary cirrhosis: relation with the disease stage and effect of bile acid treatment. Eur. J. Clin. Invest. 33: 868-874 (2003). *
Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 12: 409-412 (2003).
Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 diabetes. Proc. Natl. Acad. Sci. U.S.A. 100: 10878-10883 (2003). *
Greenbaum L. Hippatitis rex. Lancet 362: 2032 (2003). *
Greenstein RJ. Is Crohn's disease caused by a Mycobacterium? Comparisons with leprosy, tuberculosis, and Johne's disease. Lancet Infect. Dis. 3: 507-514 (2003).
Greenwood M, Meechan JG. General medicine and surgery for dental practitioners. Part 5: liver disease. Br. Dent. J. 195: 71-73 (2003). *
Greenwood M, Meechan JG. General medicine and surgery for dental practitioners. Part 3: gastrointestinal system. Br. Dent. J. 194: 659-663 (2003).
Gregersen PK, Brehrens TW. Fine mapping the phenotype in autoimmune disease: the promise and pitfalls of DNA microarray technologies. Genes Immun. 4: 175-176 (2003). *
Grendell JH. Genetic factors in pancreatitis. Curr. Gastroenterol. Rep. 5: 105-109 (2003).
Grieco A, Caminiti G, Doglietto GB, Miele L, Gasbarrini G. "Tear-drop shaped" HCC. Ann. Hepatol. 2: 140 (2003). *
Griffin DE. Immune responses to RNA-virus infections of the CNS. Nat. Rev. Immunol. 3: 493-502 (2003).
Griffin MD, Xing N, Kumar R. Vitamin D and its analogs as regulators of immune activation and antigen presentation. Annu. Rev. Nutr. 23: 117-145 (2003). *
Griffiths AM. Monitoring of azathioprine/6-mercaptopurine treatment in children with IBD is not necessary. Inflamm. Bowel Dis. 9: 389-391 (2003). *
Grimes DS. Mycobacterium avium subspecies paratuberculosis as a cause of Crohn's disease. Gut 52: 155 (2003). *
Grip O, Janciauskiene S, Lindgren S. Macrophages in inflammatory bowel disease. Curr. Drug Targets Inflamm. Allergy 2: 155-160 (2003).
Groeneweg M, Hartwig NG, Poerink-Stockschläder AB, Schweizer JJ, Bijleveld CM, Bredius RG. Two children with severe recurrent infections and the X-linked hyper-IgM syndrome. Ned. Tijdschr. Geneeskd. 147: 1024-1028 (2003).
Groeneweg M, Lankester AC, Bredius RG. From gene to disease; CD40 ligand deficiency as the cause of X-linked hyper-IgM-syndrome. Ned. Tijdschr. Geneeskd. 147: 1009-1011 (2003).
Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T. Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc. Natl. Acad. Sci. U.S.A. 100: 9452-9457 (2003). *
Grompe M. The role of bone marrow derived stem cells in liver injury responses. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 35. October 20 - 21 (2003). *
Grompe M. The role of bone marrow stem cells in liver regeneration. Semin. Liver Dis. 23: 363-372 (2003).
Gronowitz E, Pitkanen S, Kjellmer I, Heikinheimo M, Strandvik B. Association between serum oncofetal antigens CA 19-9 and CA 125 and clinical status in patients with cystic fibrosis. Acta Paediatr. 92: 1267-1271 (2003). *
Gross JB Jr, Kumar N. Simultaneous occurrence of PSC and MS in a patient. Dig. Dis. Sci. 48: 1397 (2003). *
Grover JK, Yadav S, Vats V, Joshi YK. Cyclo-oxygenase 2 inhibitors: emerging roles in the gut. Int. J. Colorectal Dis. 18: 279-291 (2003). *
Gruchy SE, Fardy JM. A meta-analysis of ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Am. J. Gastroenterol. 98: S90 (2003). *
Grunhage F, Fischer HP, Sauerbruch T, Reichel C. Drug- and toxin-induced hepatotoxicity. Z. Gastroenterol. 41: 565-578 (2003).
Gu YH, Kodama H, Du SL, Gu QJ, Sun HJ, Ushijima H. Mutation spectrum and polymorphisms in ATP7B identified on direct sequencing of all exons in Chinese Han and Hui ethnic patients with Wilson's disease. Clin. Genet. 64: 479-484 (2003). *
Guanabens N, Pares A, Ros I, Alvarez L, Pons F, Caballeria L, Monegal A, Martinez de Osaba MJ, Roca M, Peris P, Rodes J. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. Am. J. Gastroenterol. 98: 2268-2274 (2003). *
Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 361: 512-519 (2003). *
Guarner F, Malagelada JR. Role of bacteria in experimental colitis. Best Pract. Res. Clin. Gastroenterol. 17: 793-804 (2003).
Guengerich FP. Cytochromes P450, drugs, and diseases. Mol. Intervent. 3: 194-204 (2003). *
Guerini FR, Ferrante P, Losciale L, Caputo D, Lombardi ML, Pirozzi G, Luongo V, Sudomoina MA, Andreewski TV, Alekseenkov AD, Boiko AN, Gusev EI, Favorova OO. Myelin basic protein gene is associated with MS in DR4- and DR5-positive Italians and Russians. Neurology 61: 520-526 (2003).
Guicciardi ME, Gores GJ. AIP1: a new player in TNF signaling. J. Clin. Invest. 111: 1813-1815 (2003). *
Guicciardi ME, Gores GJ. Targeted use of siRNA in animal models of hepatic damage: an innovative therapy for acute liver failure. J. Hepatol. 39: 883-885 (2003). *
Guichelaar MM, Benson JT, Malinchoc M, Krom RA, Wiesner RH, Charlton MR. Risk factors for and clinical course of non-anastomotic biliary strictures after liver transplantation. Am. J. Transplant. 3: 885-890 (2003). *
Guidat A, Fleyfel M, Vallet B, Desreumaux P, Levron JC, Gambiez L, Colombel JF, Scherpereel P. Inflammation increases sufentanil requirements during surgery for inflammatory bowel diseases. Eur. J. Anaesthesiol. 20: 957-962 (2003).
Guilford WG, Matz ME. The nutritional management of gastrointestinal tract disorders in companion animals. N. Z. Vet. J. 51: 284-291 (2003).
Guimbaud R, Selves J. Detection of hereditary non-polyposis colon cancer (HNPCC). J. Chir. (Paris) 140: 317-323 (2003).
Guma M, Salinas I, Reverter JL, Roca J, Valls-Roc M, Juan M, Olive A. Frequency of antineutrophil cytoplasmic antibody in Graves' disease patients treated with methimazole. J. Clin. Endocrinol. Metab. 88: 2141-2146 (2003). *
Guo GL, Lambert G, Negishi M, Ward JM, Brewer HB Jr, Kliewer SA, Gonzalez FJ, Sinal CJ. Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. J. Biol. Chem. 278: 45062-45071 (2003). *
Guo HH, Loeb LA. Tumbling down a different pathway to genetic instability. J. Clin. Invest. 112: 1793-1795 (2003). *
Guo L, Li X, Enosawa S, Harihara Y, Funeshima N, Kimura H, Fujino M, Makuuchi M, Suzuki S. Prolongation of liver xenograft survival by adenovirus vector-mediated CTLA-4Ig gene transfer. Transpl. Immunol. 11: 155-162 (2003).
Gupta A, Neogi R, Mukherjea M, Mukhopadhyay A, Roychoudhury S, Senapati A, Gangopadhyay PK, Ray K. DNA linkage based diagnosis of Wilson disease in asymptomatic siblings. Indian J. Med. Res. 118: 208-214 (2003).
Gupta M, Nikitina-Zake L, Zarghami M, Landin-Olsson M, Kockum I, Lernmark A, Sanjeevi CB. Association between the transmembrane region polymorphism of MHC class I chain related gene-A and type 1 diabetes mellitus in Sweden. Hum. Immunol. 64: 553-561 (2003).
Gupta S. Hepatocyte transplantation: basic aspects of cell engraftment and proliferation. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 36. October 20 - 21 (2003). *
Gupta S, Chiplunkar S, Gupta A, Gollapudi S. Increased spontaneous, tumor necrosis factor receptor- and CD95 (Fas)-mediated apoptosis in cord blood T-cell subsets from Turner's syndrome. Genes Immun. 4: 239-243 (2003). *
Gursoy S, Erdal E, Herken H, Madenci E, Alasehirli B, Erdal N. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. Rheumatol. Int. 23: 104-107 (2003). *
Guslandi M. Helicobacter pylori infection in patients with inflammatory bowel disease. Am. J. Gastroenterol. 98: 2570-2571 (2003). *
Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 15: 697-698 (2003).
Gutierrez O, Akamatsu T, Cardona H, Graham DY, El-Zimaity HM. Helicobacter pylori and hetertopic gastric mucosa in the upper esophagus (the inlet patch). Am. J. Gastroenterol. 98: 1266-1270 (2003). *
Gyorfy A, Kovacs T, Szegedi I, Olah E, Kiss C. Sweet syndrome associated with 13-cis-retinoic acid (isotretinoin) therapy. Med. Pediatr. Oncol. 40: 135-136 (2003).
Ha SJ, Kim JS, Myung JW, Lee HJ, Kim JW. Analysis of genetic polymorphisms of steroid 5alpha-reductase type 1 and 2 genes in Korean men with androgenetic alopecia. J. Dermatol. Sci. 31: 135-141 (2003).
Haag M. Essential fatty acids and the brain. Can. J. Psychiatry 48: 195-203 (2003).
Haagsma EB, Van Den Berg AP, Kleibeuker JH, Slooff MJ, Dijkstra G. Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. Aliment. Pharmacol. Ther. 18: 33-44 (2003). *
Haaning Andersen AD, Lange M, Lillevang ST. Allelic variation of the inducible costimulator (ICOS) gene: detection of polymorphisms, analysis of the promoter region, and extended haplotype estimation. Tissue Antigens 61: 276-285 (2003). *
Haas S. Venous thromboembolism in medical patients-the scope of the problem. Semin. Thromb. Hemost. 29 Suppl. 1: 17-22 (2003).
Haas S, Theuerkauf I, Kuhnen A, Wickesberg A, Fischer HP. Langerhans' cell histiocytosis of the liver. Differential diagnosis of a rare chronic destructive sclerosing cholangitis. Pathologe 24: 119-123 (2003).
Haberman AM, Shlomchik MJ. Reassessing the function of immune-complex retention by follicular dendritic cells. Nat. Rev. Immunol. 3: 757-764 (2003). *
Habermann JK, Upender MB, Roblick UJ, Kruger S, Freitag S, Blegen H, Bruch HP, Schimmelpenning H, Auer G, Ried T. Pronounced chromosomal instability and multiple gene amplifications characterize ulcerative colitis-associated colorectal carcinomas. Cancer Genet. Cytogenet. 147: 9-17 (2003).
Habior A, Lewartowska A, Orlowska J, Zych W, Sankowska M, Bauer A, Butruk E. Association of coeliac disease with primary biliary cirrhosis in Poland. Eur. J. Gastroenterol. Hepatol. 15: 159-164 (2003).
Haderslev KV, Jeppesen PB, Sorensen HA, Mortensen PB, Staun M. Vitamin D status and measurements of markers of bone metabolism in patients with small intestinal resection. Gut 52: 653-658 (2003). *
Hadj Kacem H, Rebai A, Kaffel N, Masmoudi S, Abid M, Ayadi H. PDS is a new susceptibility gene to autoimmune thyroid diseases: association and linkage study. J. Clin. Endocrinol. Metab. 88: 2274-2280 (2003). *
Hadjigogos K, Marinaki P. Autoimmune hepatitis and the antiphospholipid antibody syndrome. A case report. Panminerva Med. 45: 223-224 (2003).
Hagen EA, Lautenbach E, Olthoff K, Blumberg EA. Low prevalence of colonization with vancomycin-resistant Enterococcus in patients awaiting liver transplantation. Am. J. Transplant. 3: 902-905 (2003). *
Hahn-Zoric M, Hytonen AM, Hanson LA, Nilsson LA, Padyukov L. Association of -1087 IL10 and -308 TNFA gene polymorphisms with serological markers of coeliac disease. J. Clin. Immunol. 23: 291-296 (2003). *
Hakenberg J, Nussbaum AK, Schild H, Rammensee HG, Kuttler C, Holzhutter HG, Kloetzel PM, Kaufmann SH, Mollenkopf HJ. MAPPP: MHC class I antigenic peptide processing prediction. Appl. Bioinformatics. 2: 155-158 (2003).
Halff G, Speeg KV, Washburn K, Esterl R, Abrahamian G, Mejia A, Nichols L, Neigut D, Dodd G, Cigarroa F. Liver transplantation at the University of Texas Health Science Center/University Hospital in San Antonio. Clin. Transpl. 2003: 247-253 (2003).
Halfvarson J, Bodin L, Tysk C, Lindberg E, Jarnerot G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology 124: 1767-1773 (2003). *
Hall RJ, Hollis-Moffatt JE, Merriman ME, Green RA, Baker D, Merriman TR. An autoimmune diabetes locus (Idd21) on mouse chromosome 18. Mamm. Genome 14: 335-339 (2003). *
Hall RJ, Merriman ME, Green RA, Markham VH, Smyth DJ, Heward JM, Jennings CE, Braithwaite AW, Cundy T, Darlow BA, Gow PJ, Harrison AA, Highton J, Hunt PJ, Manning P, Pokorny V, Scott RS, Taylor BJ, Willis JA, Yeoman S, McLean L, Gough SC, Pearce SH, et al. The deleted in colorectal carcinoma (DCC) gene 201 R-->G polymorphism: no evidence for genetic association with autoimmune disease. Eur. J. Hum. Genet. 11: 840-844 (2003). *
Hallden G, Kirn D. Oncolytic replication selective adenoviruses as cytocidal therapeutics for cancer. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 42. October 20 - 21 (2003). *
Haller C, Kemmler G, Judmair G, Rathner G, Kinzl H, Richter R, Gunther V. Social network and social support in patients with chronic inflammatory bowel disease. Z. Psychosom. Med. Psychother. 49: 36-48 (2003).
Hallert C, Bjorck I, Nyman M, Pousette A, Granno C, Svensson H. Increasing fecal butyrate in ulcerative colitis patients by diet: controlled pilot study. Inflamm. Bowel Dis. 9: 116-121 (2003). *
Hamajima N, Shibata A, Katsuda N, Matsuo K, Ito H, Saito T, Tajima K, Tominaga S. Subjects with TNF-A-857TT and -1031TT genotypes showed the highest Helicobacter pylori seropositive rate compared with those with other genotypes. Gastric Cancer 6: 230-236 (2003).
Hamaoui E, Hamaoui M. Nutritional assessment and support during pregnancy. Gastroenterol. Clin. North Am. 32: 59-121, v (2003). *
Hampe J, Heymann K, Krawczak M, Schreiber S. Association of inflammatory bowel disease with indicators for childhood antigen and infection exposure. Int. J. Colorectal Dis. 18: 413-417 (2003). *
Han GM, Chen SL, Shen N, Ye S, Bao CD, Gu YY. Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Genes Immun. 4: 177-186 (2003). *
Hanada S, Harada M, Koga H, Kawaguchi T, Taniguchi E, Kumashiro R, Ueno T, Ueno Y, Ishii M, Sakisaka S, Sata M. Tumor necrosis factor-alpha and interferon-gamma directly impair epithelial barrier function in cultured mouse cholangiocytes. Liver Int. 23: 3-11 (2003). *
Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, Saniabadi A, Matsushita I, Sato Y, Tozawa K, Arai H, Furuta T, Sugimoto K, Bjarnason I. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin. Gastroenterol. Hepatol. 1: 28-35 (2003). *
Hanauer SB. Factoring in growth factors for treatment of inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 485 (2003).
Hanauer SB. Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis. Am. J. Gastroenterol. 98: 215-216 (2003). *
Hanauer SB. Assessing the risk of lymphomas in inflammatory bowel disease. Rev. Gastroenterol. Disord. 3: 50-51 (2003). *
Hanauer SB. Crohn's disease: step up or top down therapy. Best Pract. Res. Clin. Gastroenterol. 17: 131-137 (2003). *
Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev. Gastroenterol. Disord. 3: 81-92 (2003). *
Hanck C, Schneider A, Whitcomb DC. Genetic polymorphisms in alcoholic pancreatitis. Best Pract. Res. Clin. Gastroenterol. 17: 613-623 (2003).
Handa R. Spondylo-arthropathies. J. Indian Med. Assoc. 101: 514, 516, 518 (2003).
Handa T, Nagai S, Ito I, Shigematsu M, Hamada K, Kitaichi M, Izumi T, Mishima M. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) exon 1 polymorphism affects lymphocyte profiles in bronchoalveolar lavage of patients with sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 20: 190-196 (2003).
Handschin C, Meyer UA. Induction of drug metabolism: the role of nuclear receptors. Pharmacol. Rev. 55: 649-673 (2003). *
Hansen A, Lipsky PE, Dorner T. New concepts in the pathogenesis of Sjogren syndrome: many questions, fewer answers. Curr. Opin. Rheumatol. 15: 563-570 (2003).
Hansen TK, Thiel S, Knudsen ST, Gravholt CH, Christiansen JS, Mogensen CE, Poulsen PL. Elevated levels of mannan-binding lectin in patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 88: 4857-4861 (2003). *
Hanyecz A, Bardos T, Berlo SE, Buzas E, Nesterovitch AB, Mikecz K, Glant TT. Induction of arthritis in SCID mice by T cells specific for the "shared epitope" sequence in the G3 domain of human cartilage proteoglycan. Arthritis Rheum. 48: 2959-2973 (2003). *
Harada K, Isse K, Tsuneyama K, Ohta H, Nakanuma Y. Accumulating CD57 + CD3 + natural killer T cells are related to intrahepatic bile duct lesions in primary biliary cirrhosis. Liver Int. 23: 94-100 (2003). *
Harada K, Ohira S, Isse K, Ozaki S, Zen Y, Sato Y, Nakanuma Y. Lipopolysaccharide activates nuclear factor-kappaB through Toll-like receptors and related molecules in cultured biliary epithelial cells. Lab. Invest. 83: 1657-1667 (2003). *
Harada K, Ozaki S, Sudo Y, Tsuneyama K, Ohta H, Nakanuma Y. Osteopontin is involved in the formation of epithelioid granuloma and bile duct injury in primary biliary cirrhosis. Pathol. Int. 53: 8-17 (2003). *
Harada M, Kumemura H, Sakisaka S, Shishido S, Taniguchi E, Kawaguchi T, Hanada S, Koga H, Kumashiro R, Ueno T, Suganuma T, Furuta K, Namba M, Sugiyama T, Sata M. Wilson disease protein ATP7B is localized in the late endosomes in a polarized human hepatocyte cell line. Int. J. Mol. Med. 11: 293-298 (2003).
Harada T, Koyama I, Kasahara T, Alpers DH, Komoda T. Heat shock induces intestinal-type alkaline phosphatase in rat IEC-18 cells. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G255-G262 (2003). *
Harbige LS. Fatty acids, the immune response, and autoimmunity: a question of n-6 essentiality and the balance between n-6 and n-3. Lipids 38: 323-341 (2003).
Hardy ML, Coulter I, Morton SC, Favreau J, Venuturupalli S, Chiappelli F, Rossi F, Orshansky G, Jungvig LK, Roth EA, Suttorp MJ, Shekelle P. S-Adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evid. Rep. Technol. Assess. 64: 1-3 (2003).
Haristoy X, Angioi-Duprez K, Duprez A, Lozniewski A. Efficacy of sulforaphane in eradicating Helicobacter pylori in human gastric xenografts implanted in nude mice. Antimicrob. Agents Chemother. 47: 3982-3984 (2003). *
Harnad S. Open access to peer-reviewed research through author/institution self-archiving: maximizing research impact by maximizing online access. J. Postgrad. Med. 49: 337-342 (2003). *
Harney S, Newton J, Milicic A, Brown MA, Wordsworth BP. Non-inherited maternal HLA alleles are associated with rheumatoid arthritis. Rheumatology (Oxford) 42: 171-174 (2003). *
Harney SM, Newton JL, Wordsworth BP. Molecular genetics of rheumatoid arthritis. Curr. Opin. Pharmacol. 3: 280-285 (2003).
Harp JA. Parasitic infections of the gastrointestinal tract. Curr. Opin. Gastroenterol. 19: 31-36 (2003).
Harpavat M, Keljo DJ. Perspectives on osteoporosis in pediatric inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 225-232 (2003).
Harrer M, Reinisch W, Dejaco C, Kratzer V, Gmeiner M, Miehsler W, Norman GL, Gangl A, Vogelsang H. Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease? Eur. J. Gastroenterol. Hepatol. 15: 1281-1285 (2003).
Harrison SA, Bacon BR. Hereditary hemochromatosis: update for 2003. J. Hepatol. 38 Suppl. 1: S14-S23 (2003). *
Hasegawa T, Sakurai K, Kambayashi Y, Saniabadi AR, Nagamoto H, Tsukada K, Takahashi A, Kuwano H, Nakano M. Effects of OPC-6535 on lipopolysaccharide-induced acute liver injury in the rat: involvement of superoxide and tumor necrosis factor-alpha from hepatic macrophages. Surgery 134: 818-826 (2003). *
Hashigucci K, Niizeki H, Naruse T, Ota M, Inamoto N, Nishikawa T, Inoko H. A clinical feature associated with polymorphisms of the TNF region in Japanese patients with palmoplantar pustulosis. Hum. Immunol. 64: 530-537 (2003).
Hashimoto H, Green J, Iwao Y, Sakurai T, Hibi T, Fukuhara S. Reliability, validity, and responsiveness of the Japanese version of the Inflammatory Bowel Disease Questionnaire. J. Gastroenterol. 38: 1138-1143 (2003). *
Hashkes PJ, Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin. Exp. Rheumatol. 21: 645-646 (2003).
Hasler P, Zouali M. Subversion of B lymphocyte signaling by infectious agents. Genes Immun. 4: 95-103 (2003). *
Hasler WL. The irritable bowel syndrome during pregnancy. Gastroenterol. Clin. North Am. 32: 385-406, viii (2003). *
Hassan AB, Nikitina-Zake L, Padyukov L, Karlsson G, Gupta M, Lundberg IE, Sanjeevi CB. MICA4/HLA-DRB1*04/TNF1 haplotype is associated with mixed connective tissue disease in Swedish patients. Hum. Immunol. 64: 290-296 (2003).
Hassoun Z, Gores GJ. Treatment of hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 1: 10-18 (2003). *
Haston CK, Tsui LC. Loci of intestinal distress in cystic fibrosis knockout mice. Physiol. Genomics 12: 79-84 (2003). *
Hata K, Watanabe T, Shinozaki M, Nagawa H. Patients with extraintestinal manifestations have a higher risk of developing pouchitis in ulcerative colitis: multivariate analysis. Scand. J. Gastroenterol. 38: 1055-1058 (2003). *
Hatoum OA, Miura H, Binion DG. The vascular contribution in the pathogenesis of inflammatory bowel disease. Am. J. Physiol. Heart Circ. Physiol. 285: H1791-H1796 (2003). *
Hattori E, Okumoto K, Adachi T, Takeda T, Ito J, Sugahara K, Watanabe H, Saito K, Saito T, Togashi H, Kawata S. Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma. Hepatol. Res. 27: 309-314 (2003).
Hawn TR, Verbon A, Lettinga KD, Zhao LP, Li SS, Laws RJ, Skerrett SJ, Beutler B, Schroeder L, Nachman A, Ozinsky A, Smith KD, Aderem A. A common dominant TLR5 stop codon polymorphism abolishes flagellin signaling and is associated with susceptibility to legionnaires' disease. J. Exp. Med. 198: 1563-1572 (2003). *
Hay JE. Osteoporosis in liver diseases and after liver transplantation. J. Hepatol. 38: 856-865 (2003). *
Hayashi PH, Forman L, Steinberg T, Bak T, Wachs M, Kugelmas M, Everson GT, Kam I, Trotter JF. Model for End-stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients. Liver Transpl. 9: 737-740 (2003). *
Hayashi T, Faustman DL. Role of defective apoptosis in type 1 diabetes and other autoimmune diseases. Recent Prog. Horm. Res. 58: 131-153 (2003).
Hayday A, Tigelaar R. Immunoregulation in the tissues by gammadelta T cells. Nat. Rev. Immunol. 3: 233-242 (2003). *
Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell. Mol. Biol. (Noisy-le-grand) 49: 277-300 (2003).
Hazama S, Oka M, Hinoda Y. Polymorphism in colorectal cancer. Nippon Rinsho 61 Suppl. 7: 42-46 (2003).
He D, Barnes S, Falany CN. Rat liver bile acid CoA:amino acid N-acyltransferase: expression, characterization, and peroxisomal localization. J. Lipid Res. 44: 2242-2249 (2003). *
He JQ, Chan-Yeung M, Becker AB, Dimich-Ward H, Ferguson AC, Manfreda J, Watson WT, Sandford AJ. Genetic variants of the IL13 and IL4 genes and atopic diseases in at-risk children. Genes Immun. 4: 385-389 (2003). *
Head KA, Jurenka JS. Inflammatory bowel disease. Part 1: ulcerative colitis - pathophysiology and conventional and alternative treatment options. Altern. Med. Rev. 8: 247-283 (2003). *
Heathcote EJ. Primary biliary cirrhosis: historical perspective. Clin. Liver Dis. 7: 735-740 (2003).
Heathcote EJ. Primary biliary cirrhosis. Clin. Liver Dis. 7: xi-xii (2003). *
Heathcote J. Overlap syndromes - outlier syndromes and changing diagnoses. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 39-41. October 15-16 (2003). *
Heaton N. Small-for-size liver syndrome after auxiliary and split liver transplantation: donor selection. Liver Transpl. 9: S26-S28 (2003). *
Hebert MF, Wacher VJ, Roberts JP, Benet LZ. Pharmacokinetics of cyclosporine pre- and post-liver transplantation. J. Clin. Pharmacol. 43: 38-42 (2003). *
Hecker M, Bohnert A, Konig IR, Bein G, Hackstein H. Novel genetic variation of human interleukin-21 receptor is associated with elevated IgE levels in females. Genes Immun. 4: 228-233 (2003). *
Heesen M, Schippers EF, Bloemeke B, Kunz D, van Dissel JT. Cytokine response to endotoxin in individuals heterozygous for the Delta32 mutation of chemokine receptor CCR5. Cytokine 21: 195-199 (2003).
Heffron TG, Smallwood GA, Oakley B, Pillen T, Welch D, Connor K, Martinez E, Romero R, Stieber AC. Adult and pediatric liver transplantation for autoimmune hepatitis. Transplant. Proc. 35: 1435-1436 (2003). *
Heffron TG, Smallwood GA, Ramcharan T, Davis L, Connor K, Martinez E, Stieber AC. Duct-to-duct biliary anastomosis for patients with sclerosing cholangitis undergoing liver transplantation. Transplant. Proc. 35: 3006-3007 (2003). *
Hegazi RA, Mady HH, Melhem MF, Sepulveda AR, Mohi M, Kandil HM. Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice. Inflamm. Bowel Dis. 9: 230-236 (2003). *
Hegedus T, Sessler T, Scott R, Thelin W, Bakos E, Varadi A, Szabo K, Homolya L, Milgram SL, Sarkadi B. C-terminal phosphorylation of MRP2 modulates its interaction with PDZ proteins. Biochem. Biophys. Res. Commun. 302: 454-461 (2003). *
Heidemann J, Spinelli KS, Otterson MF, Binion DG. Case report: magnetic resonance imaging in the diagnosis of epidural abscess complicating perirectal fistulizing Crohn's disease. Inflamm. Bowel Dis. 9: 122-124 (2003). *
Heilig R, Eckenberg R, Petit JL, Fonknechten N, Da Silva C, Cattolico L, Levy M et al. The DNA sequence and analysis of human chromosome 14. Nature 421: 601-607 (2003). *
Heiligenhaus A, Mingels A, Neudorf U, Ganser G. Juvenile idiopathic arthritis and uveitis: screening and anti-inflammatory therapy. Klin. Monatsbl. Augenheilkd. 220: 738-753 (2003).
Hein WR, Griebel PJ. A road less travelled: large animal models in immunological research. Nat. Rev. Immunol. 3: 79-84 (2003). *
Heine H, Lien E. Toll-like receptors and their function in innate and adaptive immunity. Int. Arch. Allergy Immunol. 130: 180-192 (2003).
Helbig KJ, Heatley SL, Harris RJ, Mullighan CG, Bardy PG, Marmion BP. Variation in immune response genes and chronic Q fever. Concepts: preliminary test with post-Q fever fatigue syndrome. Genes Immun. 4: 82-85 (2003). *
Held W, Coudert JD, Zimmer J. The NK cell receptor repertoire: formation, adaptation and exploitation. Curr. Opin. Immunol. 15: 233-237 (2003).
Heldt C, Listing J, Sozeri O, Blasing F, Frischbutter S, Muller B. Differential expression of HLA class II genes associated with disease susceptibility and progression in rheumatoid arthritis. Arthritis Rheum. 48: 2779-2787 (2003). *
Helio T, Halme L, Lappalainen M, Fodstad H, Paavola-Sakki P, Turunen U, Farkkila M, Krusius T, Kontula K. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut 52: 558-562 (2003). *
Heller AR, Theilen HJ, Koch T. Fish or chips? News Physiol. Sci. 18: 50-54 (2003). *
Heller F, Duchmann R. Intestinal flora and mucosal immune responses. Int. J. Med. Microbiol. 293: 77-86 (2003).
Hellerbrand C, Poppl A, Hartmann A, Scholmerich J, Lock G. HFE C282Y heterozygosity in hepatocellular carcinoma: evidence for an increased prevalence. Clin. Gastroenterol. Hepatol. 1: 279-284 (2003). *
Hellier S, Frodsham AJ, Hennig BJ, Klenerman P, Knapp S, Ramaley P, Satsangi J, Wright M, Zhang L, Thomas HC, Thursz M, Hill AV. Association of genetic variants of the chemokine receptor CCR5 and its ligands, RANTES and MCP-2, with outcome of HCV infection. Hepatology 38: 1468-1476 (2003). *
Helmby H, Grencis RK. Contrasting roles for IL-10 in protective immunity to different life cycle stages of intestinal nematode parasites. Eur. J. Immunol. 33: 2382-2390 (2003). *
Helms C, Cao L, Krueger JG, Wijsman EM, Chamian F, Gordon D, Heffernan M, Daw JA, Robarge J, Ott J, Kwok PY, Menter A, Bowcock AM. A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat. Genet. 35: 349-356 (2003). *
Hempfling W, Dilger K, Beuers U. Ursodeoxycholic acid - adverse effects and drug interactions. Aliment. Pharmacol. Ther. 18: 963-972 (2003). *
Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 38: 196-202 (2003). *
Henderson CJ, Wolf CR. Transgenic analysis of human drug-metabolizing enzymes: preclinical drug development and toxicology. Mol. Intervent. 3: 331-343 (2003). *
Heneghan MA, Tuttle-Newhall JE, Suhocki PV, Muir AJ, Morse M, Bornstein JD, Sylvestre PB, Collins B, Kuo PC, Rockey DC. De-novo cholangiocarcinoma in the setting of recurrent primary sclerosing cholangitis following liver transplant. Am. J. Transplant. 3: 634-638 (2003). *
Hensen P, Asadullah K, Windemuth C, Ruschendorf F, Huffmeier U, Stander M, Schmitt-Egenolf M, Wienker TF, Reis A, Traupe H. Interleukin-10 promoter polymorphism IL10.G and familial early onset psoriasis. Br. J. Dermatol. 149: 381-385 (2003). *
Hensen P, Windemuth C, Huffmeier U, Ruschendorf F, Stadelmann A, Hoppe V, Fenneker D, Stander M, Schmitt-Egenolf M, Wienker TF, Traupe H, Reis A. Association scan of the novel psoriasis susceptibility region on chromosome 19: evidence for both susceptible and protective loci. Exp. Dermatol. 12: 490-496 (2003). *
Hentgen V, Granel B, Dode C, Cuisset L, Delpech M, Grateau G. Tumor necrosis factor receptor superfamily 1A-associated periodic syndrome (TRAPS). Rev. Med. Interne. 24: 781-785 (2003).
Hentgen V, Reinert P. TNF receptor-associated periodic syndrome (TRAPS): clinical aspects and physiopathology of a rare familial disease. Arch. Pediatr. 10: 45-53 (2003).
Hentze MW. RNA biology. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 17. October 20 - 21 (2003). *
Herane MI, Ando I. Acne in infancy and acne genetics. Dermatology 206: 24-28 (2003).
Herbon N, Werner M, Braig C, Gohlke H, Dutsch G, Illig T, Altmuller J, Hampe J, Lantermann A, Schreiber S, Bonifacio E, Ziegler A, Schwab S, Wildenauer D, van den Boom D, Braun A, Knapp M, Reitmeir P, Wjst M. High-resolution SNP scan of chromosome 6p21 in pooled samples from patients with complex diseases. Genomics 81: 510-518 (2003). *
Herek O, Yilmaz M, Demir S, Akbulut M. The effects of intestinal ischemia on the levels of serum immunoglobulin A in rats. Pediatr. Surg. Int. 19: 601-604 (2003).
Herendeen JM, Lindley C. Use of NSAIDs for the chemoprevention of colorectal cancer. Ann. Pharmacother. 37: 1664-1674 (2003). *
Herfarth H, Goke M, Hellerbrand C, Muhlbauer M, Vogl D, Scholmerich J, Rogler G. Polymorphism of monocyte chemoattractant protein 1 in Crohn's disease. Int. J. Colorectal Dis. 18: 401-405 (2003). *
Herfarth H, Messmann H. Low grade dysplasia in ulcerative colitis. Z. Gastroenterol. 41: 351-353 (2003).
Hermiston ML, Xu Z, Weiss A. CD45: a critical regulator of signaling thresholds in immune cells. Annu. Rev. Immunol. 21: 107-137 (2003). *
Hermoso MA, Cidlowski JA. Putting the brake on inflammatory responses: the role of glucocorticoids. IUBMB Life 55: 497-504 (2003).
Herr AB, Ballister ER, Bjorkman PJ. Insights into IgA-mediated immune responses from the crystal structures of human FcalphaRI and its complex with IgA1-Fc. Nature 423: 614-620 (2003). *
Herrick CA, Bottomly K. To respond or not to respond: T cells in allergic asthma. Nat. Rev. Immunol. 3: 405-412 (2003). *
Herrine SK. Drug-induced liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).
Herrlinger KR, Deibert P, Schwab M, Kreisel W, Fischer C, Fellermann K, Stange EF. Remission maintenance by tioguanine in chronic active Crohn's disease. Aliment. Pharmacol. Ther. 17: 1459-1464 (2003). *
Hershman MJ. Developments in understanding and management of inflammatory bowel disease. Hosp. Med. 64: 702 (2003).
Hesse S, Barthel H, Hermann W, Murai T, Kluge R, Wagner A, Sabri O, Eggers B. Regional serotonin transporter availability and depression are correlated in Wilson's disease. J. Neural. Transm. 110: 923-933 (2003). *
Heuman DM, Mihas A. Utility of the MELD score for assessing 3-month survival in patients with liver cirrhosis: one more positive answer. Gastroenterology 125: 992-993 (2003). *
Hewitt EW, Lehner PJ. The ABC-transporter signature motif is required for peptide translocation but not peptide binding by TAP. Eur. J. Immunol. 33: 422-427 (2003). *
Hiasa Y, Tokumoto Y, Furukawa S, Takeshita E, Matsui H, Michitaka K, Horiike N, Onji M. Two cases of asymptomatic primary biliary cirrhosis with ascites. Nippon Shokakibyo Gakkai Zasshi 100: 1400-1404 (2003).
Hibbeln JR, Makino KK, Martin CE, Dickerson F, Boronow J, Fenton WS. Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biol. Psychiatry 53: 431-441 (2003). *
Hibbert L, Pflanz S, De Waal Malefyt R, Kastelein RA. IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. J. Interferon Cytokine Res. 23: 513-522 (2003).
Hibi T, Inoue N, Ogata H, Naganuma M. Introduction and overview: recent advances in the immunotherapy of inflammatory bowel disease. J. Gastroenterol. 38 Suppl. 15: 36-42 (2003).
Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J. Gastroenterol. 38: 740-746 (2003). *
Hicken BL, Calhoun DC, Tucker DC. Genetic testing for hemochromatosis: attitudes and acceptability among young and older adults. Genet. Test. 7: 235-239 (2003).
Higashi N, Senoo H. Distribution of vitamin A-storing lipid droplets in hepatic stellate cells in liver lobules - a comparative study. Anat. Rec. A. Discov. Mol. Cell. Evol. Biol. 271: 240-248 (2003).
Higgins PD, Fontana RJ. Liver transplantation in acute liver failure. Panminerva. Med. 45: 85-94 (2003).
Higuchi H, Gores GJ. Bile acid regulation of hepatic physiology: IV. Bile acids and death receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G734-G738 (2003). *
Higuchi H, Gores GJ. Mechanisms of liver injury: an overview. Curr. Mol. Med. 3: 483-490 (2003).
Hikami K, Tsuchiya N, Yabe T, Tokunaga K. Variations of human killer cell lectin-like receptors: common occurrence of NKG2-C deletion in the general population. Genes Immun. 4: 160-167 (2003). *
Hildebrand H, Finkel Y, Grahnquist L, Lindholm J, Ekbom A, Askling J. Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990-2001. Gut 52: 1432-1434 (2003). *
Hillebrands JL, van der Werf N, Klatter FA, Bruggeman CA, Rozing J. Role of peritoneal macrophages in cytomegalovirus-induced acceleration of autoimmune diabetes in BB-rats. Clin. Dev. Immunol. 10: 133-139 (2003).
Hiller S, Kohl A, Fiorito F, Herrmann T, Wider G, Tschopp J, Grutter MG, Wuthrich K. NMR structure of the apoptosis- and inflammation-related NALP1 pyrin domain. Structure 11: 1199-1205 (2003). *
Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C et al. The DNA sequence of human chromosome 7. Nature 424: 157-164 (2003). *
Hilsden RJ, Verhoef MJ, Best A, Pocobelli G. A national survey on the patterns of treatment of inflammatory bowel disease in Canada. BMC Gastroenterol. 3: 10 (2003). *
Hines ME 2nd, Styer EL. Preliminary characterization of chemically generated Mycobacterium avium subsp. paratuberculosis cell wall deficient forms (spheroplasts). Vet. Microbiol. 95: 247-258 (2003). *
Hino T, Kumashiro R, Ide T, Koga Y, Ishii K, Tanaka E, Morita Y, Hisamochi A, Murashima S, Tanaka K, Ogata K, Kuwahara R, Sata M. Predictive factors for remission and death in 73 patients with autoimmune hepatitis in Japan. Int. J. Mol. Med. 11: 749-755 (2003).
Hiramatsu J, Kataoka M, Nakata Y, Okazaki K, Tada S, Tanimoto M, Eishi Y. Propionibacterium acnes DNA detected in bronchoalveolar lavage cells from patients with sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 20: 197-203 (2003).
Hirano F, Kobayashi A, Makino I. Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates, the hypolipidemic drugs. Int. Immunopharmacol. 3: 225-232 (2003).
Hirano K, Shiratori Y, Komatsu Y, Yamamoto N, Sasahira N, Toda N, Isayama H, Tada M, Tsujino T, Nakata R, Kawase T, Katamoto T, Kawabe T, Omata M. Involvement of the biliary system in autoimmune pancreatitis: a follow-up study. Clin. Gastroenterol. Hepatol. 1: 453-464 (2003). *
Hirashiki A, Yamada Y, Murase Y, Suzuki Y, Kataoka H, Morimoto Y, Tajika T, Murohara T, Yokota M. Association of gene polymorphisms with coronary artery disease in low- or high-risk subjects defined by conventional risk factors. J. Am. Coll. Cardiol. 42: 1429-1437 (2003). *
Hirota M, Kuwata K, Ohmuraya M, Ogawa M. From acute to chronic pancreatitis: the role of mutations in the pancreatic secretory trypsin inhibitor gene. JOP 4: 83-88 (2003). *
Hisamatsu T, Suzuki M, Podolsky DK. Interferon-gamma augments CARD4/NOD1 gene and protein expression through interferon regulatory factor-1 in intestinal epithelial cells. J. Biol. Chem. 278: 32962-32968 (2003). *
Hisamatsu T, Suzuki M, Reinecker HC, Nadeau WJ, McCormick BA, Podolsky DK. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology 124: 993-1000 (2003). *
Hise AG, Hazlett FE, Bockarie MJ, Zimmerman PA, Tisch DJ, Kazura JW. Polymorphisms of innate immunity genes and susceptibility to lymphatic filariasis. Genes Immun. 4: 524-527 (2003). *
Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 52: 759-766 (2003). *
Ho SC, Goh SS, Khoo DH. Association of Graves' disease with intragenic polymorphism of the thyrotropin receptor gene in a cohort of Singapore patients of multi-ethnic origins. Thyroid 13: 523-528 (2003).
Hoda F, Green RM. Hepatic canalicular membrane transport of bile salt in C57L/J and AKR/J mice: implications for cholesterol gallstone formation. J. Membr. Biol. 196: 9-14 (2003). *
Hodgkinson CP, Ye S. Microarray analysis of peroxisome proliferator-activated receptor-gamma induced changes in gene expression in macrophages. Biochem. Biophys. Res. Commun. 308: 505-510 (2003). *
Hodgson H. Liver cells: biology to therapeutics. Clin. Med. 3: 161-165 (2003). *
Hoefnagels MA, van Leusen R, de Vries RA. Three patients with weight loss as a result of sarcoidosis presenting as liver disease. Ned. Tijdschr. Geneeskd. 147: 2453-2457 (2003).
Hoehe MR, Timmermann B, Lehrach H. Human inter-individual DNA sequence variation in candidate genes, drug targets, the importance of haplotypes and pharmacogenomics. Curr. Pharm. Biotechnol. 4: 351-378 (2003).
Hoentjen F, Harmsen HJ, Braat H, Torrice CD, Mann BA, Sartor RB, Dieleman LA. Antibiotics with a selective aerobic or anaerobic spectrum have different therapeutic activities in various regions of the colon in interleukin 10 gene deficient mice. Gut 52: 1721-1727 (2003). *
Hoeve MA, de Boer T, Langenberg DM, Sanal O, Verreck FA, Ottenhoff TH. IL-12 receptor deficiency revisited: IL-23-mediated signaling is also impaired in human genetic IL-12 receptor beta1 deficiency. Eur. J. Immunol. 33: 3393-3397 (2003). *
Hofer KN. Oral budesonide in the management of Crohn's disease. Ann. Pharmacother. 37: 1457-1464 (2003).
Hoffmann JC, Pawlowski NN, Kuhl AA, Hohne W, Zeitz M. Animal models of inflammatory bowel disease: an overview. Pathobiology 70: 121-130 (2003).
Hofmann AF. Inappropriate ileal conservation of bile acids in cholestatic liver disease: homeostasis gone awry. Gut 52: 1239-1241 (2003). *
Hofseth LJ, Khan MA, Ambrose M, Nikolayeva O, Xu-Welliver M, Kartalou M, Hussain SP, Roth RB, Zhou X, Mechanic LE, Zurer I, Rotter V, Samson LD, Harris CC. The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J. Clin. Invest. 112: 1887-1894 (2003). *
Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, Jhappan C, Higashimoto Y, He P, Linke SP, Quezado MM, Zurer I, Rotter V, Wink DA, Appella E, Harris CC. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc. Natl. Acad. Sci. U.S.A. 100: 143-148 (2003). *
Hogenboom S, Romeijn GJ, Houten SM, Baes M, Wanders RJ, Waterham HR. Peroxisome deficiency does not result in deficiency of enzymes involved in cholesterol biosynthesis. Adv. Exp. Med. Biol. 544: 329-330 (2003).
Hogg KG, Kumkate S, Mountford AP. IL-10 regulates early IL-12-mediated immune responses induced by the radiation-attenuated schistosome vaccine. Int. Immunol. 15: 1451-1459 (2003). *
Hojo M, Sano N, Takikawa H. Effects of lipopolysaccharide on the biliary excretion of bile acids and organic anions in rats. J. Gastroenterol. Hepatol. 18: 815-821 (2003). *
Hokama A, Kinjo F, Sugama R, Kobashigawa K, Matayoshi R, Yonamine Y, Tomiyama R, Sunagawa T, Kawane M, Saito A. Gastrointestinal: duodenal Crohn's disease. J. Gastroenterol. Hepatol. 18: 1425 (2003). *
Holick MF. Vitamin D: a millenium perspective. J. Cell Biochem. 88: 296-307 (2003). *
Holick MF. Evolution and function of vitamin D. Recent Results Cancer Res. 164: 3-28 (2003).
Holick MF. Vitamin D deficiency: what a pain it is. Mayo Clin. Proc. 78: 1457-1459 (2003). *
Hollander D. Inflammatory bowel diseases and brain-gut axis. J. Physiol. Pharmacol. 54 Suppl. 4: 183-190 (2003). *
Holm AM, Aukrust P, Aandahl EM, Müller F, Taskén K, Frøland SS. Impaired secretion of IL-10 by T cells from patients with common variable immunodeficiency - involvement of protein kinase A type I. J. Immunol. 170: 5772-5777 (2003). *
Holm SJ, Carlen LM, Mallbris L, Stahle-Backdahl M, O'Brien KP. Polymorphisms in the SEEK1 and SPR1 genes on 6p21.3 associate with psoriasis in the Swedish population. Exp. Dermatol. 12: 435-444 (2003). *
Holmlund JT. Applying antisense technology: Affinitak(TM) and other antisense oligonucleotides in clinical development. Ann. N. Y. Acad. Sci. 1002: 244-251 (2003). *
Holst D, Luquet S, Nogueira V, Kristiansen K, Leverve X, Grimaldi PA. Nutritional regulation and role of peroxisome proliferator-activated receptor delta in fatty acid catabolism in skeletal muscle. Biochim. Biophys. Acta 1633: 43-50 (2003). *
Holt JA, Luo G, Billin AN, Bisi J, McNeill YY, Kozarsky KF, Donahee M, Wang da Y, Mansfield TA, Kliewer SA, Goodwin B, Jones SA. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 17: 1581-1591 (2003). *
Holtmann M, Wanitschke R, Helisch A, Bartenstein P, Galle PR, Neurath M. Anti-TNF antibodies in the treatment of inflammatory intestinal stenoses in Crohn's disease. Z. Gastroenterol. 41: 11-17 (2003).
Holtmann MH, Neurath MF. Transplanting the genetic susceptibility to Crohn's disease. Gut 52: 1394-1396 (2003). *
Holtmann MM. RDP-58 (SangStat Medical). IDrugs 6: 1188-1194 (2003).
Holtmeier W. Compartmentalization g/d T cells and their putative role in mucosal immunity. Crit. Rev. Immunol. 23: 473-488 (2003).
Holubar S, Hyman N. Continence alterations after ileal pouch-anal anastomosis do not diminish quality of life. Dis. Colon Rectum 46: 1489-1491 (2003).
Homaidan FR, Chakroun I, El-Sabban ME. Regulation of nuclear factor-kappaB in intestinal epithelial cells in a cell model of inflammation. Mediators Inflamm. 12: 277-283 (2003). *
Hommes D. Discussion on predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 124: 2002-2003 (2003). *
Hommes DW, Peppelenbosch MP, van Deventer SJ. Mitogen activated protein (MAP) kinase signal transduction pathways and novel anti-inflammatory targets. Gut 52: 144-151 (2003). *
Hommes DW, van Deventer SJ. Infliximab therapy in Crohn's disease: safety issues. Neth. J. Med. 61: 100-104 (2003). *
Hommes DW, van Deventer SJ. Targeting tumor necrosis factor-alpha in inflammatory bowel disease: why, how, and when? Curr. Opin. Gastroenterol. 19: 350-357 (2003).
Homolya L, Varadi A, Sarkadi B. Multidrug resistance-associated proteins: export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors 17: 103-114 (2003).
Honda T, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Toyoda H, Ishiguro H, Ogawa S, Takeshima K, Kawachi T, Hibi T, Hayashi K, Katano Y, Fukuda Y, Goto H. Comparison of contrast-enhanced harmonic ultrasonography and power Doppler ultrasonography for depicting vascularity of hepatocellular carcinoma identified by angiography-assisted CT. Hepatol. Res. 27: 315-322 (2003).
Honeckman A. Current concepts in the treatment of canine chronic hepatitis. Clin. Tech. Small Anim. Pract. 18: 239-244 (2003).
Honey K, Rudensky AY. Lysosomal cysteine proteases regulate antigen presentation. Nat. Rev. Immunol. 3: 472-482 (2003).
Hong MY, Chapkin RS, Davidson LA, Turner ND, Morris JS, Carroll RJ, Lupton JR. Fish oil enhances targeted apoptosis during colon tumor initiation in part by downregulating Bcl-2. Nutr. Cancer 46: 44-51 (2003).
Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J. Biol. Chem. 278: 14677-14687 (2003). *
Hong SP, Park SW, Chung JP, Chung JB, Kang JK, Kim J, Kim MJ, Park YN, Song SY. Autoimmune pancreatitis with effective steroid therapy. Yonsei Med. J. 44: 534-538 (2003). *
Honkakoski P, Sueyoshi T, Negishi M. Drug-activated nuclear receptors CAR and PXR. Ann. Med. 35: 172-182 (2003).
Hooijberg JH, Peters GJ, Assaraf YG, Kathmann I, Priest DG, Bunni MA, Veerman AJ, Scheffer GL, Kaspers GJ, Jansen G. The role of multidrug resistance proteins MRP1, MRP2 and MRP3 in cellular folate homeostasis. Biochem. Pharmacol. 65: 765-771 (2003). *
Hopkins TA, Sugden MC, Holness MJ, Kozak R, Dyck JR, Lopaschuk GD. Control of cardiac pyruvate dehydrogenase activity in peroxisome proliferator-activated receptor-alpha transgenic mice. Am. J. Physiol. Heart Circ. Physiol. 285: H270-H276 (2003). *
Hopman WP, de Jong DJ, Naber AH, Jansen JB. Tumour necrosis factor alpha antibody affects gastrin release in Crohn disease. Scand. J. Gastroenterol. 38: 522-525 (2003). *
Hoppe B, Leumann E, von Unruh G, Laube N, Hesse A. Diagnostic and therapeutic approaches in patients with secondary hyperoxaluria. Front. Biosci. 8: e437-e443 (2003).
Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061 (2003). *
Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv. Immunol. 81: 331-371 (2003).
Horslen SP, McCowan TC, Goertzen TC, Warkentin PI, Cai HB, Strom SC, Fox IJ. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics 111: 1262-1267 (2003). *
Horton JD, Shimomura I, Ikemoto S, Bashmakov Y, Hammer RE. Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver. J. Biol. Chem. 278: 36652-36660 (2003). *
Horton KM, Lawler LP, Fishman EK. CT findings in sclerosing mesenteritis (panniculitis): spectrum of disease. Radiographics 23: 1561-1567 (2003). *
Hosono A, Ozawa A, Kato R, Ohnishi Y, Nakanishi Y, Kimura T, Nakamura R. Dietary fructooligosaccharides induce immunoregulation of intestinal IgA secretion by murine Peyer's patch cells. Biosci. Biotechnol. Biochem. 67: 758-764 (2003). *
Houchen CW. FGF-20: FGFs - they keep growing and growing and growing! Inflamm. Bowel Dis. 9: 133 (2003).
Houghton WC. Betaine and nonalcoholic steatohepatitis. Am. J. Gastroenterol. 98: 2803 (2003). *
House MG, Wistuba II, Argani P, Guo M, Schulick RD, Hruban RH, Herman JG, Maitra A. Progression of gene hypermethylation in gallstone disease leading to gallbladder cancer. Ann. Surg. Oncol. 10: 882-889 (2003). *
Houten SM, Frenkel J, Waterham HR. Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell. Mol. Life Sci. 60: 1118-1134 (2003). *
Howard M, Fischer H, Roux J, Santos BC, Gullans SR, Yancey PH, Welch WJ. Mammalian osmolytes and S-nitrosoglutathione promote Delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) protein maturation and function. J. Biol. Chem. 278: 35159-35167 (2003). *
Howard PJ, Murphy GM. Bile acid stress in the mother and baby unit. Eur. J. Gastroenterol. Hepatol. 15: 317-321 (2003).
Howard TD, Postma DS, Jongepier H, Moore WC, Koppelman GH, Zheng SL, Xu J, Bleecker ER, Meyers DA. Association of a disintegrin and metalloprotease 33 (ADAM33) gene with asthma in ethnically diverse populations. J. Allergy Clin. Immunol. 112: 717-722 (2003). *
Hrstic I, Ostojic R, Rustemovic N, Opacic M, Cukovic-Cavka S, Barbaric-Babic V. Primary sclerosing cholangitis: case report of a young patient with an atypical diagnostic process in complications of the disease. Med. Arh. 57: 29-32 (2003).
Hsu C, Chen CN, Chen LT, Wu CY, Yang PM, Lai MY, Lee PH, Cheng AL. Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 65: 242-249 (2003).
Hsu HC, Mountz JD. Origin of late-onset autoimmune disease. Immunol. Allergy Clin. North Am. 23: 65-82, vi (2003).
Hsu HC, Zhang HG, Li L, Yi N, Yang PA, Wu Q, Zhou J, Sun S, Xu X, Yang X, Lu L, Van Zant G, Williams RW, Allison DB, Mountz JD. Age-related thymic involution in C57BL/6J x DBA/2J recombinant-inbred mice maps to mouse chromosomes 9 and 10. Genes Immun. 4: 402-410 (2003). *
Hsueh WC, St Jean PL, Mitchell BD, Pollin TI, Knowler WC, Ehm MG, Bell CJ, Sakul H, Wagner MJ, Burns DK, Shuldiner AR. Genome-wide and fine-mapping linkage studies of type 2 diabetes and glucose traits in the Old Order Amish: evidence for a new diabetes locus on chromosome 14q11 and confirmation of a locus on chromosome 1q21-q24. Diabetes 52: 550-557 (2003). *
Hu X, Li S, Wu J, Xia C, Lala DS. Liver X receptors interact with corepressors to regulate gene expression. Mol. Endocrinol. 17: 1019-1026 (2003). *
Hu X, Peek R, Plomp A, ten Brink J, Scheffer G, van Soest S, Leys A, de Jong PT, Bergen AA. Analysis of the frequent R1141X mutation in the ABCC6 gene in pseudoxanthoma elasticum. Invest. Ophthalmol. Vis. Sci. 44: 1824-1829 (2003). *
Hu X, Plomp A, Wijnholds J, Ten Brink J, van Soest S, van den Born LI, Leys A, Peek R, de Jong PT, Bergen AA. ABCC6/MRP6 mutations: further insight into the molecular pathology of pseudoxanthoma elasticum. Eur. J. Hum. Genet. 11: 215-224 (2003). *
Hu X, Plomp AS, van Soest S, Wijnholds J, de Jong PT, Bergen AA. Pseudoxanthoma elasticum: a clinical, histopathological, and molecular update. Surv. Ophthalmol. 48: 424-438 (2003). *
Huang CF, Wang CL, Huang YF, Hsieh KS, Yang KD. Hyper-IgM syndrome complicated with interstitial pneumonia and peritonitis. Chang Gung Med. J. 26: 53-59 (2003).
Huang L, Zhao A, Lew JL, Zhang T, Hrywna Y, Thompson JR, de Pedro N, Royo I, Blevins RA, Pelaez F, Wright SD, Cui J. Farnesoid X receptor activates transcription of the phospholipid pump MDR3. J. Biol. Chem. 278: 51085-51090 (2003). *
Huang SM, Wu TJ, Lee TD, Yang EK, Shaw CK, Yeh CC. The association of HLA -A, -B, and -DRB1 genotypes with Graves' disease in Taiwanese people. Tissue Antigens 61: 154-158 (2003). *
Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell 115: 565-576 (2003). *
Huang W, Zhang J, Chua SS, Qatanani M, Han Y, Granata R, Moore DD. Induction of bilirubin clearance by the constitutive androstane receptor (CAR). Proc. Natl. Acad. Sci. U.S.A. 100: 4156-4161 (2003). *
Huang YT, Hsu YC, Chen CJ, Liu CT, Wei YH. Oxidative-stress-related changes in the livers of bile-duct-ligated rats. J. Biomed. Sci. 10: 170-178 (2003). *
Hubscher SG. Iron overload, inflammation and fibrosis in genetic haemochromatosis. J. Hepatol. 38: 521-525 (2003). *
Hug MJ, Tamada T, Bridges RJ. CFTR and bicarbonate secretion by epithelial cells. News Physiol. Sci. 18: 38-42 (2003). *
Hughes DE, Stolz DB, Yu S, Tan Y, Reddy JK, Watkins SC, Diehl AM, Costa RH. Elevated hepatocyte levels of the Forkhead box A2 (HNF-3beta) transcription factor cause postnatal steatosis and mitochondrial damage. Hepatology 37: 1414-1424 (2003). *
Hughes DK. Nuclear medicine and infection detection: the relative effectiveness of imaging with (111)In-oxine-, (99m)Tc-HMPAO-, and (99m)Tc-stannous fluoride colloid-labeled leukocytes and with (67)Ga-citrate. J. Nucl. Med. Technol. 31: 196-201 (2003). *
Hugot JP, Alberti C, Berrebi D, Bingen E, Cezard JP. Crohn's disease: the cold chain hypothesis. Lancet 362: 2012-2015 (2003). *
Hugot JP, Cezard JP, Colombel JF, Belaiche J, Almer S, Tysk C, Montague S, Gassull M, Christensen S, Finkel Y, Gower-Rousseau C, Modigliani R, Zouali H, Lesage S, Chamaillard M, Macry J, Thomas G, Victor JM; GETAID. Clustering of Crohn's disease within affected sibships. Eur. J. Hum. Genet. 11: 179-184 (2003). *
Hugot JP, Zouali H, Lesage S. Lessons to be learned from the NOD2 gene in Crohn's disease. Eur. J. Gastroenterol. Hepatol. 15: 593-597 (2003). *
Huhn RD, Fogarty PF, Nakamura R, Read EJ, Leitman SF, Rick ME, Kimball J, Greene A, Hansmann K, Gratwohl A, Young N, Barrett AJ, Dunbar CE. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 101: 71-77 (2003). *
Hui AY, Friedman SL. Molecular basis of hepatic fibrosis. Expert Rev. Mol. Med. 5: 1-23 (2003).
Huic D, Vukovic J, Senecic-Cala I, Dodig D. Splenic atrophy as complication of ulcerative colitis diagnosed by antigranulocyte antibodies labeled with tc-99m-pertechnetate. Croat. Med. J. 44: 767-769 (2003).
Hull KM, Shoham N, Chae JJ, Aksentijevich I, Kastner DL. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr. Opin. Rheumatol. 15: 61-69 (2003).
Huls G, Koornstra JJ, Kleibeuker JH. Non-steroidal anti-inflammatory drugs and molecular carcinogenesis of colorectal carcinomas. Lancet 362: 230-232 (2003). *
Hulzebos CV, Wolters H, Plosch T, Kramer W, Stengelin S, Stellaard F, Sauer PJ, Verkade HJ, Kuipers F. Cyclosporin A and enterohepatic circulation of bile salts in rats: decreased cholate synthesis but increased intestinal reabsorption. J. Pharmacol. Exp. Ther. 304: 356-363 (2003). *
Hunter JO. Endoscopic hydrostatic dilatation of intestinal strictures in Crohn's disease. Dig. Liver Dis. 35: 851-852 (2003).
Hunziker L, Recher M, Macpherson AJ, Ciurea A, Freigang S, Hengartner H, Zinkernagel RM. Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections. Nat. Immunol. 4: 343-349 (2003). *
Huppa JB, Davis MM. T-cell-antigen recognition and the immunological synapse. Nat. Rev. Immunol. 3: 973-983 (2003).
Huster D, Hoppert M, Lutsenko S, Zinke J, Lehmann C, Mossner J, Berr F, Caca K. Defective cellular localization of mutant ATP7B in Wilson's disease patients and hepatoma cell lines. Gastroenterology 124: 335-345 (2003). *
Huster D, Lutsenko S. The distinct roles of the N-terminal copper-binding sites in regulation of catalytic activity of the Wilson's disease protein. J. Biol. Chem. 278: 32212-32218 (2003). *
Hyams JS. Infliximab treatment of Crohn's disease in children: it's time to not go retro(spective). Am. J. Gastroenterol. 98: 5-6 (2003). *
Iannello S, Cavaleri A, Milazzo P, Cantarella S, Belfiore F. Low fasting serum triglyceride level as a precocious marker of autoimmune disorders. MedGenMed. 5: 20 (2003). *
Iannone F, Falappone P, Pannarale G, Gentile A, Grattagliano V, Covelli M, Lapadula G. Microscopic polyangiitis associated with primary biliary cirrhosis. J. Rheumatol. 30: 2710-2712 (2003).
Iannuzzi MC, Maliarik MJ, Poisson LM, Rybicki BA. Sarcoidosis susceptibility and resistance HLA-DQB1 alleles in African Americans. Am. J. Respir. Crit. Care Med. 167: 1225-1231 (2003). *
Ide A, Kawasaki E, Abiru N, Sun F, Fukushima T, Ishii R, Takahashi R, Kuwahara H, Fujita N, Kita A, Imaizumi M, Oshima K, Usa T, Uotani S, Ejima E, Yamasaki H, Ashizawa K, Yamaguchi Y, Eguchi K. Interleukin-10 gene promoter region polymorphisms in patients with type 1 diabetes and autoimmune thyroid disease. Ann. N. Y. Acad. Sci. 1005: 344-347 (2003). *
Ide A, Kawasaki E, Abiru N, Sun F, Fukushima T, Ishii R, Takahashi R, Kuwahara H, Fujita N, Kita A, Imaizumi M, Oshima K, Usa T, Uotani S, Ejima E, Yamasaki H, Ashizawa K, Yamaguchi Y, Eguchi K. Association of interleukin-18 gene promoter polymorphisms in type 1 diabetes and autoimmune thyroid disease. Ann. N. Y. Acad. Sci. 1005: 436-439 (2003). *
Ide T, Shimano H, Yoshikawa T, Yahagi N, Amemiya-Kudo M, Matsuzaka T, Nakakuki M, Yatoh S, Iizuka Y, Tomita S, Ohashi K, Takahashi A, Sone H, Gotoda T, Osuga J, Ishibashi S, Yamada N. Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism. II. LXRs suppress lipid degradation gene promoters through inhibition of PPAR signaling. Mol. Endocrinol. 17: 1255-1267 (2003). *
Iellem A, Colantonio L, D'Ambrosio D. Skin-versus gut-skewed homing receptor expression and intrinsic CCR4 expression on human peripheral blood CD4+CD25+ suppressor T cells. Eur. J. Immunol. 33: 1488-1496 (2003). *
Igarashi H, Aoyagi Y, Suda T, Mita Y, Kawai K. Studies on the correlation among the fucosylation index, concentration of alpha-fetoprotein and des-gamma-carboxy prothrombin as prognostic indicators in hepatocellular carcinoma. Hepatol. Res. 27: 280-288 (2003).
Iida A, Ozaki K, Ohnishi Y, Tanaka T, Nakamura Y. Identification of 46 novel SNPs in the 130-kb region containing a myocardial infarction susceptibility gene on chromosomal band 6p21. J. Hum. Genet. 48: 476-479 (2003). *
Iizasa H, Genda N, Kitano T, Tomita M, Nishihara K, Hayashi M, Nakamura K, Kobayashi S, Nakashima E. Altered expression and function of P-glycoprotein in dextran sodium sulfate-induced colitis in mice. J. Pharm. Sci. 92: 569-576 (2003). *
Ikeda S, Kudsk KA, Fukatsu K, Johnson CD, Le T, Reese S, Zarzaur BL. Enteral feeding preserves mucosal immunity despite in vivo MAdCAM-1 blockade of lymphocyte homing. Ann. Surg. 237: 677-685 (2003). *
Ikuma M, Geibel J, Binder HJ, Rajendran VM. Characterization of Cl-HCO3 exchange in basolateral membrane of rat distal colon. Am. J. Physiol. Cell Physiol. 285: C912-C921 (2003). *
Illig T, Bongardt F, Schopfer A, Holle R, Muller S, Rathmann W, Koenig W, Meisinger C, Wichmann HE, Kolb H; KORA Study Group. The endotoxin receptor TLR4 polymorphism is not associated with diabetes or components of the metabolic syndrome. Diabetes 52: 2861-2864 (2003). *
Iltanen S, Maki M, Collin P, Mustalahti K, Kaukinen K, Partanen J, Hulkkonen J, Hurme M, Aittoniemi J. The association between mannan-binding lectin gene alleles and celiac disease. Am. J. Gastroenterol. 98: 2808-2809 (2003). *
Imadome K, Shirakata M, Shimizu N, Nonoyama S, Yamanashi Y. CD40 ligand is a critical effector of Epstein-Barr virus in host cell survival and transformation. Proc. Natl. Acad. Sci. U.S.A. 100: 7836-7840 (2003). *
Imai K, Catalan N, Plebani A, Marodi L, Sanal O, Kumaki S, Nagendran V, Wood P, Glastre C, Sarrot-Reynauld F, Hermine O, Forveille M, Revy P, Fischer A, Durandy A. Hyper-IgM syndrome type 4 with a B lymphocyte-intrinsic selective deficiency in Ig class-switch recombination. J. Clin. Invest. 112: 136-142 (2003). *
Imai K, Slupphaug G, Lee WI, Revy P, Nonoyama S, Catalan N, Yel L, Forveille M, Kavli B, Krokan HE, Ochs HD, Fischer A, Durandy A. Human uracil-DNA glycosylase deficiency associated with profoundly impaired immunoglobulin class-switch recombination. Nat. Immunol. 4: 1023-1028 (2003). *
Imai T. Functional genetic dissection of nuclear receptor signalling in obesity, diabetes and liver regeneration using spatiotemporally controlled somatic mutagenesis in the mouse. Keio. J. Med. 52: 198-203 (2003). *
Imose M, Nagaki M, Naiki T, Osawa Y, Brenner DA, Asano T, Hayashi H, Kato T, Moriwaki H. Inhibition of nuclear factor kappaB and phosphatidylinositol 3-kinase/Akt is essential for massive hepatocyte apoptosis induced by tumor necrosis factor alpha in mice. Liver Int. 23: 386-396 (2003). *
Inadomi JM. Update on the cost-effectiveness of screening for colorectal neoplasia. Curr. Opin. Gastroenterol. 19: 44-50 (2003).
Inadomi JM. Cost-effectiveness of colorectal cancer surveillance in ulcerative colitis. Scand. J. Gastroenterol. Suppl. 237: 17-21 (2003). *
Indriethason OS, Palsson R, Eethvarethsson VO. The role of omega-3 polyunsaturated fatty acids in clinical medicine. Laeknabladid. 89: 199-211 (2003).
Infante AJ, Baillargeon J, Kraig E, Lott L, Jackson C, Hammerling GJ, Raju R, David C. Evidence of a diverse T cell receptor repertoire for acetylcholine receptor, the autoantigen of myasthenia gravis. J. Autoimmun. 21: 167-174 (2003).
Innis SM, Davidson AG, Chen A, Dyer R, Melnyk S, James SJ. Increased plasma homocysteine and S-adenosylhomocysteine and decreased methionine is associated with altered phosphatidylcholine and phosphatidylethanolamine in cystic fibrosis. J. Pediatr. 143: 351-356 (2003). *
Inohara N, Nunez G. NODs: intracellular proteins involved in inflammation and apoptosis. Nat. Rev. Immunol. 3: 371-382 (2003). *
Inohara N, Ogura Y, Fontalba A, Gutierrez O, Pons F, Crespo J, Fukase K, Inamura S, Kusumoto S, Hashimoto M, Foster SJ, Moran AP, Fernandez-Luna JL, Nunez G. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J. Biol. Chem. 278: 5509-5512 (2003). *
International Psoriasis Genetics Consortium. The International Psoriasis Genetics Study: assessing linkage to 14 candidate susceptibility loci in a cohort of 942 affected sib pairs. Am. J. Hum. Genet. 73: 430-437 (2003). *
Inui S, Lee YF, Chang E, Shyr CR, Chang C. Differential and bi-directional regulation between TR2/TR4 orphan nuclear receptors and a specific ligand mediated-peroxisome proliferator-activated receptor alpha in human HaCaT keratinocytes. J. Dermatol. Sci. 31: 65-71 (2003).
Invernizzi P, Battezzati PM, Crosignani A, Perego F, Poli F, Morabito A, De Arias AE, Scalamogna M, Zuin M, Podda M. Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. J. Hepatol. 38: 401-406 (2003). *
Ioachim E, Michael M, Katsanos C, Demou A, Tsianos EV. The immunohistochemical expression of metallothionein in inflammatory bowel disease. Correlation with HLA-DR antigen expression, lymphocyte subpopulations and proliferation-associated indices. Histol. Histopathol. 18: 75-82 (2003).
Ioannou GN, Kowdley KV. Iron, HFE mutations, and hepatocellular carcinoma: is hepatic iron a carcinogen? Clin. Gastroenterol. Hepatol. 1: 246-248 (2003). *
Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 38: 123-132 (2003). *
Iredale JP. Regulating hepatic inflammation: pathogen-associated molecular patterns take their toll. Hepatology 37: 979-982 (2003). *
Ishibashi H, Nakamura M, Shimoda S, Gershwin ME. T cell immunity and primary biliary cirrhosis. Autoimmun. Rev. 2: 19-24 (2003).
Ishikawa T, Kasamatsu S, Hagiwara Y, Mitomo H, Kato R, Sumino Y. Expression and functional characterization of human ABC transporter ABCG2 variants in insect cells. Drug Metab. Pharmacokinet. 18: 194-202 (2003). *
Ismail Y, Muhamad A. Protean manifestations of gastrointestinal tuberculosis. Med. J. Malaysia 58: 345-349 (2003).
Ismair MG, Stanca C, Ha HR, Renner EL, Meier PJ, Kullak-Ublick GA. Interactions of glycyrrhizin with organic anion transporting polypeptides of rat and human liver. Hepatol. Res. 26: 343-347 (2003).
Isomoto H, Fukuda Y, Bando Y, Machida I, Machida H, Omagari K, Mizuta Y, Murase K, Fukushima T, Murata I, Kohno S. Pure red cell aplasia associated with parvovirus B19 infection in a patient with ulcerative colitis. Dig. Dis. Sci. 48: 2104-2107 (2003). *
Isomoto H, Furusu H, Onizuka Y, Kawaguchi Y, Mizuta Y, Maeda T, Kohno S. Colonic involvement by adult T-cell leukemia/lymphoma mimicking ulcerative colitis. Gastrointest. Endosc. 58: 805-808 (2003).
Ito H. IL-6 and Crohn's disease. Curr. Drug Targets Inflamm. Allergy 2: 125-30 (2003).
Ito H. Anti-interleukin-6 therapy for Crohn's disease. Curr. Pharm. Des. 9: 295-305 (2003).
Ito T. Physiological function of ABCG1. Drug News Perspect. 16: 490-492 (2003).
Ito Y, Miyazono K. RUNX transcription factors as key targets of TGF-beta superfamily signaling. Curr. Opin. Genet. Dev. 13: 43-47 (2003). *
Itoh S, Kanazuka A, Akimoto T. Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis. Dig. Dis. Sci. 48: 2182-2186 (2003). *
Itzkowitz SH. Fingerprinting the colon? Inflamm. Bowel Dis. 9: 338-339 (2003). *
Ivanyi J. Milan Hasek and the discovery of immunological tolerance. Nat. Rev. Immunol. 3: 591-597 (2003). *
Iwahori T, Matsuura T, Maehashi H, Sugo K, Saito M, Hosokawa M, Chiba K, Masaki T, Aizaki H, Ohkawa K, Suzuki T. CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver. Hepatology 37: 665-673 (2003). *
Iwai M, Harada Y, Ishii M, Tanaka S, Muramatsu A, Mori T, Nakashima T, Okanoue T, Hirohata S. Autoimmune hepatitis in a patient with systemic lupus erythematosus. Clin. Rheumatol. 22: 234-236 (2003). *
Iwanaga Y, Davey MP, Martin TM, Planck SR, DePriest ML, Baugh MM, Suing CM, Rosenbaum JT. Cloning, sequencing and expression analysis of the mouse NOD2/CARD15 gene. Inflamm. Res. 52: 272-276 (2003). *
Iwasaki K, Okawa-Takatsuji M, Aotsuka S, Ono T. Detection of anti-SS-A/Ro and anti-SS-B/La antibodies of IgA and IgG isotypes in saliva and sera of patients with Sjogren's syndrome. Nihon Rinsho Meneki Gakkai Kaishi 26: 346-354 (2003).
Iwasaki N, Cox NJ, Wang YQ, Schwarz PE, Bell GI, Honda M, Imura M, Ogata M, Saito M, Kamatani N, Iwamoto Y. Mapping genes influencing type 2 diabetes risk and BMI in Japanese subjects. Diabetes 52: 209-213 (2003). *
Iwata M, Eshima Y, Kagechika H. Retinoic acids exert direct effects on T cells to suppress Th1 development and enhance Th2 development via retinoic acid receptors. Int. Immunol. 15: 1017-1025 (2003). *
Izumi Y, Tanaka S, Hidaka Y, Shimaoka Y, Tatsumi KI, Takano T, Kaneko A, Oku K, Amino N. Relation between post-partum liver dysfunction and anti-cytochrome 2D6 antibodies. Am. J. Reprod. Immunol. 50: 355-362 (2003). *
Jabbar A, Chang WK, Dryden GW, McClave SA. Gut immunology and the differential response to feeding and starvation. Nutr. Clin. Pract. 18: 461-482 (2003).
Jablonska-Kaszewska I, Dabrowska E, Jurowiecka AD, Falklewicz B. Treatment of Wilson's disease. Med. Sci. Monit. 9 Suppl. 3: 5-8 (2003).
Jablonska-Kaszewska I, Droblnska-Jurowiecka A, Dabrowska E, Trocha H. Results of treatment of Wilson's disease - own observations. Med. Sci. Monit. 9 Suppl. 3: 9-14 (2003).
Jackson AU, Galecki AT, Burke DT, Miller RA. Genetic polymorphisms in mouse genes regulating age-sensitive and age-stable T cell subsets. Genes Immun. 4: 30-39 (2003). *
Jacob SE, Martin LK, Kerdel FA. Cutaneous Wegener's granulomatosis (malignant pyoderma) in a patient with Crohn's disease. Int. J. Dermatol. 42: 896-898 (2003). *
Jacobi A, Manger B, Schuler G, Hertl M. Therapeutic application of TNF-alpha inhibitors infliximab and etanercept in inflammatory skin disorders. J. Dtsch. Dermatol. Ges. 1: 259-372 (2003).
Jaeckel E, Manns MP. The role of autoantigens and autoantibodies in PBC. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 28. October 15-16 (2003). *
Jagadeesh D, Syngal S. Genetic testing for hereditary nonpolyposis colorectal cancer. Curr. Opin. Gastroenterol. 19: 57-63 (2003).
Jain A, Mazariegos G, Pokharna R, Parizhskaya M, Kashyap R, Kosmach-Park B, Smith A, Fung JJ, Reyes J. The absence of chronic rejection in pediatric primary liver transplant patients who are maintained on tacrolimus-based immunosuppression: a long-term analysis. Transplantation 75: 1020-1025 (2003).
Jalan R. Intracranial hypertension in acute liver failure: pathophysiological basis of rational management. Semin. Liver Dis. 23: 271-282 (2003).
Jalan R, Shawcross D, Davies N. The molecular pathogenesis of hepatic encephalopathy. Int. J. Biochem. Cell Biol. 35: 1175-1181 (2003). *
Jalouli M, Carlsson L, Ameen C, Linden D, Ljungberg A, Michalik L, Eden S, Wahli W, Oscarsson J. Sex difference in hepatic peroxisome proliferator-activated receptor alpha expression: influence of pituitary and gonadal hormones. Endocrinology 144: 101-109 (2003). *
Jamain S, Betancur C, Giros B, Leboyer M, Bourgeron T. Genetics of autism: from genome scans to candidate genes. Med. Sci. (Paris) 19: 1081-1090 (2003).
Jamerson BD, Krishnan KR, Roberts J, Krishen A, Modell JG. Effect of bupropion SR on specific symptom clusters of depression: analysis of the 31-item Hamilton Rating Scale for depression. Psychopharmacol. Bull. 37: 67-78 (2003).
James LP, Mayeux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. Drug Metab. Dispos. 31: 1499-1506 (2003). *
James MJ, Proudman SM, Cleland LG. Dietary n-3 fats as adjunctive therapy in a prototypic inflammatory disease: issues and obstacles for use in rheumatoid arthritis. Prostaglandins Leukot. Essent. Fatty Acids 68: 399-405 (2003). *
James OFW. Epidemiology of primary biliary cirrhosis. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 17. October 15-16 (2003). *
James SP. 19. Immunologic, gastroenterologic, and hepatobiliary disorders. J. Allergy Clin. Immunol. 111: S645-S658 (2003). *
James SY, Lin F, Kolluri SK, Dawson MI, Zhang XK. Regulation of retinoic acid receptor beta expression by peroxisome proliferator-activated receptor gamma ligands in cancer cells. Cancer Res. 63: 3531-3538 (2003). *
Janosikova B, Pavlikova M, Kocmanova D, Vitova A, Vesela K, Krupkova L, Kahleova R, Krijt J, Kraml P, Hyanek J, Zvarova J, Andel M, Kozich V. Genetic variants of homocysteine metabolizing enzymes and the risk of coronary artery disease. Mol. Genet. Metab. 79: 167-175 (2003). *
Jansen G, Scheper RJ, Dijkmans BA. Multidrug resistance proteins in rheumatoid arthritis, role in disease-modifying antirheumatic drug efficacy and inflammatory processes: an overview. Scand. J. Rheumatol. 32: 325-336 (2003).
Jansen PL, Sturm E. Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int. 23: 315-322 (2003). *
Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC; European Group for the Study of Vascular Disorders of the Liver. Budd-Chiari syndrome: a review by an expert panel. J. Hepatol. 38: 364-371 (2003). *
Janssens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin. Microbiol. Rev. 16: 637-646 (2003). *
Janssens S, Burns K, Vercammen E, Tschopp J, Beyaert R. MyD88S, a splice variant of MyD88, differentially modulates NF-kappaB- and AP-1-dependent gene expression. FEBS Lett. 548: 103-107 (2003). *
Jaruga B, Hong F, Sun R, Radaeva S, Gao B. Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: up-regulating eotaxins and IL-5 and recruiting leukocytes. J. Immunol. 171: 3233-3244 (2003). *
Jarvinen HJ. Genetic testing for polyposis: practical and ethical aspects. Gut 52 Suppl. 2: ii19-ii22 (2003). *
Jassem W, Koo DD, Cerundolo L, Rela M, Heaton ND, Fuggle SV. Cadaveric versus living-donor livers: differences in inflammatory markers after transplantation. Transplantation 76: 1599-1603 (2003).
Jawaheer D, Seldin MF, Amos CI, Chen WV, Shigeta R, Etzel C, Damle A, Xiao X, Chen D, Lum RF, Monteiro J, Kern M, Criswell LA, Albani S, Nelson JL, Clegg DO, Pope R, Schroeder HW Jr, Bridges SL Jr, Pisetsky DS, Ward R, Kastner DL, Wilder RL, et al. Screening the genome for rheumatoid arthritis susceptibility genes: a replication study and combined analysis of 512 multicase families. Arthritis Rheum. 48: 906-916 (2003). *
Jazayeri M, Bakayev V, Adibi P, Haghighi Rad F, Zakeri H, Kalantar E, Zali MR. Frequency of HFE gene mutations in Iranian beta-thalassaemia minor patients. Eur. J. Haematol. 71: 408-411 (2003). *
Jazrawi SF, Zaman A, Muhammad Z, Rabkin JM, Corless CL, Olyaei A, Biggs A, Ham J, Chou S, Rosen HR. Tumor necrosis factor-alpha promoter polymorphisms and the risk of rejection after liver transplantation: a case control analysis of 210 donor-recipient pairs. Liver Transpl. 9: 377-382 (2003). *
Jefferies H, Bot J, Coster J, Khalil A, Hall JC, McCauley RD. The role of glutathione in intestinal dysfunction. J. Invest. Surg. 16: 315-323 (2003).
Jennings JS, Howdle PD. New developments in celiac disease. Curr. Opin. Gastroenterol. 19: 118-129 (2003).
Jensen BA, Leeman RJ, Schlezinger JJ, Sherr DH. Aryl hydrocarbon receptor (AhR) agonists suppress interleukin-6 expression by bone marrow stromal cells: an immunotoxicology study. Environ. Health 2: 16 (2003). *
Jewell DP. Genes and immunopathology. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 57. September 12 - 13 (2003). *
Jeyarajah DR, Kielar ML, Frantz N, Lindberg G, Lu CY. Infection by gram-negative organisms via the biliary route results in greater mortality than portal venous infection. Clin. Diagn. Lab. Immunol. 10: 664-669 (2003). *
Ji C, Kaplowitz N. Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology 124: 1488-1499 (2003). *
Jia D, Otsuki M. Bezafibrate, a peroxisome proliferator-activated receptor (PPAR)-alpha activator, prevents pancreatic degeneration in obese and diabetic rats. Pancreas 26: 286-291 (2003).
Jiang J, He M. Clinical features of primary biliary cirrhosis and treatment of it by integrated traditional Chinese and western medicine. Zhong Xi Yi Jie He Xue Bao 1: 99-102 (2003).
Jiang XH, Fang XY, Zhong RQ, Wang XP, Hu Y, Kong XT. Development of an enzyme immune assay for detecting M2 autoantibodies specific for primary biliary cirrhosis. Hepatobiliary Pancreat. Dis. Int. 2: 290-294 (2003). *
Jiang XH, Li N, Li JS. Intestinal permeability in patients after surgical trauma and effect of enteral nutrition versus parenteral nutrition. World J. Gastroenterol. 9: 1878-1880 (2003). *
Jiang XH, Zhong RQ, Yu SQ, Hu Y, Li WW, Kong XT. Construction and expression of a humanized M2 autoantigen trimer and its application in the diagnosis of primary biliary cirrhosis. World J. Gastroenterol. 9: 1352-1355 (2003). *
Jiang YG, Wang YM, Liu TH, Liu J. Association between HLA class II gene and susceptibility or resistance to chronic hepatitis B. World J. Gastroenterol. 9: 2221-2225 (2003). *
Jimenez-Saenz M, Villar-Rodriguez JL, Torres Y, Carmona I, Salas-Herrero E, Gonzalez-Vilches J, Herrerias-Gutierrez JM. Biliary tract disease: a rare manifestation of eosinophilic gastroenteritis. Dig. Dis. Sci. 48: 624-627 (2003). *
Jin LH, Kim DW, Eum WS, Yoon CS, Jang SH, Choi HS, Choi SH, Kim YH, Kim SY, Jung MR, Kang TC, Won MH, Lee HY, Kang JH, Kwon OS, Cho SW, Lee KS, Park J, Choi SY. Human liver catalase: cloning, expression and characterization of monoclonal antibodies. Mol. Cells 15: 381-386 (2003). *
Jin Y, Teng W, Ben S, Xiong X, Zhang J, Xu S, Shugart YY, Jin L, Chen J, Huang W. Genome-wide scan of Graves' disease: evidence for linkage on chromosome 5q31 in Chinese Han pedigrees. J. Clin. Endocrinol. Metab. 88: 1798-1803 (2003). *
Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, Kimura R, Miyagi T, Mochizuki K, Sasaki Y, Hayashi N. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int. J. Cancer 104: 354-361 (2003). *
Jo Y, Matsumoto T, Mibu R, Iida M. Addition of leukocytapheresis to steroid therapy: is it beneficial in recurrence of moderate-to-severe ulcerative colitis? Dis. Colon Rectum 46: S3-S9 (2003).
Jo Y, Matsumoto T, Yada S, Fujisawa K, Esaki M, Onai N, Matsushima K, Iida M. CCR4 is an up-regulated chemokine receptor of peripheral blood memory CD4+ T cells in Crohn's disease. Clin. Exp. Immunol. 132: 332-338 (2003). *
Johansson S, Lie BA, Cambon-Thomsen A, Pociot F, Nerup J, Kockum I, Thorsby E, Undlien DE. No evidence of type 1 diabetes susceptibility genes in the region centromeric of the HLA complex. Hum. Immunol. 64: 951-959 (2003).
Johansson S, Lie BA, Pociot F, Nerup J, Cambon-Thomsen A, Kockum I, Thorsby E, Undlien DE. HLA associations in type 1 diabetes: DPB1 alleles may act as markers of other HLA-complex susceptibility genes. Tissue Antigens 61: 344-351 (2003). *
Johansson S, Lie BA, Todd JA, Pociot F, Nerup J, Cambon-Thomsen A, Kockum I, Akselsen HE, Thorsby E, Undlien DE. Evidence of at least two type 1 diabetes susceptibility genes in the HLA complex distinct from HLA-DQB1, -DQA1 and -DRB1. Genes Immun. 4: 46-53 (2003). *
Johansson-Lindbom B, Svensson M, Wurbel MA, Malissen B, Márquez G, Agace W. Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J. Exp. Med. 198: 963-969 (2003). *
Johnson CD, Harmsen WS, Wilson LA, Maccarty RL, Welch TJ, Ilstrup DM, Ahlquist DA. Prospective blinded evaluation of computed tomographic colonography for screen detection of colorectal polyps. Gastroenterology 125: 311-319 (2003). *
Johnson CD, Toledano AY, Herman BA, Dachman AH, McFarland EG, Barish MA, Brink JA, Ernst RD, Fletcher JG, Halvorsen RA Jr, Hara AK, Hopper KD, Koehler RE, Lu DS, Macari M, Maccarty RL, Miller FH, Morrin M, Paulson EK, Yee J, Zalis M. Computerized tomographic colonography: performance evaluation in a retrospective multicenter setting. Gastroenterology 125: 688-695 (2003). *
Johnson S. Do mitochondria regulate cellular iron homeostasis through citric acid and haem production? Implications for cancer and other diseases. Med. Hypotheses 60: 106-111 (2003). *
Johnson-Pais TL, Singer FR, Bone HG, McMurray CT, Hansen MF, Leach RJ. Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. J. Bone Miner. Res. 18: 376-380 (2003).
Johnstone RF, Dolen WK, Hoffman HM. A large kindred with familial cold autoinflammatory syndrome. Ann. Allergy Asthma Immunol. 90: 233-237 (2003).
Jones BJ. Recent developments in the delivery of home parenteral nutrition in the UK. Proc. Nutr. Soc. 62: 719-725 (2003). *
Jones DE. Addison's other disease: primary biliary cirrhosis as a model autoimmune disease. Clin. Med. 3: 351-356 (2003). *
Jones DE. Pathogenesis of primary biliary cirrhosis. J. Hepatol. 39: 639-648 (2003). *
Jones DE, Donaldson PT. Genetic factors in the pathogenesis of primary biliary cirrhosis. Clin. Liver Dis. 7: 841-864 (2003).
Jones DEJ. Is microchimaerism an etiological factor of PBC? Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 21-22. October 15-16 (2003). *
Jones R, Adel-Alvarez LA, Alvarez OR, Broaddus R, Das S. Arachidonic acid and colorectal carcinogenesis. Mol. Cell. Biochem. 253: 141-149 (2003). *
Jones SA, Parks DJ, Kliewer SA. Cell-free ligand binding assays for nuclear receptors. Methods Enzymol. 364: 53-71 (2003).
Jonkers IJ, Smelt AH, Ledeboer M, Hollum ME, Biemond I, Kuipers F, Stellaard F, Boverhof R, Meinders AE, Lamers CH, Masclee AA. Gall bladder dysmotility: a risk factor for gall stone formation in hypertriglyceridaemia and reversal on triglyceride lowering therapy by bezafibrate and fish oil. Gut 52: 109-115 (2003). *
Jonsson R, Gordon TP, Konttinen YT. Recent advances in understanding molecular mechanisms in the pathogenesis and antibody profile of Sjogren's syndrome. Curr. Rheumatol. Rep. 5: 311-316 (2003).
Jonuleit H, Adema G, Schmitt E. Immune regulation by regulatory T cells: implications for transplantation. Transpl. Immunol. 11: 267-276 (2003).
Joo SS, Kang HC, Won TJ, Lee DI. Ursodeoxycholic acid inhibits pro-inflammatory repertoires, IL-1beta and nitric oxide in rat microglia. Arch. Pharm. Res. 26: 1067-1073 (2003).
Joosten LA, Radstake TR, Lubberts E, van den Bersselaar LA, van Riel PL, van Lent PL, Barrera P, van den Berg WB. Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum. 48: 339-347 (2003). *
Joplin R. Infectious etiology of primary biliary cirrhosis? Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 19-20. October 15-16 (2003). *
Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9: 213-219 (2003). *
Juan J, Estiarte R, Colome E, Artes M, Jimenez FJ, Alonso J. Burden of illness of Crohn's disease in Spain. Dig. Liver Dis. 35: 853-861 (2003).
Jubelirer SJ, Wells JB, Emmett M, Broce M. Incidence of colorectal cancer in West Virginia from 1993-1999: an update by gender, age, subsite and stage. W.V. Med. J. 99: 182-186 (2003).
Jude BA, Pobezinskaya Y, Bishop J, Parke S, Medzhitov RM, Chervonsky AV, Golovkina TV. Subversion of the innate immune system by a retrovirus. Nat. Immunol. 4: 573-578 (2003). *
Jun HS, Yoon JW. A new look at viruses in type 1 diabetes. Diabetes Metab. Res. Rev. 19: 8-31 (2003). *
Jung D, Kullak-Ublick GA. Hepatocyte nuclear factor 1 alpha: a key mediator of the effect of bile acids on gene expression. Hepatology 37: 622-631 (2003). *
Jung YS, Kwak HE, Choi KH, Kim YC. Effect of acute ethanol administration on S-amino acid metabolism: increased utilization of cysteine for synthesis of taurine rather than glutathione. Adv. Exp. Med. Biol. 526: 245-252 (2003).
Jurevic RJ, Bai M, Chadwick RB, White TC, Dale BA. Single-nucleotide polymorphisms (SNPs) in human beta-defensin 1: high-throughput SNP assays and association with Candida carriage in type I diabetics and nondiabetic controls. J. Clin. Microbiol. 41: 90-96 (2003). *
Justice CM, Miller NH, Marosy B, Zhang J, Wilson AF. Familial idiopathic scoliosis: evidence of an X-linked susceptibility locus. Spine 28: 589-594 (2003).
Jyrkkarinne J, Makinen J, Gynther J, Savolainen H, Poso A, Honkakoski P. Molecular determinants of steroid inhibition for the mouse constitutive androstane receptor. J. Med. Chem. 46: 4687-4695 (2003). *
Kaassis M, Boyer J, Dumas R, Ponchon T, Coumaros D, Delcenserie R, Canard JM, Fritsch J, Rey JF, Burtin P. Plastic or metal stents for malignant stricture of the common bile duct? Results of a randomized prospective study. Gastrointest. Endosc. 57: 178-182 (2003). *
Kabashima K, Sakata D, Nagamachi M, Miyachi Y, Inaba K, Narumiya S. Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat. Med. 9: 744-749 (2003). *
Kabesch M, Peters W, Carr D, Leupold W, Weiland SK, von Mutius E. Association between polymorphisms in caspase recruitment domain containing protein 15 and allergy in two German populations. J. Allergy Clin. Immunol. 111: 813-817 (2003). *
Kabesch M, Tzotcheva I, Carr D, Hofler C, Weiland SK, Fritzsch C, von Mutius E, Martinez FD. A complete screening of the IL4 gene: novel polymorphisms and their association with asthma and IgE in childhood. J. Allergy Clin. Immunol. 112: 893-898 (2003). *
Kadokawa Y, Omagari K, Hazama H, Ohba K, Masuda J, Kinoshita H, Hayashida K, Isomoto H, Mizuta Y, Murase K, Murata I, Kohno S. Evaluation of newly developed ELISA using "MESACUP-2 test mitochondrial M2" kit for the diagnosis of primary biliary cirrhosis. Clin. Biochem. 36: 203-210 (2003). *
Kadokawa Y, Omagari K, Matsuo I, Otsu Y, Yamamoto U, Nishino T, Ohba K, Miyazaki M, Harada T, Taguchi T, Kohno S. Primary sclerosing cholangitis associated with lupus nephritis: a rare association. Dig. Dis. Sci. 48: 911-914 (2003). *
Kadowaki T, Hara K, Yamauchi T, Terauchi Y, Tobe K, Nagai R. Molecular mechanism of insulin resistance and obesity. Exp. Biol. Med. (Maywood) 228: 1111-1117 (2003). *
Kadry Z, Mullhaupt B, Renner EL, Bauerfeind P, Schanz U, Pestalozzi BC, Studer G, Zinkernagel R, Clavien PA. Living donor liver transplantation and tolerance: a potential strategy in cholangiocarcinoma. Transplantation 76: 1003-1006 (2003).
Kageyama F, Takehira Y, Yamada M, Murohisa G, Hirasawa K, Kataoka H, Iwaoka Y, Iwaizumi M, Kawata K, Hamaya Y, Nakamura A, Makino S, Hirano M, Kitagawa M, Ikematsu Y, Ozawa T, Yasumi K, Kobayashi Y. A case of intrahepatic biliary papillomatosis associated with autoimmune hepatitis. Nippon Shokakibyo Gakkai Zasshi 100: 1322-1327 (2003).
Kahan BD. Individuality: the barrier to optimal immunosuppression. Nat. Rev. Immunol. 3: 831-838 (2003). *
Kahana DD, Cass O, Jessurun J, Schwarzenberg SJ, Sharp H, Khan K. Sclerosing cholangitis associated with Trichosporon infection and natural killer cell deficiency in an 8-year-old girl. J. Pediatr. Gastroenterol. Nutr. 37: 620-623 (2003). *
Kahl S, Zimmermann S, Genz I, Glasbrenner B, Pross M, Schulz HU, Mc Namara D, Schmidt U, Malfertheiner P. Risk factors for failure of endoscopic stenting of biliary strictures in chronic pancreatitis: a prospective follow-up study. Am. J. Gastroenterol. 98: 2448-2453 (2003). *
Kaiserling E, Krober S, Geleff S. Lymphatic vessels in the colonic mucosa in ulcerative colitis. Lymphology 36: 52-61 (2003).
Kajander EO, Ciftcioglu N, Aho K, Garcia-Cuerpo E. Characteristics of nanobacteria and their possible role in stone formation. Urol. Res. 31: 47-54 (2003).
Kakizaki S, Ishikawa T, Koyama Y, Yamada H, Kobayashi R, Sohara N, Otsuka T, Takagi H, Mori M. Primary biliary cirrhosis complicated with sigmoid colonic varices: the usefulness of computed tomographic angiography. Abdom. Imaging 28: 831-834 (2003).
Kakizoe T. Chemoprevention of cancer - focusing on clinical trials. Jpn. J. Clin. Oncol. 33: 421-442 (2003). *
Kakko S, Kelloniemi J, von Rohr P, Hoeschele I, Tamminen M, Brousseau ME, Kesaniemi YA, Savolainen MJ. ATP-binding cassette transporter A1 locus is not a major determinant of HDL-C levels in a population at high risk for coronary heart disease. Atherosclerosis 166: 285-290 (2003).
Kalantari T, Mostafavi H, Pezeshki AM, Farjadian S, Doroudchi M, Yeganeh F, Ghaderi A. Exon-1 polymorphism of ctla-4 gene in Iranian patients with Graves' disease. Autoimmunity 36: 313-316 (2003).
Kaletha K, Chodorowski Z, Anand IS, Rybakowska I, Nagel-Starczynowska G. Lipoproteins HDL and coronary artery disease: a molecular mechanism of fibrate. Przegl. Lek. 60: 223-225 (2003).
Kalfa VC, Roberts RL, Stiehm ER. The syndrome of chronic mucocutaneous candidiasis with selective antibody deficiency. Ann. Allergy Asthma Immunol. 90: 259-264 (2003).
Kalicinski PJ, Ismail H, Jankowska I, Kaminski A, Pawlowska J, Drewniak T, Markiewicz M, Szymczak M. Surgical treatment of progressive familial intrahepatic cholestasis: comparison of partial external biliary diversion and ileal bypass. Eur. J. Pediatr. Surg. 13: 307-311 (2003).
Kalis C, Kanzler B, Lembo A, Poltorak A, Galanos C, Freudenberg MA. Toll-like receptor 4 expression levels determine the degree of LPS-susceptibility in mice. Eur. J. Immunol. 33: 798-805 (2003). *
Kalish RS, Gilhar A. Alopecia areata: autoimmunity - the evidence is compelling. J. Investig. Dermatol. Symp. Proc. 8: 164-167 (2003). *
Kalliomaki M, Isolauri E. Role of intestinal flora in the development of allergy. Curr. Opin. Allergy Clin. Immunol. 3: 15-20 (2003).
Kam I. Cadaveric versus living donor liver transplantation - analysis of costs. Transplant. Proc. 35: 971 (2003).
Kamata Y, Kamimura T, Yoshio T, Hirata D, Masuyama J, Isoda N, Kanai N, Minota S. Systemic lupus erythematosus with steroid induced non-alcoholic steatohepatitis: a case report. Ryumachi 43: 667-671 (2003).
Kamath PS, Kim WR. Is the change in MELD score a better indicator of mortality than baseline MELD score? Liver Transpl. 9: 19-21 (2003). *
Kamihira T, Shimoda S, Harada K, Kawano A, Handa M, Baba E, Tsuneyama K, Nakamura M, Ishibashi H, Nakanuma Y, Gershwin ME, Harada M. Distinct costimulation dependent and independent autoreactive T-cell clones in primary biliary cirrhosis. Gastroenterology 125: 1379-1387 (2003). *
Kaminen N, Hannula-Jouppi K, Kestila M, Lahermo P, Muller K, Kaaranen M, Myllyluoma B, Voutilainen A, Lyytinen H, Nopola-Hemmi J, Kere J. A genome scan for developmental dyslexia confirms linkage to chromosome 2p11 and suggests a new locus on 7q32. J. Med. Genet. 40: 340-345 (2003). *
Kamisako T, Ogawa H. Regulation of biliary cholesterol secretion is associated with abcg5 and abcg8 expressions in the rats: effects of diosgenin and ethinyl estradiol. Hepatol. Res. 26: 348-352 (2003).
Kamisako T, Ogawa H. Effect of obstructive jaundice on the regulation of hepatic cholesterol metabolism in the rat. Disappearance of abcg5 and abcg8 mRNA after bile duct ligation. Hepatol. Res. 25: 99-104 (2003).
Kamisawa T, Egawa N, Nakajima H. Autoimmune pancreatitis is a systemic autoimmune disease. Am. J. Gastroenterol. 98: 2811-2812 (2003). *
Kamisawa T, Egawa N, Nakajima H, Tsuruta K, Okamoto A, Kamata N. Clinical difficulties in the differentiation of autoimmune pancreatitis and pancreatic carcinoma. Am. J. Gastroenterol. 98: 2694-2699 (2003). *
Kamisawa T, Funata N, Hayashi Y, Eishi Y, Koike M, Tsuruta K, Okamoto A, Egawa N, Nakajima H. A new clinicopathological entity of IgG4-related autoimmune disease. J. Gastroenterol. 38: 982-984 (2003). *
Kamisawa T, Funata N, Hayashi Y, Tsuruta K, Okamoto A, Amemiya K, Egawa N, Nakajima H. Close relationship between autoimmune pancreatitis and multifocal fibrosclerosis. Gut 52: 683-687 (2003). *
Kanagawa S, Morinobu A, Koshiba M, Kageyama G, Hayashi N, Yoshino S, Tokano Y, Hashimoto H, Kumagai S. Association of the TAP2*Bky2 allele with presence of SS-A/Ro and other autoantibodies in Japanese patients with systemic lupus erythematosus. Lupus 12: 258-265 (2003).
Kanai T, Totsuka T, Uraushihara K, Makita S, Nakamura T, Koganei K, Fukushima T, Akiba H, Yagita H, Okumura K, Machida U, Iwai H, Azuma M, Chen L, Watanabe M. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation. J. Immunol. 171: 4156-4163 (2003). *
Kanai T, Uraushihara K, Totsuka T, Okazawa A, Hibi T, Oshima S, Miyata T, Nakamura T, Watanabe M. Macrophage-derived IL-18 targeting for the treatment of Crohn's disease. Curr. Drug Targets Inflamm. Allergy 2: 131-136 (2003).
Kanauchi O, Mitsuyama K, Araki Y, Andoh A. Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr. Pharm. Des. 9: 333-346 (2003).
Kanda T, Yokosuka O, Imazeki F, Saisho H. Bezafibrate treatment: a new medical approach for PBC patients? J. Gastroenterol. 38: 573-578 (2003). *
Kane S. Inflammatory bowel disease in pregnancy. Gastroenterol. Clin. North Am. 32: 323-340 (2003). *
Kane S, Altschuler EL, Kast RE. Crohn's disease remission on bupropion. Gastroenterology 125: 1290 (2003). *
Kane S, Huo D, Aikens J, Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am. J. Med. 114: 39-43 (2003). *
Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin. Gastroenterol. Hepatol. 1: 170-173 (2003). *
Kane SV, Bjorkman DJ. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev. Gastroenterol. Disord. 3: 210-218 (2003). *
Kane SV, Sandborn WJ, Rufo PA, Zholudev A, Boone J, Lyerly D, Camilleri M, Hanauer SB. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am. J. Gastroenterol. 98: 1309-1314 (2003). *
Kankonkar S, Jeyanti G, Singhal BS, Shankarkumar U. Evidence for novel DRB1*15 allele association among clinically definite multiple sclerosis patients from Mumbai, India. Hum. Immunol. 64: 478-482 (2003).
Kankuri E, Hamalainen M, Hukkanen M, Salmenpera P, Kivilaakso E, Vapaatalo H, Moilanen E. Suppression of pro-inflammatory cytokine release by selective inhibition of inducible nitric oxide synthase in mucosal explants from patients with ulcerative colitis. Scand. J. Gastroenterol. 38: 186-192 (2003). *
Kanno K, Tazuma S, Niida S, Chayama K. Unique reciprocal changes of hepatocellular membrane transporter expression and fluidity in rats with selective biliary obstruction. Hepatol. Res. 26: 157-163 (2003).
Kantarci A, Van Dyke TE. Lipoxins in chronic inflammation. Crit. Rev. Oral Biol. Med. 14: 4-12 (2003). *
Kantarci OH, Hebrink DD, Achenbach SJ, Atkinson EJ, Waliszewska A, Buckle G, McMurray CT, de Andrade M, Hafler DA, Weinshenker BG. CTLA4 is associated with susceptibility to multiple sclerosis. J. Neuroimmunol. 134: 133-141 (2003).
Kantor R, Bakhanashvili M, Achiron A. A mutated CCR5 gene may have favorable prognostic implications in MS. Neurology 61: 238-240 (2003).
Kanz MF, Dugas TR, Liu H, Santa Cruz V. Glutathione depletion exacerbates methylenedianiline toxicity to biliary epithelial cells and hepatocytes in rats. Toxicol. Sci. 74: 447-456 (2003). *
Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat. Rev. Immunol. 3: 984-993 (2003). *
Karaman A, Demirbilek S, Sezgin N, Gurbuz N, Gurses I. Protective effect of polyunsaturated phosphatidylcholine on liver damage induced by biliary obstruction in rats. J. Pediatr. Surg. 38: 1341-1347 (2003).
Karell K, Louka AS, Moodie SJ, Ascher H, Clot F, Greco L, Ciclitira PJ, Sollid LM, Partanen J; European Genetics Cluster on Celiac Disease. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum. Immunol. 64: 469-477 (2003).
Karjalainen J, Hulkkonen J, Nieminen MM, Huhtala H, Aromaa A, Klaukka T, Hurme M. Interleukin-10 gene promoter region polymorphism is associated with eosinophil count and circulating immunoglobulin E in adult asthma. Clin. Exp. Allergy 33: 78-83 (2003). *
Karlsson T, Vahlquist A, Kedishvili N, Torma H. 13-cis-Retinoic acid competitively inhibits 3 alpha-hydroxysteroid oxidation by retinol dehydrogenase RoDH-4: a mechanism for its anti-androgenic effects in sebaceous glands? Biochem. Biophys. Res. Commun. 303: 273-278 (2003). *
Karvonen AL. Treatment of cholestatic liver diseases. Duodecim. 119: 533-539 (2003).
Kasahara Y, Kaneko H, Fukao T, Terada T, Asano T, Kasahara K, Kondo N. Hyper-IgM syndrome with putative dominant negative mutation in activation-induced cytidine deaminase. J. Allergy Clin. Immunol. 112: 755-760 (2003). *
Kashif W, Siddiqi N, Dincer AP, Dincer HE, Hirsch S. Proteinuria: how to evaluate an important finding. Cleve. Clin. J. Med. 70: 535-537, 541-544, 546-547 (2003).
Kassam A, Miao B, Young PR, Mukherjee R. Retinoid X receptor (RXR) agonist-induced antagonism of farnesoid X receptor (FXR) activity due to absence of coactivator recruitment and decreased DNA binding. J. Biol. Chem. 278: 10028-10032 (2003). *
Katabi N, Albores-Saavedra J. The extrahepatic bile duct lesions in end-stage primary sclerosing cholangitis. Am. J. Surg. Pathol. 27: 349-355 (2003).
Katayama K, Wada K, Nakajima A, Mizuguchi H, Hayakawa T, Nakagawa S, Kadowaki T, Nagai R, Kamisaki Y, Blumberg RS, Mayumi T. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 124: 1315-1324 (2003). *
Kato S, Kamagata S, Asakura T, Ozawa K, Nio M, Ohi R, Munakata M, Iinuma K. A newly developed small-caliber videoduodenoscope for endoscopic retrograde cholangiopancreatography in children. J. Clin. Gastroenterol. 37: 173-176 (2003).
Katoh M. WNT2 and human gastrointestinal cancer (review). Int. J. Mol. Med. 12: 811-816 (2003).
Katsanos KH, Christodoulou DK, Zioga A, Tsianos EV. Cutaneous nevi pigmentosus during infliximab therapy in a patient with Crohn's disease: fallacy or coincidence? Inflamm. Bowel Dis. 9: 279 (2003). *
Katz J, Shenkman A, Stavropoulos F, Melzer E. Oral signs and symptoms in relation to disease activity and site of involvement in patients with inflammatory bowel disease. Oral Dis. 9: 34-40 (2003). *
Katznelson L, Fairfield WP, Zeizafoun N, Sands BE, Peppercorn MA, Rosenthal DI, Klibanski A. Effects of growth hormone secretion on body composition in patients with Crohn's disease. J. Clin. Endocrinol. Metab. 88: 5468-5672 (2003). *
Kaunitz JD, Akiba Y. Acid-sensing protective mechanisms of duodenum. J. Physiol. Pharmacol. 54 Suppl. 4: 19-26 (2003). *
Kaur G, Rapthap CC, Xavier M, Saxena R, Choudhary VP, Reuben SK, Mehra NK. Distribution of C282Y and H63D mutations in the HFE gene in healthy Asian Indians and patients with thalassaemia major. Natl. Med. J. India 16: 309-310 (2003).
Kavanaugh A, Keystone EC. The safety of biologic agents in early rheumatoid arthritis. Clin. Exp. Rheumatol. 21 (5 Suppl. 31): S203-S208 (2003).
Kawaguchi Y, Tochimoto A, Ichikawa N, Harigai M, Hara M, Kotake S, Kitamura Y, Kamatani N. Association of IL1A gene polymorphisms with susceptibility to and severity of systemic sclerosis in the Japanese population. Arthritis Rheum. 48: 186-192 (2003). *
Kawai K, Michitaka K, Miyauchi S, Sano M, Abe M, Ninomiya T, Matsuura B, Masumoto T, Akbar SM, Horiike N, Onji M. Acute-onset autoimmune hepatitis treated with living donor-liver transplantation. Intern. Med. 42: 158-162 (2003). *
Kawai M, Otake Y, Hara Y. High-molecular-mass isoform of aminopeptidase N/CD13 in serum from cholestatic patients. Clin. Chim. Acta 330: 141-149 (2003). *
Kawana K, Ikuta T, Kobayashi Y, Gotoh O, Takeda K, Kawajiri K. Molecular mechanism of nuclear translocation of an orphan nuclear receptor, SXR. Mol. Pharmacol. 63: 524-531 (2003). *
Kawanishi M, Yoshida Y, Sakaguchi I, Nagano F, Kato K, Miyake H. Cerebral venous sinus thrombosis in a patient with ulcerative colitis. J. Stroke Cerebrovasc. Dis. 12: 271-275 (2003).
Kawashima M, Miossec P. Heterogeneity of response of rheumatoid synovium cell subsets to interleukin-18 in relation to differential interleukin-18 receptor expression. Arthritis Rheum. 48: 631-637 (2003). *
Kay MA. Hepatic gene transfer. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 49. October 20 - 21 (2003). *
Kazama H, Usui S, Okazaki M, Hosoi T, Ito H, Orimo H. Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes. Diabetes Res. Clin. Pract. 59: 181-189 (2003).
Kefalas CH. Gastroduodenal Crohn's disease. Proc. Bayl. Univ. Med. Cent. 16: 147-151 (2003).
Kehlen A, Pachnio A, Thiele K, Langner J. Gene expression induced by interleukin-17 in fibroblast-like synoviocytes of patients with rheumatoid arthritis: upregulation of hyaluronan-binding protein TSG-6. Arthritis Res. Ther. 5: R186-R192 (2003). *
Keighley MR, Stockbrugger RW. Inflammatory bowel disease. Aliment. Pharmacol. Ther. 18 Suppl. 3: 66-70 (2003).
Keim V. Identification of patients with genetic risk factors of pancreatitis: impact on treatment and cancer prevention. Dig. Dis. 21: 346-350 (2003).
Keim V, Witt H, Bauer N, Bodeker H, Rosendahl J, Teich N, Mossner J. The course of genetically determined chronic pancreatitis. JOP 4: 146-154 (2003). *
Keino H, Sakai J, Usui M. Association between HLA-A2 in Japanese psoriasis arthritis and susceptibility to uveitis. Graefes Arch. Clin. Exp. Ophthalmol. 241: 777-778 (2003).
Keller BM, Aebischer CC, Kraemer R, Schoni MH. Growth in prepubertal children with cystic fibrosis, homozygous for the Delta F508 mutation. J. Cyst. Fibros. 2: 76-83 (2003).
Keller JJ, Giardiello FM. Chemoprevention strategies using NSAIDs and COX-2 inhibitors. Cancer Biol. Ther. 2: S140-S149 (2003). *
Kelly-Welch AE, Hanson EM, Boothby MR, Keegan AD. Interleukin-4 and interleukin-13 signaling connections maps. Science 300: 1527-1528 (2003). *
Kempuraj D, Frydas S, Kandere K, Madhappan B, Letourneau R, Christodoulou S, Boucher W, Riccioni G, Conti P, Theoharides TC. Interleukin-19 (IL-19) network revisited. Int. J. Immunopathol. Pharmacol. 16: 95-97 (2003).
Kennedy A, Nelson E, Reeves D, Richardson G, Roberts C, Robinson A, Rogers A, Sculpher M, Thompson D. A randomised controlled trial to assess the impact of a package comprising a patient-orientated, evidence-based self-help guidebook and patient-centred consultations on disease management and satisfaction in inflammatory bowel disease. Health Technol. Assess. 7: 1-126 (2003). *
Kennedy A, Robinson A, Hann M, Thompson D, Wilkin D; The North-West Region Gastrointestinal Research Group. A cluster-randomised controlled trial of a patient-centred guidebook for patients with ulcerative colitis: effect on knowledge, anxiety and quality of life. Health Soc. Care Community 11: 64-72 (2003).
Kerkar N, Choudhuri K, Ma Y, Mahmoud A, Bogdanos DP, Muratori L, Bianchi F, Williams R, Mieli-Vergani G, Vergani D. Cytochrome P4502D6(193-212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J. Immunol. 170: 1481-1489 (2003). *
Kerry JE, Marshall C, Griffiths PA, Scott BB, Griffiths G. White cell scanning for inflammatory bowel disease: are biochemical markers useful referral criteria? Nucl. Med. Commun. 24: 1145-1148 (2003).
Kershenobich Stalnikowitz D, Weissbrod AB. Liver fibrosis and inflammation. A review. Ann. Hepatol. 2: 159-163 (2003). *
Keshavarzian A, Banan A, Farhadi A, Komanduri S, Mutlu E, Zhang Y, Fields JZ. Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease. Gut 52: 720-728 (2003). *
Kew S, Banerjee T, Minihane AM, Finnegan YE, Muggli R, Albers R, Williams CM, Calder PC. Lack of effect of foods enriched with plant- or marine-derived n-3 fatty acids on human immune function. Am. J. Clin. Nutr. 77: 1287-1295 (2003). *
Keystone EC, Haraoui B, Bykerk VP. Role of infliximab in the treatment of early rheumatoid arthritis. Clin. Exp. Rheumatol. 21 (5 Suppl. 31): S200-S202 (2003).
Khakoo SI, Brooks CR. MHC class I receptors on natural killer cells: on with the old and in with the new. Clin. Sci. (Lond.) 105: 127-140 (2003). *
Khalili K, Metser U, Wilson SR. Hilar biliary obstruction: preliminary results with Levovist-enhanced sonography. AJR Am. J. Roentgenol. 180: 687-693 (2003). *
Khan SA, Davidson BR, Goldin R, Pereira S, Rosenberg WMC, Taylor-Robinson SD, Thillainayagam AV, Thomas HC, Thursz MR, Wasan H. GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHOLANGIOCARCINOMA - CONSENSUS DOCUMENT. (http://www.basl.org.uk/cholan.pdf) (2003). *
Khan SA, Vanden Heuvel JP. Role of nuclear receptors in the regulation of gene expression by dietary fatty acids (review). J. Nutr. Biochem. 14: 554-667 (2003). *
Khanna D, Aggarwal A, Bhakuni DS, Dayal R, Misra R. Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis. J. Rheumatol. 30: 1248-1252 (2003).
Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. J. Dermatolog. Treat. 14: 229-232 (2003).
Khare S, Cerda S, Wali RK, von Lintig FC, Tretiakova M, Joseph L, Stoiber D, Cohen G, Nimmagadda K, Hart J, Sitrin MD, Boss GR, Bissonnette M. Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer. Cancer Res. 63: 3517-3523 (2003). *
Khattri R, Cox T, Yasayko SA, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 4: 337-342 (2003). *
Khettry U, Anand N, Faul PN, Lewis WD, Pomfret EA, Pomposelli J, Jenkins RL, Gordon FD. Liver transplantation for primary biliary cirrhosis: a long-term pathologic study. Liver Transpl. 9: 87-96 (2003). *
Khettry U, Keaveny A, Goldar-Najafi A, Lewis WD, Pomfret EA, Pomposelli JJ, Jenkins RL, Gordon FD. Liver transplantation for primary sclerosing cholangitis: a long-term clinicopathologic study. Hum. Pathol. 34: 1127-1136 (2003). *
Khoo AL, Tham LS, Lee KH, Lim GK. Acute liver failure with concurrent bupropion and carbimazole therapy. Ann. Pharmacother. 37: 220-223 (2003).
Khovidhunkit W, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR. Endotoxin down-regulates ABCG5 and ABCG8 in mouse liver and ABCA1 and ABCG1 in J774 murine macrophages: differential role of LXR. J. Lipid Res. 44: 1728-1736 (2003). *
Khubchandani RP, D'Souza S. Antiphospholipid antibody syndrome as a cause of Budd-Chiari syndrome. Indian Pediatr. 40: 907-908 (2003).
Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev. 8: 223-246 (2003). *
Kido J, Kido R, Suryono, Kataoka M, Fagerhol MK, Nagata T. Calprotectin release from human neutrophils is induced by Porphyromonas gingivalis lipopolysaccharide via the CD-14-Toll-like receptor-nuclear factor kappaB pathway. J. Periodontal Res. 38: 557-563 (2003). *
Kiechle FL, Holland-Staley CA. Genomics, transcriptomics, proteomics, and numbers. Arch. Pathol. Lab. Med. 127: 1089-1097 (2003). *
Kielar ML, Jeyarajah DR, Zhou XJ, Lu CY. Docosahexaenoic acid ameliorates murine ischemic acute renal failure and prevents increases in mRNA abundance for both TNF-alpha and inducible nitric oxide synthase. J. Am. Soc. Nephrol. 14: 389-396 (2003). *
Kikuchi K, Tanaka A, Miyakawa H, Kawashima Y, Kawaguchi N, Matsushita M, Gershwin ME. Eta-1/osteopontin genetic polymorphism and primary biliary cirrhosis. Hepatol. Res. 26: 87-90 (2003).
Kikutani H, Kumanogoh A. Semaphorins in interactions between T cells and antigen-presenting cells. Nat. Rev. Immunol. 3: 159-167 (2003). *
Kilding R, Akil M, Till S, Amos R, Winfield J, Iles MM, Wilson AG. A biologically important single nucleotide polymorphism within the Toll-like receptor-4 gene is not associated with rheumatoid arthritis. Clin. Exp. Rheumatol. 21: 340-342 (2003).
Kilic SS, Oral HB, Budak F, Aydogdu H, Yavascaoglu B, Goral G. Immunoglobulin subclasses and HLA alleles in immunoglobulin A deficiency. Indian J. Pediatr. 70: 389-392 (2003).
Kilpatrick DC. Introduction to mannan-binding lectin. Biochem. Soc. Trans. 31: 745-747 (2003). *
Kim EH, Mok JW, Bang DS, Lee ES, Lee SN, Park KS. Intercellular adhesion molecule-1 polymorphisms in Korean patients with Behcet's disease. J. Korean Med. Sci. 18: 415-418 (2003). *
Kim EY, Shin CH, Yang SW. Polymorphisms of HLA class II predispose children and adolescents with type 1 diabetes mellitus to autoimmune thyroid disease. Autoimmunity 36: 177-181 (2003).
Kim GD, Kim MH, Hyung CH, Song JW, Choi JJ, Kim JK, Lee TH, Kim WJ, Koh SJ, Lee SS, Lee SK, Seo DW, Min YI, Jun SY, Yu ES. A case of liver transplantation for primary sclerosing cholangitis. Korean J. Gastroenterol. 42: 431-435 (2003).
Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, LeRoith D. Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52: 1770-1778 (2003). *
Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 17: 895-904 (2003). *
Kim HS, Lee JW, Soung YH, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Jeong SW, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology 125: 708-715 (2003). *
Kim JA, Choi SC, Yun KJ, Kim DK, Han MK, Seo GS, Yeom JJ, Kim TH, Nah YH, Lee YM. Expression of protease-activated receptor 2 in ulcerative colitis. Inflamm. Bowel Dis. 9: 224-229 (2003). *
Kim JD, Choi BK, Bae JS, Lee UH, Han IS, Lee HW, Youn BS, Vinay DS, Kwon BS. Cloning and characterization of GITR ligand. Genes Immun. 4: 564-569 (2003). *
Kim JE, Kim KS, Seo JK. Diagnostic role of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in pediatric inflammatory bowel disease. Korean J. Gastroenterol. 42: 297-302 (2003).
Kim JJ, Kim JG, Kwon DH. Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and underestimation of antimicrobial susceptibility testing. Helicobacter 8: 202-206 (2003). *
Kim JU, Chang HK, Lee SS, Kim JW, Kim KT, Lee SW, Chung WT. Endothelial nitric oxide synthase gene polymorphisms in Behcet's disease and rheumatic diseases with vasculitis. Ann. Rheum. Dis. 62: 1083-1087 (2003). *
Kim MS, Shigenaga J, Moser A, Feingold K, Grunfeld C. Repression of farnesoid X receptor during the acute phase response. J. Biol. Chem. 278: 8988-8995 (2003). *
Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. Eur. J. Clin. Invest. 33 Suppl. 2: 1-5 (2003).
Kim TG, Pyo CW, Hur SS, Kim YK, Hwang HY, Youn JI, Kim TY. Polymorphisms of tumor necrosis factor (TNF) alpha and beta genes in Korean patients with psoriasis. Arch. Dermatol. Res. 295: 8-13 (2003). *
Kim TH, Kim BG, Shin HD, Kim JW, Kim CG, Kim JS, Jung HC, Song IS. Tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in Korean patients with inflammatory bowel disease. Korean J. Gastroenterol. 42: 377-386 (2003).
Kim TY, Park YJ, Hwang JK, Song JY, Park KS, Cho BY, Park do J. A C/T polymorphism in the 5'-untranslated region of the CD40 gene is associated with Graves' disease in Koreans. Thyroid 13: 919-925 (2003).
Kim WR. Pretransplantation disease severity and posttransplantation outcome. Liver Transpl. 9: 124-125 (2003). *
Kim YI. Role of folate in colon cancer development and progression. J. Nutr. 133: 3731S-3739S (2003). *
Kim YK, Pyo CW, Hur SS, Kim TY, Kim TG. No associations of CTLA-4 and ICAM-1 polymorphisms with psoriasis in the Korean population. J. Dermatol. Sci. 33: 75-77 (2003).
Kimbrough RD, Krouskas CA. Human exposure to polychlorinated biphenyls and health effects: a critical synopsis. Toxicol. Rev. 22: 217-233 (2003).
Kimura R, Nishioka T, Ishida T. The SDF1-G801A polymorphism is not associated with SDF1 gene expression in Epstein-Barr virus-transformed lymphoblastoid cells. Genes Immun. 4: 356-361 (2003). *
King AL, Moodie SJ, Fraser JS, Curtis D, Reid E, Dearlove AM, Ciclitira PJ. Coeliac disease: investigation of proposed causal variants in the CTLA4 gene region. Eur. J. Immunogenet. 30: 427-432 (2003). *
King K, Moody A, Fisher SA, Mirza MM, Cuthbert AP, Hampe J, Sutherland-Craggs A, Sanderson J, MacPherson AJ, Forbes A, Mansfield J, Schreiber S, Lewis CM, Mathew CG. Genetic variation in the IGSF6 gene and lack of association with inflammatory bowel disease. Eur. J. Immunogenet. 30: 187-190 (2003). *
Kingo K, Koks S, Silm H, Vasar E. IL-10 promoter polymorphisms influence disease severity and course in psoriasis. Genes Immun. 4: 455-457 (2003). *
Kinikli G, Ates A, Turgay M, Akay G, Kinikli S, Tokgoz G. HLA-DRB1 genes and disease severity in rheumatoid arthritis in Turkey. Scand. J. Rheumatol. 32: 277-280 (2003).
Kinney T, Rawlins M, Kozarek R, France R, Patterson D. Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions. Am. J. Gastroenterol. 98: 608-612 (2003). *
Kinnman N, Francoz C, Barbu V, Wendum D, Rey C, Hultcrantz R, Poupon R, Housset C. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab. Invest. 83: 163-173 (2003).
Kinoshita K, Yoo BS, Nozaki Y, Sugiyama M, Ikoma S, Ohno M, Funauchi M, Kanamaru A. Retinoic acid reduces autoimmune renal injury and increases survival in NZB/W F1 mice. J. Immunol. 170: 5793-5798 (2003). *
Kinouchi Y, Matsumoto K, Negoro K, Takagi S, Takahashi S, Hiwatashi N, Shimosegawa T. HLA-B genotype in Japanese patients with Crohn's disease. Dis. Colon Rectum 46: S10-S14 (2003).
Kiortsis DN, Nikas S, Hatzidimou K, Tsianos E, Elisaf MS. Lipid-lowering drugs and serum liver enzymes: the effects of body weight and baseline enzyme levels. Fundam. Clin. Pharmacol. 17: 491-494 (2003). *
Kirsch R, Clarkson V, Shephard EG, Marais DA, Jaffer MA, Woodburne VE, Kirsch RE, Hall Pde L. Rodent nutritional model of non-alcoholic steatohepatitis: species, strain and sex difference studies. J. Gastroenterol. Hepatol. 18: 1272-1282 (2003). *
Kirsner JB. Commentary on the 1958 National Institutes of Health conference on "New frontiers in ulcerative colitis". Inflamm. Bowel Dis. 9: 61-69 (2003). *
Kishimoto H, Hamada K, Saunders M, Backman S, Sasaki T, Nakano T, Mak TW, Suzuki A. Physiological functions of Pten in mouse tissues. Cell Struct. Funct. 28: 11-21 (2003). *
Kishimoto T, Hamazaki T, Yasui M, Sasabe M, Okamura T, Sakata N, Inoue M, Yagi K, Kawa K. Autologous hematopoietic stem cell transplantation for 3 patients with severe juvenile rheumatoid arthritis. Int. J. Hematol. 78: 453-456 (2003).
Kita H. Primary biliary cirrhosis and E. coli-induced pyelonephritis; are infectious agents related to the pathogenesis of primary biliary cirrhosis? Intern. Med. 42: 1063-1064 (2003). *
Kita H, Ansari AA, He XS, Lian ZX, Van de Water J, Coppel RL, Luketic V, Kaplan M, Inamori H, Isoda N, Sugano K, Imawari M, Gershwin ME. Proteasome is required for class I-restricted presentation by Fcgamma receptor-mediated endocytosis in primary biliary cirrhosis. J. Autoimmun. 21: 175-182 (2003). *
Kita H, He XS, Gershwin ME. Application of tetramer technology in studies on autoimmune diseases. Autoimmun. Rev. 2: 43-49 (2003).
Kita H, Nalbandian G, Keeffe EB, Coppel RL, Gershwin ME. Pathogenesis of primary biliary cirrhosis. Clin. Liver Dis. 7: 821-839 (2003).
Kitada H, Miyata M, Nakamura T, Tozawa A, Honma W, Shimada M, Nagata K, Sinal CJ, Guo GL, Gonzalez FJ, Yamazoe Y. Protective role of hydroxysteroid sulfotransferase in lithocholic acid-induced liver toxicity. J. Biol. Chem. 278: 17838-17844 (2003). *
Kitchens RL, Thompson PA, Munford RS, O'Keefe GE. Acute inflammation and infection maintain circulating phospholipid levels and enhance lipopolysaccharide binding to plasma lipoproteins. J. Lipid Res. 44: 2339-2348 (2003). *
Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, Adim SB, Yerci O, Memik F. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can. J. Gastroenterol. 17: 713-718 (2003).
Kizilisik AT, Grewal HP, Shokouh-Amiri MH, Vera SR, Hathaway DK, Gaber AO. Impact of long-term immunosuppressive therapy on psychosocial and physical well being in liver transplant recipients. Prog. Transplant. 13: 278-283 (2003).
Klampfer L, Huang J, Sasazuki T, Shirasawa S, Augenlicht L. Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. Mol. Cancer Res. 1: 855-862 (2003). *
Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB. A lupus-like syndrome associated with infliximab therapy. Inflamm. Bowel Dis. 9: 176-178 (2003). *
Klaunig JE, Babich MA, Baetcke KP, Cook JC, Corton JC, David RM, DeLuca JG, Lai DY, McKee RH, Peters JM, Roberts RA, Fenner-Crisp PA. PPARalpha agonist-induced rodent tumors: modes of action and human relevance. Crit. Rev. Toxicol. 33: 655-780 (2003).
Klebl FH, Bataille F, Bertea CR, Herfarth H, Hofstadter F, Scholmerich J, Rogler G. Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease. Inflamm. Bowel Dis. 9: 302-307 (2003). *
Klebl FH, Bregenzer N, Rogler G, Straub RH, Scholmerich J, Andus T. Treatment of pouchitis with dehydroepiandrosterone (DHEA) - a case report. Z. Gastroenterol. 41: 1087-1090 (2003).
Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kooistra T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 101: 545-551 (2003). *
Kleideiter E, Friedrich U, Mohring A, Walker S, Horing E, Maier K, Fritz P, Thon KP, Klotz U. Telomerase activity in chronic inflammatory bowel disease. Dig. Dis. Sci. 48: 2328-2332 (2003). *
Klein D, Einspanier R, Bolder U, Jeschke MG. Differences in the hepatic signal transcription pathway and cytokine expression between thermal injury and sepsis. Shock 20: 536-543 (2003). *
Klein R, Goller S, Bianchi L. Nodular regenerative hyperplasia (NRH) of the liver - a manifestation of 'organ-specific antiphospholipid syndrome'? Immunobiology 207: 51-57 (2003).
Klein W, Tromm A, Griga T, Folwaczny C, Hocke M, Eitner K, Marx M, Duerig N, Epplen JT. Interaction of polymorphisms in the CARD15 and CD14 genes in patients with Crohn disease. Scand. J. Gastroenterol. 38: 834-836 (2003). *
Kleinau S. The impact of Fc receptors on the development of autoimmune diseases. Curr. Pharm. Des. 9: 1861-1870 (2003).
Kliewer SA. The nuclear pregnane X receptor regulates xenobiotic detoxification. J. Nutr. 133: 2444S-2447S (2003). *
Kliewer SA. Anthrax mounts a nuclear attack on glucocorticoid signaling. Trends Pharmacol. Sci. 24: 558-559 (2003).
Klitz W, Maiers M, Spellman S, Baxter-Lowe LA, Schmeckpeper B, Williams TM, Fernandez-Vina M. New HLA haplotype frequency reference standards: high-resolution and large sample typing of HLA DR-DQ haplotypes in a sample of European Americans. Tissue Antigens 62: 296-307 (2003). *
Klomp AE, Juijn JA, van der Gun LT, van den Berg IE, Berger R, Klomp LW. The N-terminus of the human copper transporter 1 (hCTR1) is localized extracellularly, and interacts with itself. Biochem. J. 370: 881-889 (2003). *
Klomp AE, van de Sluis B, Klomp LW, Wijmenga C. The ubiquitously expressed MURR1 protein is absent in canine copper toxicosis. J. Hepatol. 39: 703-709 (2003). *
Klump B, Hsieh CJ, Dette S, Holzmann K, Kiebetalich R, Jung M, Sinn U, Ortner M, Porschen R, Gregor M. Promoter methylation of INK4a/ARF as detected in bile-significance for the differential diagnosis in biliary disease. Clin. Cancer Res. 9: 1773-1778 (2003). *
Knapp S, Yee LJ, Frodsham AJ, Hennig BJ, Hellier S, Zhang L, Wright M, Chiaramonte M, Graves M, Thomas HC, Hill AV, Thursz MR. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 4: 411-419 (2003). *
Knight BL, Patel DD, Humphreys SM, Wiggins D, Gibbons GF. Inhibition of cholesterol absorption associated with a PPAR alpha-dependent increase in ABC binding cassette transporter A1 in mice. J. Lipid Res. 44: 2049-2058 (2003). *
Knolle P. Immunological functions. Falk Symposium 138. XII FALK LIVER WEEK 2003 (Part III) In Honour of Hans Popper’s 100th Birthday. State-of-the-art of hepatology: Molecular and Cell Biology. Freiburg (Germany). p. 23. October 20 - 21 (2003). *
Knutson D, Greenberg G, Cronau H. Management of Crohn's disease - a practical approach. Am. Fam. Physician 68: 707-714 (2003). *
Ko MC, Lee H, Song MS, Sobczyk-Kojiro K, Mosberg HI, Kishioka S, Woods JH, Naughton NN. Activation of kappa-opioid receptors inhibits pruritus evoked by subcutaneous or intrathecal administration of morphine in monkeys. J. Pharmacol. Exp. Ther. 305: 173-179 (2003). *
Kobayashi K, Bang Lu Y, Xian Li M, Nishi I, Hsiao KJ, Choeh K, Yang Y, Hwu WL, Reichardt JK, Palmieri F, Okano Y, Saheki T. Screening of nine SLC25A13 mutations: their frequency in patients with citrin deficiency and high carrier rates in Asian populations. Mol. Genet. Metab. 80: 356-359 (2003). *
Kobayashi M, Kweon MN, Kuwata H, Schreiber RD, Kiyono H, Takeda K, Akira S. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J. Clin. Invest. 111: 1297-1308 (2003). *
Kobayashi N, Okitsu T, Nakaji S, Tanaka N. Hybrid bioartificial liver: establishing a reversibly immortalized human hepatocyte line and developing a bioartificial liver for practical use. J. Artif. Organs 6: 236-244 (2003).
Koch KL, Frissora CL. Nausea and vomiting during pregnancy. Gastroenterol. Clin. North Am. 32: 201-234, vi (2003). *
Kocher O, Pal R, Roberts M, Cirovic C, Gilchrist A. Targeted disruption of the PDZK1 gene by homologous recombination. Mol. Cell. Biol. 23: 1175-1180 (2003). *
Kocher O, Yesilaltay A, Cirovic C, Pal R, Rigotti A, Krieger M. Targeted disruption of the PDZK1 gene in mice causes tissue-specific depletion of the high density lipoprotein receptor scavenger receptor class B type I and altered lipoprotein metabolism. J. Biol. Chem. 278: 52820-52825 (2003). *
Koedel U, Angele B, Rupprecht T, Wagner H, Roggenkamp A, Pfister HW, Kirschning CJ. Toll-like receptor 2 participates in mediation of immune response in experimental pneumococcal meningitis. J. Immunol. 170: 438-444 (2003). *
Koffeman GI, van Gemert WG, George EK, Veenendaal RA. Classification, epidemiology and aetiology. Best Pract. Res. Clin. Gastroenterol. 17: 879-893 (2003). *